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Abstract 
 
Type 2 diabetes is the most common form of diabetes in humans and cats, and senior age and 
obesity are major risk factors. Diabetes is typically diagnosed in cats once clinical signs are 
evident. In humans, prediabetes is a metabolic state between normal glucose homeostasis and 
diabetes, and is diagnosed by demonstrating impaired glucose tolerance (IGT) and/or 
impaired fasting glucose (IFG). However, prediabetes has not yet been defined in cats, and 
reference values for these variables have not been reported for senior cats.  
In this thesis, the first experiment investigated if the current practice of dosing glucose by 
bodyweight results in spurious effects on measures of glucose tolerance in obese cats. 
Glucose data from glucose tolerance and insulin sensitivity tests were analysed before and 
after 16 cats were fed ad libitum for 9 - 12 months to promote weight gain. Bodyweight and 
body condition score (BCS) were positively correlated with 2-min, 2-h glucose 
concentrations and glucose half-life following a glucose tolerance test (GTT) when glucose 
dosing was by bodyweight. To avoid obese cats being incorrectly classified as having 
impaired glucose tolerance when glucose was dosed on a bodyweight basis, equations were 
developed to adjust either glucose dose or 2-h glucose to compensate for obesity.  This has 
important implications for clinical studies assessing the effects of interventions on glucose 
tolerance when lean and obese cats are compared. 
The second experiment established methodology and cutpoints for fasting and 2-h glucose 
during a GTT in healthy, client-owned senior cats (> 8yrs, n=78), by using ear/ paw samples 
and a portable glucose meter calibrated for feline blood. Fasting blood glucose was measured 
from ear/paw samples and glucose (0.5 g/kg bodyweight) administered IV, followed by blood 
glucose measurements at 2 min and 2 h. Cutpoints for fasting and 2-h glucose concentrations 
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were established as the upper limits of 95% reference intervals using cats with BCS 4 or 5 on 
a 9-point scale and were 6.5 mmol/L for fasting glucose and 9.8 mmol/L for 2-h glucose.  
The third experiment established a methodology and reference interval for screening blood 
glucose in senior cats. Blood glucose was measured at the beginning of the consultation in 
clinically healthy cats (≥8 years, n=120) from an ear/ paw sample using a portable glucose 
meter, and again after physical examination from a jugular sample. The cutpoint for 
screening blood glucose was 10.5 mmol/L. Mean screening blood glucose was greater than 
mean fasting glucose. Based on these results, it is recommended that cats with screening 
blood glucose from 6.5 mmol/L to 10.5 mmol/L be retested several hours later, and cats with 
screening values >10.5 mmol/L or a second test > 6.5 mmol/L should have fasting and 2-h 
blood glucose measured after overnight hospitalization.  
Metabolomic markers of obesity and prediabetes have been investigated in humans, but there 
is limited data available in cats. Additionally, there is limited research on metabolomics in 
Burmese cats, which are reported to have dyslipidaemia and are 3- 4 times more likely to 
develop diabetes than domestic cats. The last two experiments in the thesis address the effect 
of obesity and the Burmese breed on the metabolome.  
A study was performed to identify metabolomic changes associated with obesity in senior 
cats, and to determine if such metabolites are associated with biochemical measures of 
abnormal glucose metabolism. Biochemical and GC-MS analyses were performed on blood 
samples from 21 lean and 18 obese non-Burmese cats. In obese cats, metabolomic analysis 
identified increased fatty acids (palmitoleic and myristoleic), glycerol, glycolic acid, and 
phenylanine, whilst only the amino acid alanine was decreased. Palmitoleic acid was 
positively, and alanine negatively correlated (p<0.05) with leptin concentrations, and glycolic 
iv 
 
acid and glycerol were positively associated (p<0.05) with insulin. This study is the first to 
report on metabolomic changes of obesity in senior cats.  
The final study examined metabolomic differences between Burmese (n=19) and non-
Burmese cats (n=30) by GC-MS analysis. In Burmese cats many glucogenic amino acids, 
together with hydroxyproline and aminobutyric acids were increased, whilst beta-alanine was 
decreased.  Fructose and glucose, cholesterol and some fatty acids, glycerol-3-phosphate and 
various acids were all decreased in Burmese cats. Urea was also increased in Burmese. 
Burmese cats had increased insulin, triglyceride, and MCP-1 concentrations which had 
moderate positive associations with amino acids. Numerous relationships were identified 
between GC-MS metabolites and measures of glucose metabolism. This study is the first to 
report metabolite differences between healthy senior non-Burmese and Burmese cats. 
The findings in this thesis have established the test methodology and reference intervals for 
fasting and screening blood glucose and glucose tolerance in senior cats. These results have 
direct application to clinical practice to facilitate earlier diagnosis of prediabetes in cats.  
Additionally, the identification of metabolite differences in cats associated with obesity or 
Burmese breed represents potential new biomarkers of metabolic dysfunction in cats at high 
risk of developing diabetes. 
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Chapter 1: Review of the Literature 
 
Section 1: Diabetes Overview 
Classification 
In humans, diabetes mellitus is considered a group of metabolic diseases diagnosed by 
demonstrating persistent hyperglycaemia1. This hyperglycaemia can be the result of defects 
in insulin secretion by the beta-cells (ie. when there is beta-cell damage), insulin action, or 
both 2. In humans, chronic hyperglycaemia leads to long term tissue damage and failure of 
various organs including the eyes, kidney, nerves, heart and blood vessels3. Pathogenic 
processes include either an insulin deficiency caused by autoimmune destruction of beta- 
cells in the pancreas (type 1) or insulin resistance compounded by beta- cell failure as a result 
of incompletely understood mechanisms (type 2)4. The classification of diabetes mellitus in 
humans is now based on aetiology rather than treatment, as was used in the past2. 
 
Type 1 diabetes 
Type 1 diabetes results from cellular- mediated autoimmune destruction of beta- cells of the 
pancreas resulting in reduced secretion and an absolute deficiency of insulin4. Autoantibodies 
to islet cells, insulin, glutamic acid decarboxylase and tyrosine phosphatase have been 
identified, and one or more are present in 85-90% of individuals affected by the disease1. 
 
Type 2 diabetes in humans 
Type 2 diabetes accounts for about 90-95% diabetic cases3 and involves resistance to insulin 
action and, at least initially, a relative (compensatory) rather than absolute decrease in insulin 
secretion5. Type 2 diabetes occurs when insulin sensitivity decreases along with impaired 
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insulin secretion due to beta-cell failure6,7. Reduced insulin action on target tissues results in 
abnormal carbohydrate, fat, and protein metabolism8,9. It can sometimes be difficult to know 
whether the hyperglycaemia is caused by reduced insulin secretion and/ or reduced tissue 
response, but ultimately there is a resultant beta-cell failure2,3,5. In human patients, one set of 
criteria for the diagnosis of diabetes includes the presence of one of the following three 
indicators, repeated on two different days 5: 
1. Symptoms of diabetes plus a casual plasma glucose concentration > 11.1 mmol/L. 
Casual is defined as ‘any time of day without regard to time since last meal’ 
2. A fasting plasma glucose >7.0 mmol/L10. Fasted is defined as no caloric intake for at 
least 8 hours 
3. A 2-h plasma glucose 7.8 <11.0 mmol/L following an oral GTT (an oral glucose load 
containing the equivalent of 75 g anhydrous glucose dissolved in water). This 
diagnostic procedure is used if the casual or fasting results are abnormal, and to 
screen for gestational diabetes2,3. 
 
Overt clinical symptoms of diabetes include polyuria, polydipsia, weight loss, polyphagia and 
occasionally blurred vision, impaired growth and increased susceptibility to infections10. 
Long- term complications resulting from microvascular and macrovascular degeneration 
include retinopathy, which often results in blindness, nephropathy resulting in renal failure, 
peripheral neuropathy (ulcers and possible need for limb amputation) and autonomic 
neuropathy affecting the gastrointestinal, genitourinary, and cardiovascular systems3,5,11. 
Histopathological findings in type 2 diabetes in humans include concurrent loss of beta-cells 
and deposition of islet amyloid derived from islet amyloid polypeptide12. This suggests that 
the amyloid deposition could play a role in functional beta-cell dysfunction in humans12-15. 
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Epidemiological and laboratory evidence suggest that both the increased insulin resistance 
and the failing beta-cell response have genetic and environmental components6,16-20. In fact, 
the genes associated with insulin resistance and metabolic syndrome in humans are closely 
associated with genes of lipid metabolism21. In human type 2 diabetes, most individuals are 
obese or have more body fat around the abdominal region22-24, and obesity is the most 
common cause of acquired insulin resistance25,26. The relative risk for IGT, defined as 2-h 
glucose levels of 7.8 to 11.0 mmol/l on the 75-g oral glucose tolerance test27, is increased 
more than fourfold in obese subjects compared with normal-weight subjects, yet only 25% of 
subjects with IGT are obese28. Risk factors also include increased age29-31, a lack of physical 
activity29,32, and a genetic predisposition33. Human subjects with IGT more frequently have 
first-degree relatives with diabetes compared to subjects with normal glucose tolerance, but 
>70% of humans with IGT report no heredity background of diabetes28.  
 
Glucose is the primary regulator of postprandial insulin secretion which is controlled by 
nutritional and hormonal signals in humans and animals34. Glucagon-like peptide-1 (GLP-
1)35, a peptide hormone produced in the intestinal epithelial endocrine L-cells, free fatty 
acids9, and amino acids increase this effect once the blood glucose concentration reaches a 
threshold, and are considered insulin secretagogues34. In both humans and animals, the 
progression from an obese insulin- resistant state to clinical type 2 diabetes is caused by beta- 
cell failure34. The first acute phase of insulin release occurs approximately 10 minutes after 
glucose stimulation and the second phase of insulin secretion, which is more sustained, 
follows within 30 minutes and plateaus in 2 to 3 hours34. The first-phase insulin secretion is 
defective initially in impaired fasting glucose36 along with a deficiency in the ability of 
glucose to potentiate insulin secretagogues8. As hyperglycaemia progresses, beta-cell failure 
also progresses37. By the time the fasting blood glucose concentration is above the 7.8 
4 
 
mmol/L, there is a 75% loss of beta-cell function8.  
 
Gestational Diabetes in humans 
Gestational diabetes mellitus is defined as any degree of glucose intolerance diagnosed 
during pregnancy, irrespective of whether the condition is treated with insulin or with dietary 
modification and even if it is not controlled after pregnancy2,4. A fasting plasma glucose level 
of >7.0 mmol/L or a casual plasma glucose >11.1 mmol/L on a subsequent day followed by a 
1-hr and/or 2-hr plasma glucose concentrations of 10.0 mmol/L and 8.6 mmol/L, respectively 
during an oGTT with a 75g glucose load2-4. Gestational diabetes has not been reported in 
cats. 
 
Type 2 diabetes in cats 
Feline diabetes mellitus shares many similarities to human type 2 diabetes38-42. More than 
80% of cats with diabetes have clinical characteristics (polyuria, polydipsia, and polyphagia) 
and histologic abnormalities (such as amyloid accumulation in beta-cells14,15) consistent with 
type 2 diabetes in humans. The typical onset for diabetes in cats and humans is  middle- age 
or later43,44. Over 50% of diabetic cats were over 10 years old and age was identified as the 
most important single risk factor in the development of diabetes in cats44,45.  The reported 
incidence of diabetes in cats varies from one in 50 to one in 400 cats, depending on the 
population studied44,46,47. As in humans, the main preventable predisposing factors for the 
development of diabetes in cats are unlimited access to a nutrient dense diet leading to 
obesity, and a sedentary lifestyle12, and the prevalence of obesity and diabetes is increasing  
concomitantly48-50. Obese cats are 3.9 times more likely to develop diabetes mellitus than 
lean cats51. 
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Neutered cats have nearly twice the risk and male cats have 1.5 times the risk of developing 
diabetes14,45,52.  Diabetes in cats, as in humans, appears to be associated with diseases, 
pharmacological agents, and hormones that impair peripheral tissue insulin sensitivity, such 
as acromegaly or hyperadrenocorticism (80% of cats with hyperadrenocorticism develop 
diabetes mellitus53), hyperthyroidism or treatment with corticosteroids or progestins46. 
 
Obesity is a major risk factor in the development of diabetes and thus the aim of dietary 
management should include weight loss40,54. It is reported that cats at high risk of developing 
diabetes (ie. sedentary neutered indoor cats) should not be fed ad libitum40,55,56 but rather 
given rations to ensure controlled consumption of calories. Added water in canned foods not 
only increases hydration but more importantly increases food volume thus increasing satiety, 
and the effect is reported to be greater than high fibre dry foods57. A study in the U.K. 
reported that cats fed only wet food were 3 times more likely and cats fed only dry food 2 
times more likely to develop diabetes than cats fed a mix of wet and dry food58 whereas 
another study reported that whether cats are fed wet or dry food made no difference to the 
risk59. However, the latter study had a limited number of cats which may have limited the 
power. 
 
Breed as a risk factor for feline diabetes 
Inbreeding in cats over 20 years has led to a number of genetic-related disorders60 and there is 
evidence to support genetic predisposition to diabetes in cats61. Burmese cats from the UK, 
Sweden, Australia and New Zealand are now almost four times more likely to develop type 2 
diabetes mellitus than other cats47,62-64, with one in 50 of the breed in the UK being affected58. 
Lean Burmese cats have been reported to have peripheral blood leukocyte gene expression, 
namely increased expression of ATP citrate lyase and fatty acid synthase, similar to age and 
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gender matched obese domestic cats65. In fact, lean Burmese cats were found to have double 
the VLDL cholesterol level to that of obese domestic cats indicating lipid, especially 
triglyceride, dysregulation65. A preliminary study of genetic predisposition of Burmese cats 
to diabetes reported a likely involvement of a major locus with a significant risk allele 
prevalence which was likely autosomal rather than sex-linked66.  
 
Pathophysiology of beta-cell failure in humans and cats 
The most important common pathophysiologic features of type 2 diabetes in cats and humans 
are obesity-induced insulin-resistance22,23,67,68, loss of beta-cell mass6,7,39,69, and amyloid 
deposition in pancreatic islets12,15,70. In addition to amyloid, the cat pancreas is extremely 
sensitive to the toxic effects of hyperglycaemia71. Indeed, within 2 days of a hyperglycaemic 
clamp (25 to 30 mmol/L), hyperglycaemia in healthy cats induces a marked reduction of 
insulin secretory capacity, and subsequently a 50 % decrease in beta-cells per pancreatic 
area71. The cat is an excellent model for studying the pathophysiology of islet amyloid, as it is 
one of few species (human, macaque39, and wild carnivores including jaguar72 and the 
African spotted leopard73) to develop amyloid deposits with type 2 diabetes. In one study, 3 
of 9 cats with impaired glucose tolerance and a significantly reduced first phase of insulin 
secretion had islet amyloid deposition, whereas 6 of the 7 diabetic cats, with significantly 
decreased insulin release during the first 45 min of the IVGTT compared to healthy or 
glucose-intolerant cats, had islet amyloid. However, there was no association between the 
severity of islet dysfunction and amyloid deposition45,74 and in one study, 10% of healthy cats 
were reported to have amyloid deposits equal to more than 50% of the islet volume75 
indicating that the theory of amyloid deposition as a cause of progression to type 2 diabetes 
may not be valid. Also reported is that islet amyloid formation induces oxidative stress, 
which in the short term does not mediate beta cell apoptosis, but in the longer term may 
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feedback to further exacerbate amyloid formation and contribute to beta cell apoptosis76. 
Recently, studies have suggested that only the early stages of fibril assembly, and in 
particular small islet amyloid oligomers, are responsible for beta cell cytotoxicity77. 
 
The mechanisms which result in beta-cell failure are incompletely understood78. Originally, it 
was hypothesized that increased insulin secretion was associated with decreasing insulin 
sensitivity until it reached a point when beta-cells are unable to increase insulin production 
further79 and was referred to as beta-cell exhaustion. However, obesity independently can 
have this effect and obesity does not necessarily lead to diabetes.  
 
The accumulation of amyloid in beta-cell islets has been hypothesized to play a role in beta- 
cell failure13. This theory has been supported by reports that amyloid is present in type 2 
diabetes in both humans and cats14,80 and experimentally- induced diabetes results in amyloid 
accumulation in the islets15. Amyloid is an extracellular accumulation of proteinaceous 
substance (from the precursor amylin) which refolds forming beta-pleated sheets or fibrils in 
cats and humans but not in dogs, leading to loss of beta-cell mass. These fibrils are highly 
toxic to the beta- cells. However, this theory has also been rejected for several reasons 
including that amyloid accumulates not only in the beta-cells but also the alpha and gamma 
cells, however they seem to function normally81,82 and also that some individuals have 
amyloid accumulation but normal beta-cell function15,75,83. 
  
Amylin is a hormone and precursor of amyloid, but is produced (along with insulin) only by 
beta-cells and modulates insulin action70. There is progressive accumulation of folded beta 
pleated sheets of intracellular amylin fibrils within the beta-cells. The misfolded amylin 
oligomers form toxic intracellular fibrils in the endoplasmic reticulum, leading to 
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programmed cell death (apoptosis) when misfolded protein is detected8. Models of marked 
insulin resistance that lead to increased amylin secretion have been shown to increase 
amyloid deposition in cats15. As insulin and amylin are cosecreted, it is not clear why 
individuals with insulin resistance and hyperinsulinaemia and thus high amylin secretion do 
not always form toxic amylin oligomers. It has been reported that hyperamylinaemia may 
then lead to reduced insulin secretion and insulin resistance, and feline diabetes80,84. Of the 
numerous mechanisms resulting in beta-cell failure, islet amyloid deposition and toxic amylin 
oligomers may help explain species differences in the development of type 2 diabetes. 
 
Another theory for beta-cell failure is glucose toxicity, which has been defined as 
‘nonphysiological and potentially irreversible beta-cell damage caused by chronic exposure 
to supraphysiological glucose concentrations’85. In humans, it is postulated that glucose 
toxicity can cause progressive impairment in insulin secretion and possibly result in insulin 
resistance86. Cats are susceptible to glucose toxicity at high concentrations (2 days of a 
hyperglycaemic clamp (25 to 30 mmol/L)), which is thought to cause changes in the 
microenvironment of the endoplasmic reticulum and cause beta-cell death71,87-89. However, to 
have hyperglycaemia initially would require a pre-existing impaired insulin response or 
production, thus negating this theory as the sole cause of beta-cell failure. 
 
Another valid theory for beta-cell death is the effect of reactive oxygen species which are 
produced in the cell when there is excessive glucose and/or fatty acids90. Insulin normally 
controls glucose homeostasis by stimulating glucose uptake into peripheral tissues and 
suppresses the release of stored lipids from adipose tissue26,34. Insulin deficiency leads to 
dyslipidaemia, and dysfunctional metabolism of fatty acids, triglycerides and 
lipoproteins22,23,91. These chronic increases in circulating glucose and lipid levels can further 
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impair insulin secretion and action, and cause other forms of tissue damage6,34,90. This is also 
referred to as glucolipotoxicity, and is thought to cause beta-cell toxicity via increased 
electrochemical gradients across the mitochondrial membrane caused by oxidation of 
intracellular glucose and fatty acids92. Oxidative stress leads to beta-cell apoptosis. In diabetic 
humans, chronic hyperglycaemia leads to further production of reactive oxygen species and 
deterioration of beta-cell function, which increases circulating fatty acids and the severity of 
the type 2 diabetes93. This theory, however, does not explain why cats develop type 2 diabetes 
and dogs do not, unlike the fibrils of amylin theory. To date, literature on the relationship of 
reactive oxygen species and diabetes in cats is lacking. 
 
A further theory is the possibility of an autoimmune response causing the expression of 
inflammatory mediators such as cytokines and chemokines (for example TNF-αand IL-1) 
leading to an inflammatory cascade in response to a nutrient overload which could trigger 
beta-cell apoptosis94,95. These mechanisms leading to beta- cell destruction have not been 
studied in cats. 
 
Type 2 Prediabetes 
The development of overt diabetes is often preceded for months to years by a subclinical 
condition, prediabetes, which induces changes in target tissues. The terms impaired glucose 
tolerance (IGT) and impaired fasting glucose (IFG) refer to a stage intermediate between 
normal glucose homeostasis and diabetes, now referred to as prediabetes3,5. Patients with IGT 
and IFG do not fulfil the criteria for diagnosis of diabetes and usually return to reasonable 
glycaemic control with weight loss, dietary management, and exercise. Humans with fasting 
glucose levels ≥ 6.1 mmol/L but <7.0 mmol/L are considered to have IFG2. A variable but 
relatively high proportion (25–75%) of people with IGT at a first test will have a normal 
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response at the second16. Humans with prediabetes are at increased diabetic risk17,18,30,96. 
There is no literature on the progression of IFG and IGT in cats to clinical diabetes. However, 
cats in diabetic remission (n = 20) were more likely to relapse if: 1. the fasting blood glucose 
concentrations were ≥7.5 to 9.9 mmol/L or, 2. a blood glucose concentration at 5 hours after a 
IVGTT was more than 6.5 mmol/L, than cats with lower glucose values or shorter return to 
baseline. In this study, the unadjusted odds ratios (OR) for potential predictors of relapse by 
9 months after baseline testing in diabetic cats in remission were 12.8 and 15.2 mmol/L 
respectively)97.  
 
Insulin resistance is also present in most human and feline diabetic patients7,34,39,87,98.  Insulin 
levels increase to compensate for the resistance of muscle, fat, liver and pancreas to the 
effects of insulin8. A higher plasma insulin concentration is required to produce the same 
glucose uptake into tissues compared with when insulin sensitivity is normal40.  
Decompensation and absolute hypoinsulinaemia occurs well before the renal threshold for 
glucose is exceeded (16 mmol/L in cats)46.  
 
 Insulin resistance develops as a consequence of the effects of inflammatory and hormonal 
factors7, endoplasmic reticulum stress (by chronic exposure to excessive nutrients and 
dysfunctional protein kinases), and glucolipotoxicity induced by beta- cell dysfunction34,92.   
In both animals and humans, the triggering factor for transition from an obese, insulin-
resistant state to overt type 2 diabetes is beta-cell failure, which involves both a partial loss of 
beta-cell mass and a deterioration of beta-cell function8,19,99. However, obese and insulin-
resistant humans can remain in a state of beta-cell compensation, but later some individuals 
progress to beta cell failure and diabetes34.  Obese patients with fasting hyperglycaemia all 
have abnormal islet function8. Failure of the beta-cells to release insulin appropriately is a 
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common abnormality between human type 2 diabetes100 and feline diabetes101.  
 
Using the euglycaemic hyperinsulinaemic clamp- an accepted measure of insulin sensitivity102- 
obese cats have been shown to be markedly insulin resistant54,102,103. A 50% increase in body 
mass index led to a 60% decrease in insulin sensitivity and at basal insulin concentrations, there 
was a decreased ability to regulate glucose production by the liver103. Obesity also leads to 
changes in insulin secretion. While fasting blood glucose concentrations are still maintained 
within the normal range39, the insulin secretion pattern has already changed in obese cats 
compared with lean cats, there is loss of first phase insulin secretion followed by a large 
increase in second-phase release104. In some individuals, prolonged insulin resistance 
eventually leads to a decrease in the insulin secretory capacity15. 
 
One study in the U.K. screened 11,858 people through a survey sent to a census population, 
and used interview data and oral glucose tolerance testing. Based on the data, it was 
estimated that as many as 50% of people in the UK were undiagnosed diabetics105. Consistent 
with other studies, one-third to one-half of people in U.S. populations over 20 years of age 
with type 2 diabetes are undiagnosed and, hence, untreated11,25,105,106. 
  
Diet as a risk factor for feline diabetes 
Cats are obligate carnivores and their natural diet is protein-rich prey59,107. Cats have a 
reduced adaptation to managing a carbohydrate load including low glucokinase activity in the 
liver and muscle108,109 which limits their ability to metabolize large amounts of 
carbohydrate110. They also have a significantly higher protein requirement than other 
mammals and require the protein to be mainly from an animal source to supply essential 
amino acids111.  However, with domestication they have become more sedentary animals 
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eating a more energy dense diet, higher in carbohydrates59.  
 
Fat is an essential nutrient in a cat’s diet, however, a high fat diet (50% ME) can promote 
obesity112,113, increase insulin concentrations postprandially113, slow glucose clearance and a 
decrease acute insulin response114 and obesity is a major risk factor for feline diabetes46. 
It is frequently reported that obesity and type 2 diabetes can be influenced by a variety of 
factors which include diet and management, and it is clear that the interaction of the different 
nutrients has a confounding effect on many of the results reported46,85,107,112.  
 
The effects of carbohydrate, fat, and protein on glucose metabolism in healthy cats has been 
studied extensively115-120. However, due to the lack of standardization of nutrient content of 
the diets, the short timespan over which the studies were performed and the lack of 
standardization of the length of fasting prior to initial sampling it makes comparison results 
between studies difficult. For example, numerous studies reporting the effects of 
carbohydrate on blood glucose concentrations used diets containing carbohydrate ranging 
from <25% ME to > 50% ME115,121-124. Additionally, studies have shown that it can take over 
8 hours to reach the postprandial peak blood glucose concentration and 12 to 24 hours for 
blood glucose concentration to return to fasting levels after a single meal110,116,118,125. 
 
Persistent postprandial hyperglycaemia is detrimental to beta-cell function and it is the 
carbohydrate and not protein content of the diet which determines the postprandial glucose 
concentration123,126,127. Therefore, a low carbohydrate diet is likely beneficial to reduce 
postprandial hyperglycaemia and therefore decrease the risk of developing diabetes such as in 
cats with IFG or IGT54,123,128.  In fact, it has been reported that cats on a high carbohydrate 
diet, the mean postprandial blood glucose concentration over the entire 24-h period was 8-9 
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mmol/L117 and after moderate weight gain reached 13.4 mmol/L in some cats. 
 
Diets lower in carbohydrate and higher in protein are associated with a lower postprandial 
blood glucose and insulin concentration129-131. One study reported that cats on a high 
carbohydrate (51% ME) low protein (21%) diet had higher postprandial blood glucose and 
insulin concentrations compared to a low carbohydrate (23%) high protein (47%) diet but the 
low carbohydrate diet had higher fat content which promoted greater weight gain when fed 
ad libitum117. A recent study of 63 diabetic cats found that low carbohydrate (12% ME) and 
low fibre (0.1 g/100g as fed) diet was more likely to lead to remission than a moderate 
carbohydrate (26% ME) and high fibre diet (3.1 g/100g as fed)132.  
 
In one study, the energy density of dry food diets was not significantly associated with the 
development of diabetes mellitus, whereas both indoor confinement and low physical activity 
were in data from cats collected via a questionnaire (n=96 diabetic, n=192 matched 
controls)59. However, questionnaire data can be unreliable133. In overweight cats, source of 
dietary carbohydrate has been reported to have an effect on blood glucose concentration, 
insulin secretion and food intake124. A mixture of sorghum and corn was reported to lead to 
less glucose intolerance and insulin resistance than rice and may thus decrease the risk of 
diabetes124. However, the quantity of food eaten was not discussed.  
 
Diet for treatment of feline diabetes 
Dietary management is important in managing a cat at risk of developing diabetes. The aims 
should include to minimize stress on the beta-cells to produce insulin134, weight control40, and 
minimizing postprandial hyperglycaemia and fluctuations in blood glucose 
concentration124,135. Studies show that a diet high in protein (>40% ME) and very low in 
14 
 
carbohydrate (<15% ME) is the most effective to achieve the aims related to glucose and 
insulin homeostasis131,132,136. A high protein diet also helps maintain muscle mass during 
weight loss and assists in preventing hepatic lipidosis, normalizing insulin function and 
increasing metabolism120,134,137138 However, the high fat content of commercial high protein, 
low carbohydrate diets can promote weight gain because weight gain increases with 
increasing fat content113. Another study reported that diabetic cats (n=6) on twice daily 
glargine and fed a low carbohydrate (3.34g/ 100 kcal), high protein diet (13.88g/ 100 kcal), 
when compared with controls (n=6) showed no difference in the control of diabetes139. 
 
Diagnosis of diabetes in cats 
Clinical signs in some cats are subtle initially and progressive over months to years140. These 
cats may show none of the classic signs until progressive beta- cell failure impairs insulin 
secretion to the point that hyperglycaemia exceeds the renal threshold (16 mmol/L)140,143.  At 
this point, before the classic signs of polyuria, polydipsia, polyphagia, muscle wasting, 
neuropathy especially in the hindlimbs and weight loss are seen141, gastrointestinal signs such 
as vomiting may develop140. Diseases which are reported to occur concurrently at the time of 
diagnosis include hyperthyroidism, inflammatory bowel disease, eosinophilic granuloma 
complex, anaemia, neoplasia, and renal failure142, however what must be considered is that 
older cats are overrepresented, and they are also at higher risk of developing these diseases. 
 
A diagnosis of diabetes mellitus is made when the appropriate clinical signs are evident, 
along with a persistent hyperglycaemia which is typically above 16 mmol/L (the renal 
threshold in cats143) and glucosuria141. When these cats present at clinics, a thorough history, 
physical examination, complete blood count, serum biochemistry, and urinalysis should be 
measured40. Cats with clinical diabetes will need treatment with insulin and dietary and 
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weight management to control the disease and to increase the likelihood of diabetic 
remission139,144-146. 
 
In general, lithium heparinised plasma samples analysed by automated chemical analysers 
using either hexokinase or glucose oxidase methods are considered the gold standard for 
determining an animal’s venous blood glucose concentration 147,148. Upper limits for normal 
blood glucose concentration in cats cited in established texts range from 6.1 mmol/L 149 to 7.3 
mmol/L150,151. Idexx Laboratories, a major veterinary diagnostic laboratory, have a reference 
range of blood glucose of 3.2-7.5 mmol/L in healthy cats. This was established by analysis of 
patient data (filtered) from mid-1990 and rechecked against patient data (filtered) from 2006-
07 (Dr. John Mackie, personal communication). The 2006-07 analysis of 2,862 samples is 
potentially biased at the upper end because of the failure to rigorously exclude non-fasted or 
stressed cats. However, the upper limit is similar to those quoted in the literature.  
 
Stress hyperglycaemia is a complicating factor when interpreting blood glucose 
concentrations in cats152,153. Struggling scores and lactate concentrations were predictive of 
stress hyperglycaemia in a study of 20 healthy adult cats given a 5-minute spray bath. Blood 
glucose of individual cats increased from a baseline of 4.6 mmol/L to 10.8 mmol/L153. Stress 
hyperglycaemia persists for at least 90–120 minutes in healthy cats that have been restrained 
or exposed to other types of short-term stress153. In a 4-year retrospective study of 2278 sick 
cats at initial presentation at a veterinary hospital, 1388 cats (61%) had normal blood glucose 
concentrations, 827 cats (36%) were hyperglycaemic (blood glucose > 8 mmol/l) and, 63 cats 
(3%) were hypoglycaemic154. Blood glucose concentrations in cats with stress 
hyperglycaemia were between 8.1 and 60.4 mmol/l (median 10.3 mmol/L), and in cats with 
diabetes mellitus between 8.5 and 70.0 mmol/L (median 27.7mmol/L)154.  
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Diagnosis of prediabetes in cats 
There are no reports in the literature of a suitable non-stressful and relatively non-invasive 
screening test available for diagnosing prediabetes in client owned cats in a clinical 
environment. Diabetes in cats is usually only diagnosed once clinical signs are evident, ie. 
once the renal threshold of blood glucose has been reached46. These cats usually need insulin 
treatment61,155,156 which is stressful to both owner and cat. Studies have reported an increased 
postprandial blood glucose concentration for 12-19 hours with a diet containing 30-50% ME 
of carbohydrate in lean cats, 18 hours for obese cats and in some cases over 24 hours54,117,122, 
suggesting that cats should be fasted for at least 18 hours for any screening test which 
involves a fasting blood glucose concentration. A validated screening test for prediabetes in 
cats, as exists for human patients, is lacking and would improve diagnosis of prediabetes so 
that preventive health programs can be implemented before insulin-dependent diabetes 
ensues.  
 
Glucose tolerance tests 
Intravenous glucose tolerance testing has been used frequently as a research tool to measure 
glucose tolerance in cats, and reference intervals for parameters such as t ½ and area under 
the curve established 72,104,157. The classic test involves intravenous catheterization, and a 
bolus injection of glucose (usually 50% glucose infusion via an indwelling iv catheter) 
followed by 10 blood glucose measurements from an indwelling jugular catheter inserted 
under a general anaesthetic114,117,157. From a clinical perspective, these tests have been too 
labour intensive and invasive to be used as a routine screening method. A simplified glucose 
tolerance test was established158, where cats did not need to be anaesthetised for catheter 
placement before the test. Instead, 2 cephalic catheters were placed aseptically and the test 
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started after 3 hours. One catheter was used for the infusion of glucose and the other for 
blood sampling with a portable blood glucose monitor. Reference intervals for healthy cats 
were established for this methodology159. To date, there are no studies reporting the 
methodology and reference interval for a more simplified, potentially less stressful method 
for diagnosing feline prediabetes in a clinical setting. 
 
Portable glucose meters 
Portable blood glucose meters are commonly used in veterinary medicine for quick and 
convenient measurement of blood glucose concentration148,160-162. They use only a small 
amount of blood and require minimal restraint148. Two methods are commonly used by 
PBGM for measuring blood glucose concentration: reflectance photometric systems and 
amperometric biosensor systems163. 
 
 
The significant benefit of portable blood glucose meters is their ability to be used by owners 
for home monitoring 160,163-165. When investigating the feasibility of home-monitoring of 
blood glucose in diabetic cats by owners166, it was reported that the majority of problems with 
respect to restraint and obtaining an adequate blood sample were resolved during the study.  
 
There have been numerous studies of human portable blood glucose monitors to deem them 
acceptable when used with cats including comparison to the ‘gold standard’ hexokinase 
reference method 148,160,167,168. Abbott Animal Health (now owned by Zoetis inc., U.S.A.) 
introduced a new PBGM that has been calibrated for use in cats and dogs. The AlphaTRAK 
needs only a minute (0.3 uL) blood sample in comparison to most other PBGMs on the 
market. The glucometer was validated by comparing the performance of the AlphaTRAK and 
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the Ascensia ELITE® (Bayer HealthCare, Zurich, Switzerland) which was developed for 
humans160. At low blood glucose concentrations, the AlphaTRAK (Zoetis) tended to 
underestimate true concentrations, whereas other PBGMs arbitrarily under- or overestimated 
true values, which can be considered a disadvantage163. 
 
Capillary sampling 
Capillary blood sampling is a useful method of obtaining a drop of blood for analysis by 
PBGMs. The marginal ear vein technique has been successfully used in cats163 and can be 
used by owners for home monitoring166, unlike venepuncture which involves more restraint 
and stress169. The protocols can vary, but most methods involve warming the pinna, using a 
lancing device to form a blood droplet and contacting the strip of the glucose meter with the 
droplet to perform the analysis169. A similar method can be used on the pad of the paw.  
 
Venous and capillary blood samples were studied from 33 dogs, males and females, of 
different breeds, weights and ages161. The results with the different types of blood were 
statistically not different, which implies that that venous and capillary samples can be used 
interchangeably. Blood glucose concentrations measured with a PBGM using blood samples 
obtained from a marginal ear vein nick technique, from a peripheral venous catheter, and 
from direct venipuncture were compared in 10 healthy and 11 diabetic cats170 and considered 
the marginal ear vein nick technique a reasonable alternative to venous blood collection when 
taking serial measurement of blood glucose concentrations in cats.  
 
The suitability of the microlet vaculance lancing device and a PBGM for use by pet owners in 
cats and dogs were evaluated171. It was reported that all dog owners (n=7) and three cat 
owners (n=7) were able to perform a reliable blood glucose curve of 6 blood glucose 
19 
 
measurements. The most frequently encountered problems were inadequate formation of a 
blood drop due to excessive digital pressure on the pinna, repeatedly depressing the plunger 
of the lancet device instead of allowing the negative pressure to slowly build up, and failure 
to fill the test strip adequately with blood. The authors concluded that these steps of the 
procedure need to be clearly explained and demonstrated to owners and that home monitoring 
of blood glucose concentrations is good alternative to hospitalisation. Abbott Animal Health 
(now part of Zoetis) has developed a lancing device which is suitable for use in cats and dogs. 
It does not cause a vacuum but does reliably produce a blood droplet large enough (>0.3 µL) 
for the AlphaTRAK PBGM. 
 
Other indicators of abnormal glucose metabolism, insulin resistance, obesity, and 
diabetes  
Fructosamine 
Fructosamine (also known as glycated plasma proteins) is formed by the glycosylation of 
plasma proteins and its concentration is dependent on the mean blood glucose concentration 
in the 10 to 15 days preceding sampling172. It has been used as a measure of long term 
glycaemic control in cats173,174 and its differentiation from transient stress hyperglycaemia175. 
Body weight is positively correlated with serum fructosamine concentration, and lean cats 
have lower concentrations than obese cats176.  Fructosamine was reported to be a very 
sensitive (92%) and specific (96%) in differentiating non-diabetic from diabetic cats177. 
However, in cats with moderate hyperglycaemia (17 mmol/L), fructosamine concentration 
mostly fluctuated under the upper limit of the reference range (95% reference interval 154-
331 µmol/L) during a 42-day glucose infusion. Additionally, the range of fructosamine 
concentrations associated with a given glucose concentration was wide, with the critical 
difference for fructosamine being 33 µmol/l178. Differences in serial measurements of less 
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than 33 µmol/l may not be indicative of fluctuations in blood glucose measurements. 
Fructosamine is not suitable to use as a screening test for prediabetes in cats where blood 
glucose concentrations of 6.5 to 16 mmol/L are expected.  
 
Insulin sensitivity 
The HEC and MinMod techniques have been used to estimate insulin sensitivity in cats102,157. 
The HEC involves the infusion of insulin at a constant rate and glucose is infused to maintain 
blood glucose at the baseline value. The Min Mod requires 31 blood samples and a 
specialized computer program to calculate the insulin sensitivity index. Thus, neither of these 
techniques are practical in a clinical environment. The most useful predictors of insulin 
sensitivity in cats were basal plasma insulin concentrations after food was withheld for 12 
hours and the HOMA, which is the product of basal glucose and insulin concentrations 
divided by 22.5179. Insulin sensitivity and glucose tolerance test were performed on 16 cats 
which were fed ad libitum for 9-12 months to gain weight before and after weight gain54. The 
findings of this study included an increased risk of developing impaired glucose tolerance in 
cats with high basal insulin concentrations, suggesting that some cats have an underlying 
predisposition to develop glucose intolerance as a result of intrinsic insulin resistance. It was 
suggested that if these cats became obese they were at higher risk of developing clinical 
diabetes. Through early detection of insulin resistance, early intervention programs could be 
introduced to aid in preventing impaired glucose tolerance and clinical diabetes. Insulin, 
however, cannot be measured quickly as a screening test in a clinic environment and is not 
routinely measured in veterinary laboratories, although five radioimmunoassay kits designed 
to measure human insulin concentrations were tested on feline insulin180 and more recently, 
new ELISA test kits have now become available and have been validated for feline blood by 
the Morinaga Institute of Biological Science, Kanagawa, Japan and Mercodia AB, Uppsala, 
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Sweden. None of the tested kits is available anymore. 
 
Feline pancreatic lipase 
Measurement of serum fPLi has been proposed as a sensitive and specific test for the 
detection of pancreatitis in cats181. It has been hypothesised that pancreatitis induces death of 
pancreatic beta-cells, which could lead to the development of clinical diabetes46, but this has 
not yet been substantiated in cats and it is unknown whether pancreatitis in cats is the trigger 
or the result of diabetes61,181-183.  
 
Triglycerides 
Many (28%) Australian Burmese cats exhibit marked post-prandial hypertriglyceridaemia 4 
and 6 hours after an oral fat tolerance test compared to the control cats (median 4-h 
triglyceride 2.8 mmol/L and 1.5 mmol/L for Burmese and control respectively, median 6-h 
triglyceride 8.2 mmol/L and 1.0 mmol/L for Burmese and control respectively). However, 
they did not have significantly different fasting insulin, fructosamine, NEFA, or lipoprotein 
concentrations 184,185. Burmese cats are also at increased risk of developing lipid aqueous, 
which includes an underlying disorder of lipid metabolism that results in increased serum 
triglyceride concentrations185. It is unknown whether this is related to Burmese being 3-4 
times more likely to develop diabetes than other breeds of cats62. However, fatty acids have 
been reported to be toxic to beta-cells186 which could increase the likely progression to 
clinical diabetes. Obesity and type 2 diabetes in cats is associated with hypertriglyceridaemia, 
insulin resistance, an overproduction of VLDL in the liver187, and decreased adiponectin, thus 
leading to a decrease in its insulin-sensitizing function188,189. There are no studies to date that 
compare baseline triglycerides in Burmese cats and other cats at risk of developing diabetes 
to other measures of glucose tolerance. 
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Adipokines 
Adipokines are biologically active proteins originating from adipose tissue that have local 
and systemic effects190. The relationship between obesity and adipokines as markers of 
inflammation has been studied extensively in humans191,192, dogs193, and cats194-197. 
 
Leptin 
Leptin is the best characterized adipokine in domestic animal species190. The main 
physiologic role of leptin is to regulate body fat mass through modulating energy intake and 
energy metabolism197. Appetite suppression occurs via binding to receptors in the 
hypothalamic satiety centres. Adipocytes are the main site of leptin synthesis and the main 
contributor to serum leptin concentrations, which increase with obesity120,198,199. Other tissues 
such as liver, gastric mucosa, mammary glands and placenta may also secrete leptin190. 
Serum concentration is predominantly defined by body fat mass, but transiently increases 
with a meal and decreases with fasting. In cats, this postprandial increase was only seen in 
cats after weight gain and not in lean cats125. In humans, leptin has been reported to have a 
direct anti-diabetic effect through triglyceride depletion200. In humans, the association of 
leptin with body composition and type 2 diabetes were studied and it was reported that fat 
mass rather than insulin resistance has a more significant influence on leptin fluctuations201. 
In cats, despite high concentrations of leptin, overweight and obese cats continue to gain 
weight and appear to be less sensitive to the appetite suppressing action of leptin compared 
with cats of ideal body condition score, suggesting leptin resistance198,199. Regardless of fat 
mass, insulin-resistant cats have higher circulating leptin concentrations compared with 
insulin sensitive cats, suggesting that hyperinsulinaemia associated with insulin resistance 
itself may stimulate leptin production198. An ELISA test for leptin has been validated for use 
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in cats202. 
 
Adiponectin 
Adiponectin is thought to be produced almost exclusively by mature adipocytes190. 
Adiponectin has been investigated widely due to its association with adiposity and the 
metabolic syndrome in humans192,203,204. It directly sensitizes the body to insulin by 
increasing fatty acid oxidation and decreases triglyceride content in the liver and other 
tissues194. Unlike other adipokines, adiponectin is decreased with obesity and is a contributor 
to the insulin resistance of obesity in humans189. Plasma adiponectin in obese cats is 
significantly lower than in lean controls, and may also be associated with insulin function in 
cats194,205,206. In the circulation, adiponectin may form trimers, hexamers or high molecular 
weight multimers. The high molecular weight multimers have the most biological activity 
and are best correlated with insulin sensitivity in cats207. Increases in fat mass result in 
decreased circulating adiponectin, whereas weight loss results in increased adiponectin 
concentrations120. In the liver, adiponectin improves insulin sensitivity while reducing 
triglyceride content and gluconeogenesis189,195,197. In one study of 104 lean, overweight and 
obese dogs, it was reported that plasma leptin concentrations after a 24-h fast were associated 
with obesity-associated changes in insulin sensitivity measured by HOMA and compensatory 
hyperinsulinaemia in obese dogs, but adiponectin did not appear to be involved208. In cats, 
adiponectin expression was demonstrated in fat pads and expression was significantly greater 
in visceral compared to subcutaneous depots206. In cats, associations with diet composition 
have been reported207,209. Cats were randomly allocated either a low carbohydrate (19% ME; 
n=15) and a high carbohydrate (52% ME; n=16) diet and it was reported that a high 
carbohydrate diet fed at maintenance energy requirements was associated with higher fasting, 
but not postprandial concentrations of HMW adiponectin. 
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Monocyte chemoattractant protein-1 (MCP-1) 
Circulating MCP-1 is significantly increased in patients with type 2 diabetes210-215. An 
inflammatory adipokine, MCP-1 is produced by monocytes and adipocytes and increases in 
concentration with obesity in humans195 and dogs216. A positive relationship between plasma 
levels of MCP-1 and HOMA scores has been identified in baboons217 and in overweight and 
obese humans who are prone to having low insulin sensitivity218. An increase in MCP-1 
expression in adipose tissue in mice contributes to the macrophage infiltration into adipose 
tissue. It also impairs insulin-stimulated glucose uptake in adipocytes, resulting in insulin 
resistance219, and hepatic steatosis associated with obesity in mice220. MCP-1 protein 
expression was higher in omental fat than in subcutaneous fat in severely obese patients, and 
was associated with increased macrophage infiltration into omental fat221. Similar 
relationships have not been reported in cats. However, the expression of MCP-1 was 
quantified in isolated islets of healthy cats using feline-specific real-time PCR primers nested 
within the mRNA sequences222 and MCP-1 mRNA was detected in subcutaneous and visceral 
fat but not in skeletal muscle in cats223. 
 
Section 2: Metabolomics 
Definitions  
Metabolomics has been defined as the measurement of a comprehensive set of metabolites, 
excluding enzymes, structural molecules, and genetic material, in a body fluid or tissue 
extract using a global approach, meaning that all the metabolites are measured 
simultaneously224-226. The metabolites which are measured include carbohydrates, lipids, 
peptides, and some proteins. The aim of metabolomics, using high-throughput sample 
analysis and software pattern recognition processes is to define a metabolic phenotype 
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(metabotype) in the study species226 that could determine the full metabolite profile 
(metabolome) of a cell, tissue, or organism227. 
 
Metabolomics has numerous advantages over genomics, transcriptomics, proteomics101. 
Firstly, the number of molecules is smaller (n= 6500), compared to genes (n=25000), 
transcripts (n=100000) and proteins (n=100000)228. Secondly, metabolites provide a more 
‘whole system’ profile of biological status, measuring chemical phenotypes that are the net 
result of the other ‘omic’ variabilities. Thirdly, metabolomics is a powerful investigative tool 
that provides information on drug therapy outcomes228.  
 
Alterations in the metabolic profile often present much earlier in the course of disease than 
induced histopathological changes229,230. Metabolomics can therefore be used as a sensitive, 
early indicator of a disease process. Unlike many genes and proteins, metabolites are 
conserved across species lines. Therefore, screening patterns can be applied to a wide range 
of species and so the detection methods and equipment used in one organism can easily be 
applied to another without the need for recalibration224,226. This versatility means that 
metabolomics-based approaches can be applied to studies in a wide variety of disciplines226. 
Other advantages of studying metabolites include cost-effectiveness and rapid measurements. 
These features enable large numbers of samples to be processed quickly, thereby providing a 
high-throughput analytical tool.  
 
Type 2 diabetes, obesity, and metabolic syndrome are all disorders involving multiple organ 
systems and to interpret the biochemical changes that occur in one organ it is necessary to 
understand how these interact in the entire body system. In this respect, by sampling a tissue/ 
blood or urine for multiple markers of a disease state, it is possible to monitor changes at the 
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whole animal level231.  
 
Diagnostic applications 
Metabolomics can be either targeted (where metabolites are identified and exact 
concentrations measured), or non-targeted (where two biological states are compared by 
simultaneously measuring as many metabolites as possible in a biological specimen), often 
referred to as the global approach231.  
 
Non-targeted metabolomics technologies have the potential for providing novel biomarkers 
of disease and drug efficacy, and are increasingly being incorporated into biomarker 
exploration studies232. Biomarkers have been defined as ‘a characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes of pharmacological 
responses to therapeutic intervention’233. The aim is to find a metabolite or groups of 
metabolites most representative of the condition evaluated224; multiple markers may be of 
greater diagnostic value than single ones234. For example, using pattern recognition 
methods235,236, biomarkers for neurodegeneration associated with Alzheimer disease have 
been studied to improve the clinical diagnosis from 10-15%237, to assess disease severity and 
in the future, commence treatment when it is most effective in the early stages of the 
disease238. Mass spectrometry has been used to identify biomarkers for women’s cancers 
(breast, ovarian and cervical) in urine239, capillary gas chromatography–mass spectrometry 
for biomarkers in lung cancer240, NMR for prostatic cancer in prostatic fluid and tissues in 
humans241. Numerous other studies report the identification of potential biomarkers in 
cardiovascular disease in humans242-244 and dogs234, predictive biomarkers of liver 
dysfunction in humans when patients are deprived of choline245 and fatty liver disease246, and 
toxicity studies such as with herbicides in rats247. 
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The three criteria for an ideal biomarker (or -markers) for cardiovascular disease in humans 
has been discussed248 but are applicable to any disease in human or veterinary medicine: 1. 
Can the clinician measure it (ie. following biomarker discovery, a targeted approach is 
necessary)? 2. Does it add new information (ie. the need for external validation)? and 3. Does 
it help the clinician to manage the patients (ie. early detection of subclinical disease, 
assessment of risk, early treatment of disease and monitoring of therapeutic success)? 
Novel biomarkers that better reflect insulin resistance and/or beta-cell function may help 
identify patients who are, more or less, likely to respond to the various current, as well as 
future anti-diabetic pharmaceutical products.   A targeted approach where a number of 
predefined metabolites are measured would allow for monitoring treatment success and 
disease progression249,250. 
 
Technologies used 
Sample Preparation and metabolite extraction 
Sample preparation is a crucial step in any metabolomics assay to ensure preservation of the 
molecules studied230. This is dependent on the type of sample being used (tissue, cell or 
fluid), the degree of fractionation necessary, where the sample is gel based or free and 
whether mass spectrometry, needing filtration, will be applied230. For example, mouse liver 
samples for GC x GC-MS analysis were freeze-dried overnight and homogenized249 and 
solid-phase microextraction240 was used for studying lung cancers and other volatile disease 
markers in blood.  The methanol–chloroform technique enables extraction of both aqueous 
metabolites and lipids simultaneously to allow, for example, numerous brain pathologies in 
which both aqueous metabolite and lipid changes occur to be studied simultaneously251. 
Using muscle and liver tissues from fish, homogenous tissues were extracted using perchloric 
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acid, acetonitrile/water, methanol/water, and methanol/chloroform/water. It was stated that 
single organic solvent extractions are quick and easy and produce reasonable results but they 
concluded that the methanol/chloroform/water extraction is the preferred method252 due to its 
superior results with both hydrophilic hydrophobic metabolites.  
 
Chemical Analysis via platforms 
Metabolomics can be performed using individual biochemical assays based on enzymatic 
reactions, but the cost and time involved would make it impractical to be used routinely. 
Griffin and colleagues state that ‘metabolomics offers a conceptual leap forward in measuring 
as many metabolites as possible in one assay’231. However, no single analytical approach is 
sufficient to cover the whole metabolome226, because of the wide range of concentrations, 
masses and polarities. Thus, a combination of analytical platforms is often used. 
 
Nuclear magnetic resonance 253, mass spectrometry 254, the latter often in combination with 
either gas or liquid chromatography are the technologies used255. Nuclear magnetic resonance 
has been the main technique used in metabolomics and involves the application of strong 
magnetic resonance fields and radio-frequency pulses to the nuclei of atoms232 which change 
from a low energy to high energy state and the radiation emitted once they relax back to the 
low energy state is detected226.  Little or no sample preparation is required for NMR251,256, is 
rapid and provides highly reproducible results (CV 1-2%) with up to 200 samples measured 
within a day229. Since NMR spectroscopy is a very reproducible technique it is well suited as 
a diagnostic tool in a clinical setting238,241,252,253,257-.  A disadvantage, however, is that NMR 
lacks the sensitivity of MS258.  
 
Mass spectrometry involves firstly ionization of the metabolite and then separation of the 
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ions using an electromagnetic field255. It provides high sensitivity but lacks reproducibility 
229. When used for screening the metabolome therefore not readily applicable in clinical 
analysis. However, MS offers possibilities for developing robust methods for quantifying 
metabolites in a biomarker profile256,259. Mass spectrometry is usually combined for better 
analytical separation of the metabolites. The two MS and NMR methods used in parallel 
complement each other to ensure better biomarker identification and validation260. For 
example, combining LC and NMR does increase sensitivity but still is unlikely to reach the 
levels provided by MS. 
 
Gas chromatography coupled to mass spectrometry is a highly suitable technique for 
metabolomics analyses due to the high separation power, reproducible retention times, 
sensitive, selective-mass detection, and established databases. After isolating a sample, 
derivatives are prepared then gas chromatography is used for separations and mass 
spectrometry for identification226,261. It is often considered the ‘gold standard’ in 
metabolomics226,262,263. Many of the metabolites detected by GC-MS are involved in amino 
acid metabolism263, the Krebs cycle100, glycolysis263 and beta-oxidation231. Disadvantages 
include the increased processing and analysis time needed per sample and the fact that 
structural isomers are sometimes difficult to differentiate254. 
 
A new two-dimensional technique has been reported, GC x GC–MS, has higher 
chromatographic separation power, a broader dynamic range and lower detection limits than 
GC-MS, and it was suggested that it be the preferred technique for metabolomics analysis. 
However, quantification of metabolites in samples using GC x GC–MS is a challenge249. 
 
In drug development studies LC-MS shows great promise, is more sensitive than NMR, and 
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has the added advantage over GC-MS in that sample volatility is not needed264. It is thus 
potentially a universal technique226,265,266. However, because several different ionization 
techniques are in use spectral libraries are not as available and there is poor reproducibility of 
results226. 
 
Interpretation: pattern recognition and data processing 
Scaling and pre-processing can vary results significantly256. In metabolomics experiments, 
the biological variation of interest is inevitably confounded with unwanted variation, often 
due to both the unwanted experimental and unwanted biological variability (confounding 
factors) which may be difficult to quantify and differentiate from the wanted variation (ie. the 
biological factors of interest being studied)267. The ﬁrst step involves identifying overall 
sources of variation and the second step involves normalizing (either removing the overall 
unwanted variation component or accommodating it in an appropriate statistical model). The 
third step involves assessing the normalizing method. 
 
Regardless of method chosen, both statistical and biological variations are critical for 
accurate analysis of data256. Commonly used approaches to handling unwanted variation 
include: 
1. Scaling factors, which assign an appropriate weight to each sample attempting to 
make them comparable267-269. The disadvantage is that when one group of metabolites 
is increased in abundances then this method automatically decreases other groups of 
metabolites. 
2. Use of quality control samples, which are composed of identical amounts of 
metabolites which are supposedly representative of those of the biological 
samples267,270. However, there may be preparation issues in large scale studies and 
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cannot remove unwanted biological variability. 
3. Use of internal standards: these are known metabolites added to the sample before 
extraction267. In single internal standard, the log metabolite abundance of a single 
internal standard is subtracted from the log abundances of the metabolites in each 
sample. This can lead to highly variable normalized values, which depend on the 
compound that is used as the internal standard271. In multiple internal standards, two 
methods are commonly used. Average internal standard, involves subtracting the 
average of the multiple internal standards from the log abundances of the metabolites 
individually. Normalization using optimal selection of multiple internal standards268 
selecting the optimal combination of multiple internal standards using multiple linear 
regression.  
4. Use of quality control metabolites involves using metabolites in the biological 
samples which are unassociated with the wanted variation (factors of interest)268, 
allowing the unwanted variation to be accommodated. 
 
Statistical analysis of metabolomic data 
Visualization of the wanted and unwanted variation 
One of the main aims of metabolomics research is classifying groups of individuals based on 
their metabolic profile272. Metabolomics involves analysing a large number of biological 
samples and extremely complex datasets, often with considerable overlaps. Thus, univariate 
statistics such as Student’s t- test are impractical due to the sheer volume of data and the 
inability to correlate numerous variables at once226. Multivariate methods are invariably 
always used in metabolomics analyses because one biomarker is usually not sufficiently 
specific for a condition and all variables in a dataset can be considered simultaneously226. 
These multivariate statistical techniques are categorized as either unsupervised (where values 
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are assessed without knowing the class into which the metabolites belong) or supervised (i.e., 
control and diseased animals, where there is prior knowledge of class membership). The 
latter allows maximal separation of groups studied but care must be taken not to ‘overfit’ the 
data. To avoid this, cross-validation with supervised methods is always recommended226,256. 
A combination of multivariate statistics and targeted univariate techniques are likely to yield 
the best results226 for pattern recognition273. 
 
Relative log abundance plots are often used as the first step in visualizing metabolomics 
data271. The median of each metabolite in the data matrix within (for within group RLA plot) 
or across (for across group RLA plot) the factors of interest are computed and then the 
median subtracted from each metabolite. Box plots of this centred data matrix are presented 
as the RLA plots. Within group RLA plots should have a median close to zero and low 
variation around the median which is used to assess the tightness of the replicates274. 
 
A volcano plot is a type of scatter-plot that is used to quickly identify changes in large data 
sets composed of replicate data267 by plotting the negative log of the P-value on the y 
axis (usually base 10). This results in data points with low P-values appearing toward the top 
of the plot. Volcano plots can be used as a means of visualizing differentially abundant 
metabolites which deviate markedly from the rest274. 
 
Principal component analysis is a statistical procedure that uses an orthogonal 
transformation to convert a set of observations of possibly correlated variables into a set of 
values of linearly uncorrelated variables called principal components or clusters within 
multivariate data275-277. It gives an overview of the dataset, ie. does it contain groups, are 
there any outliers and can a single calibration model be fitted or are separate models required. 
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PCA can be performed on sample subgroups or across the whole dataset. The former allow 
easier detection of outliers and time trends and the latter whether there are any undesirable 
qualities in the data275,278. 
 
Another group of multivariate techniques which have been used to visualize the biological 
factors of interest and also the factors of unwanted variation is hierarchical cluster analysis 
279, which is used to sequentially pair variables, clusters, or variables and clusters to build 
a hierarchy of clusters. The clusters and unclustered variables are tried in all possible pairs, 
and the pair producing the highest average inter-correlation within the trial cluster is chosen 
as the new cluster280.  
 
The orthogonal signal correction method is a technique used for pre-processing in various 
analytical platforms including NIR-spectra used in NMR before they are subjected to a 
multivariate calibration281. The method filters the data to allow pattern recognition without 
loss of the measured response variable (factors of interest), while eliminating unwanted 
variation. Results of a study comparing OSC with other processing methods as well as no 
pre-processing and reported that OSC gave substantial improvements to the results showed 
that OSC is the only effective method for correcting excessive background272. They 
suggested that on this basis, OSC is likely to find widespread application in pattern 
recognition for high-information-density data sets such as metabolomics. 
 
Once the data is pre-processed classification of the biomarkers is made using linear methods, 
which use loading values such as PLS (partial least squares regression) or OPLS (orthogonal 
projections to latent structures). A multivariate classification method, PLS-DA, based on 
PLS, the regression extension of PCA282 shows maximum separation between the identified 
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subgroups in the data and once calculated and validated can be used to predict into which 
class metabolites fit. Whilst it has been reported that PLS-DA overfits the data and stringent 
validation is necessary282, it has been successfully used in numerous studies, including 
identifying markers for coronary heart disease in humans using the NMR platform2242 and 
comparing the changes in the metabolome of urine in rats, mice and humans with type 2 
diabetes283. Orthogonal projections to latent structures, whereby OSC is performed prior to 
PLS, has the benefit of reduced unwanted variation. The results indicate that the OPLS-DA 
has a good capability for the classiﬁcation of the prediabetic state and/or diabetic status284 in 
ddY mice. Based on the above, the best method(s) to be adopted to study metabolomics in 
healthy and obese cats should include supervised multivariate analysis along with pattern 
recognition via RLA, PCA, and volcano plots along with cross validation. 
 
Metabolomic studies in obesity and diabetes 
A very prolific area of research in metabolomics is the field of obesity285-287, insulin 
resistance284,288-290 and type 2 diabetes255,291-293. In diabetes and obesity research, the non-
targeted approach has provided the opportunity to assess large human populations or 
investigate a range of different tissues in animal studies both rapidly and cheaply.  Numerous 
metabolites have been identified as novel biomarkers for insulin resistance and type 2 
diabetes in humans.  
 
Several studies on the metabolomics of type 2 diabetes have been performed in vivo using 
mice. The db/db mouse has a single-gene autosomal recessive defect in the leptin receptor 
gene283. The db/db mouse produces clinical signs of leptin resistance, hyperphagia, obesity, 
and subsequent insulin resistance. The obese Zucker (fa/fa) rat also has a single-gene 
autosomal recessive mutation in the leptin receptor, causing clinical signs of leptin resistance, 
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obesity, hyperlipidaemia, hyperinsulinaemia, and, post-6 weeks of age, fasting 
hyperglycaemia and type 2 diabetes. Metabolomic studies were performed on samples from 
diabetic mice (ddY-H) and normal mice (ddY-L) were globally separated by ultra-
performance liquid chromatography (UPLC) and detected by electrospray ionization time-of-
flight mass spectrometry (ESI-TOF-MS). Biomarker candidates related to diabetes mellitus 
were extracted from a multivariate statistical analysis294. N-acetyl-L-leucine, an endogenous 
compound, was found in all biological specimens (plasma, hair, liver and kidney) and was 
therefore identified as a potential candidate biomarker related to diabetes. In another study, 
NMR was used to detect metabolomics in urine samples highlighted at least 24 distinct 
pathways that distinguish diabetic and control mice232. The pathways most affected were 
amino acid degradation (threonine, valine, lysine, leucine, isoleucine, glycine, tyrosine, 
tryptophan), amino group metabolism (creatinine synthesis and degradation) and the urea 
cycle (glutamate metabolism and the ornithine pathway). A set of mouse liver samples to 
study the development and progression of insulin resistance249. Using both GC–MS and GC x 
GC–MS, a total of 170 and 691 peaks, respectively, were quantified and preserved and 
several extra candidate biomarkers for insulin resistance were found. 
 
Multivariate statistical analyses of proton NMR data from human, Zucker rat, and db mouse 
urine demonstrate metabolic similarities among the three species involving glucose 
metabolism, the Krebs cycle and the nucleotide and methylamine metabolism295. It was 
speculated that this could provide markers not only for detecting diabetes in humans, but also 
for following its progression, although another study suggested that this was over-
claiming256.  
 
Numerous studies have identified the metabolite profiles of diabetes in humans. 
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Investigations on whether metabolite profiles could predict the development of diabetes have 
been reported296. Five branched-chain and aromatic amino acids had highly significant 
associations with future diabetes: isoleucine, leucine, valine, tyrosine and phenylalanine. A 
combination of three amino acids predicted future diabetes. These findings underscore the 
potential key role of amino acid metabolism early in the pathogenesis of diabetes and suggest 
that amino acid profiles could aid in diabetes risk assessment296. Numerous other studies have 
supported the finding of amino acids as potential markers of type 2 diabetes in humans297-300.  
Increased bone resorption and consequent possible risk of fractures has been reported in 
diabetic patients by measuring increased urinary excretion of hydroxyproline and that this is 
related to alterations in renal function301. No such evidence has been reported in cats and to 
the authors’ knowledge no data is available on increases in hydroxyproline in the urine of 
diabetic cats.  
 
Metabolic profiling using GC-MS via multivariate methods was applied to a small pilot study 
of samples from patients with impaired fasting glucose263. The results showed that the 
metabolomic patterns of the two groups were different and the linear combination of eleven 
discriminators: lactate, 2-ketoisocaproic acid, alanine, alpha-hydroxyisobutyric acid, urea, 
phosphoric acid, alpha-glycerophosphoric acid, palmitic acid, stearic acid, 1-monopalmitin 
and 1-monostearin, may be considered as the potential biomarkers of impaired fasting 
glucose. Plasma and urine of 51 non-diabetic humans fasted overnight was investigated 
aiming to separate subjects with IGT from controls, to investigate prediabetes302and identified 
prediabetes associated alterations in fatty acid-, tryptophan-, uric acid-, bile acid-, and 
lysophosphatidylcholine- metabolism, as well as the TCA cycle. Studies of 40 individuals 
with self-reported diabetes and 60 controls (males, over 54 years of age) reported 
perturbations of metabolic pathways linked to kidney dysfunction (3‐indoxyl sulfate), lipid 
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metabolism (glycerophospholipids, free fatty acids), and interaction with the gut microflora 
(bile acids)303. The study suggests that metabolic markers hold the potential to detect 
diabetes‐related sub‐clinical conditions in the general population. Studies of 263 non-obese 
Asian-Indian and Chinese men demonstrated that alterations in amino acid homeostasis, but 
not inflammatory markers or free fatty acids, are associated with insulin resistance in lean 
humans297. Numerous other studies support aberrations in lipid metabolism in prediabetes 
and265,287 and type 2 diabetes in humans263,287,304,305. 
 
The biomarker alpha- hydroxybutyrate (alpha-HB) has been studied using ultra high 
performance liquid chromatography-mass spectrometry and GC-MS306. A non-targeted 
(global) approach was conducted in 399 non-diabetic subjects, representing a broad spectrum 
of insulin sensitivity and glucose tolerance (based on the hyperinsulinaemic euglycaemic 
clamp and oral glucose tolerance testing, respectively). Alpha–HB was identified as a 
biomarker identifying clamp-derived insulin resistance in subjects with normal glucose 
tolerance and correlated with IFG and IGT independently of, and in addition to, insulin 
resistance. Importantly, these associations were independent of sex, age, and BMI. Thus, 
together with other biomarkers, alpha–HB may provide a diagnostic tool to identify insulin 
resistance and/or IGT earlier than currently used clinical tests306. 
 
Oral glucose tolerance tests have been used in humans to identify glucose intolerance and 
prediabetes10.  Numerous studies using this technique have been performed to better 
understand the effect of simulated hyperglycaemia in both rats and man. For example, the 
oral glucose tolerance test effect in healthy and diabetic rats and the metabolic changes in 
tissues of rats fed with high-fructose diet was studied using mass spectrometry based 
metabolomics278. Several differentiating metabolites were identified involving amino acid 
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biosynthesis, polyunsaturated fatty acids, phospholipids and purine metabolism.  
 
 In humans, a study identified the metabolic pattern in plasma during an oGTT in healthy 
subjects266. Free fatty acids, acylcarnitines, bile acids, and lysophosphatidylcholines were 
detected as the most discriminating oGTT biomarkers. Fatty acid levels were also found to be 
strongly decreased during the oGTT in humans using chromatography/mass spectrometry-
based metabolomics307. 
 
Glyoxylic acid (glyoxylate) was found to be increased in humans at risk of developing 
diabetes mellitus when metabolite profiling was performed on a total of 177 healthy subjects, 
121 prediabetic subjects, 30 diabetic subjects diagnosed by fasting blood glucose 
concentrations and 28 diabetic subjects diagnosed by impaired glucose tolerance.  A new 
metabolic footprint, consisting of glyoxylate and a panel of metabolites known to be 
associated with diabetes and its complications, was found to be significantly altered in plasma 
samples of non-fasted subjects228. When prediabetic subjects were compared to controls, 
glyoxylate was significantly increased in subjects primarily classified by IFG as well as in 
those primarily classified by IGT. The relationship between glyoxylic acid and type 2 
diabetes has been supported by other studies285,308. 
 
The application of metabolomics in veterinary medicine is still in the early stages but the 
potential is vast224. A recent report of the metabolomic changes associated with weight gain 
in dogs, suggest there are increases in pyruvate and mannose, some long chain fatty acids and 
lysophospholipids, homocysteine, cysteine, cystine and decreases in citrate α- ketoglutarate 
and anhydrogluticol309. Additionally, the effect of dietary macronutrients on the feline plasma 
metabolome was studied using LC and GC-MS260. It was reported that cats fed high protein 
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(50% ME), high fat (50% ME) and high carbohydrate (50%) diets had distinct clusters using 
principal component analysis. The profile of cats fed a high protein diet had a decreased 
nucleotide catabolism and increased amino acid metabolism, those fed a high fat diet showed 
increased lipid metabolism, but few changes were seen in cats fed the high carbohydrate diet 
when compared to cats fed the control diet.  
 
Given the similarities between the pathophysiology of type 2 diabetes in humans and diabetes 
in cats, it is likely that metabolomic derangements in early disease may also be the same. To 
date there have been no studies published on the use of metabolomics to help diagnose 
prediabetes (insulin resistance) in cats though markers of obesity in Burmese cats were 
studied briefly65. 
 
The aim of our study is to discover if metabolomics could fulfil our goal of establishing 
effective clinical screening tests for prediabetes in cats. 
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Chapter 2: Introduction  
 
The prevalence of diabetes in cats varies from 0.3% to 2%, depending on the population 
studied; Burmese cats originating from Europe and Australasia are 4 times more likely to 
develop the disease1,2, as are Russian Blue, Maine Coon and Siamese from the USA3. In 
humans, the term prediabetes is used to classify a metabolic stage intermediate between 
normal glucose homeostasis and diabetes; these patients have impaired glucose tolerance 
and/or impaired fasting glucose4,5. Either impaired glucose tolerance or impaired fasting 
glucose is identified in the previous 5 years in more than 60 % of humans who develop 
diabetes6. In fact, it is reported that 33% of people with impaired glucose tolerance develop 
diabetes over a two year period7.  If prediabetes is identified, management through a low 
carbohydrate diet and weight loss regime can be implemented to delay or even prevent the 
onset of overt diabetes. 
In cats, as in humans, impaired fasting glucose and impaired glucose tolerance can progress 
to clinical diabetes. Within 9 months of testing, cats in diabetic remission with moderate 
impaired fasting glucose or glucose intolerance developed diabetes (75% and 38% 
respectively)8. Impaired fasting glucose is rarely diagnosed in cats unlike in humans, where 
12 to 26% have impaired fasting glucose9 in USA, Europe and Australia, increasing to 39% 
by the age of 65 years10. Mild increases in blood glucose in cats are often classified as stress 
hyperglycaemia associated with travel, a visit to a clinic or with illness6,11. The identification 
prediabetic cats and cats with subclinical diabetes is likely to be as important as in humans to 
help prevent progression to clinical disease.  An objective screening test similar to that used 
in humans would aid in identification of high risk cats, so that control measures can be 
implemented to help decrease the risk of clinical diabetes. 
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The aims of this thesis were to design and validate screening tests for prediabetes in senior 
cats, and to identify metabolomic changes in two groups of cats at high risk of developing 
diabetes - obese and Burmese. 
A recent study in dogs reported a spurious effect on evaluation of glucose tolerance when 
glucose was dosed on a bodyweight basis in obese dogs, resulting in higher peak glucose 
concentrations and higher area under the glucose curve values, incorrectly implying impaired 
glucose tolerance12. For the analysis of glucose tolerance, this was resolved by adjusting the 
measured glucose concentrations, based on peak glucose concentration. The effect of obesity 
on the dosage of glucose used in a glucose tolerance test has not previously been investigated 
in cats. The primary objective of the study in Chapter 4 (“Dosing obese cats based on 
bodyweight spuriously affects some measures of glucose tolerance”; published) was to 
investigate whether dosing glucose by body weight results in spurious effects on measures of 
glucose tolerance in obese cats, because volume of distribution does not increase linearly 
with body weight. The aim was to retrospectively analyse glucose concentration data from 
glucose tolerance and insulin sensitivity tests in cats before and after they were fed ad libitum 
for 9 to 12 months to promote weight gain, to determine the adjustment required to 
compensate for the ‘dosage’ effects of obesity in overweight and obese cats.  
The risk of developing type 2 diabetes in cats is highest after 8 years of age13. Humans with 
fasting and 2-h blood glucose concentrations that are above normal following a glucose 
tolerance test but below diabetic are classed as having impaired fasting glucose or impaired 
glucose tolerance respectively; they are considered prediabetic14. However, such data are not 
available for senior cats and a lack of standardization of these tests was evident. Additionally, 
these tests were found to not be convenient to use in a clinical environment. The ‘gold 
standard’ intravenous glucose tolerance test requires multiple samples and analysis is not 
practical in private practice because of the complex calculations required to generate the 
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necessary statistics, such as glucose half- life, glucose clearance time, and area under the 
curve15.  The aim of Chapter 5 (“Diagnosis of prediabetes in cats: glucose concentration 
cutpoints for impaired fasting glucose and impaired glucose tolerance”; published) was to 
establish the methodology and cutpoints for fasting and 2-h blood glucose concentrations in 
healthy client-owned senior cats (> 8 years of age) using ear/ paw samples and a portable 
glucose meter calibrated for feline blood. 
Casual blood glucose, defined as blood glucose measured unrelated to time of eating or type 
of food, is used as a screening test to diagnose diabetes in humans4. No standardized 
methodology and cutpoints for normal have been established for cats.  The aim of Chapter 6 
(“Cutpoints for screening blood glucose concentrations in healthy senior cats”; in press) was 
to standardize the methodology for a screening test similar to that used in humans, and 
develop reference intervals which would aid identification of high risk cats, that is, cats with 
impaired fasting glucose or subclinical diabetes, so that interventions can be implemented to 
decrease the risk of progression to clinical diabetes 
Metabolomics is a new method using liquid or gas chromatography together with mass 
spectroscopy to measure a comprehensive set of metabolites in a given body fluid or tissue 
extract16. In the progression of disease alterations in the metabolic profile often present much 
earlier than clinical signs. Therefore, metabolomics can potentially be used as a sensitive, 
early indicator of a disease process. There is scant information on metabolite changes with 
obesity in pets, despite obesity being similar in dogs and cats to humans17-20. The aim of 
Chapter 7 (“Metabolomic differences between lean and obese neutered senior cats and 
associations with glucose tolerance”) was to identify the metabolic profile in spontaneous 
obesity in senior neutered cats, and to determine associations with measures of glucose 
metabolism and diabetes.  
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Burmese cats from the UK, Sweden, Australia and New Zealand are now almost four times 
more likely to develop type 2 diabetes mellitus than other cats1,21,22,23. Reports show that 28% 
of Australian Burmese cats have altered lipid metabolism as evidenced by an exaggerated 
postprandial triglyceride response after an oral fat tolerance test24,25 which possibly could 
contribute to the increased risk of diabetes. Chapter 8 (“Metabolite differences between 
healthy senior Burmese and non-Burmese cats, and associations between metabolites and 
measures of glucose metabolism”) investigated metabolite differences between healthy 
Burmese and non-Burmese cats, after adjusting for age, sex, and body condition score. Again, 
like obese cats (Chapter 7), associations between identified metabolites and measures of 
glucose metabolism and diabetes were examined.    
The overall aim of the thesis was to establish a screening test that is easy to perform for 
prediabetes in senior cats to be used in a clinical setting, and to improve the understanding of 
the metabolic differences in cats at high risk of developing diabetes, namely obese and 
Burmese senior cats, in the hope of helping prevent clinical disease in the future. 
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Chapter 3: Study design diagrams 
The following pages are diagrammatic summary of the major experiments of this thesis. 
 
Experiment 1 
Aims 
• To investigate changes induced by obesity in absolute glucose concentrations 
measured at various times after a bolus dose of intravenous glucose 
•  To investigate the effect of these changes on the diagnosis of glucose intolerance 
based on 2-h glucose concentrations 
• Such information will be important to underpin the development of reference 
values for a simple clinical test for glucose intolerance in cats that requires only a 
fasting and a 2-h blood sample.  
Animals 
 Data analysed retrospectively from 16 cats (aged 1-5 years, BCS 1-5/5). All cats were 
clinically healthy. All cats were acclimatized to their environment and fed the same food. 
Methods 
• All cats were anaesthetized and jugular catheters inserted at least 24 h prior to 
tests and food was withheld for 12 h. 
• Glucose tolerance tests were performed at an IV glucose dosage of 0.3g/ kg and 
1.0 g/kg bodyweight before and after adlib feeding which led to weight gain.  
Relevant research chapters 
Chapter 4- Dosing obese cats based on body weight spuriously affects some measures of 
glucose tolerance 
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Experiment 2 
Aims 
• To design a simplified intravenous glucose tolerance test to use in a clinic environment 
using paw/ pinna samples and a portable glucose meter  
• To determine precision and accuracy of a portable glucose meter  
• To establish cutpoints for fasting and 2-h blood glucose concentrations in healthy cats 8 
years and older 
• To apply the adjustment equations from experiment 2 to 2-h blood glucose 
concentrations in overweight and obese cats 
• To compare glucose tolerance tests of healthy neutered Burmese cats to healthy 
neutered domestic cats of the same age group and matched body condition score 
Animals 
Healthy client-owned cats 8 years and older (n=78) were classified as non-Burmese (n=59) or 
Burmese (n=19). Body condition scores (out of 9) were 4 or 5 (27 cats), 6 or 7 (31 cats), 8 or 9 
(20 cats). 
Methods 
Cats were fasted for 18-20 hours and a cephalic catheter inserted. Three hours later, a 
simplified IVGTT was performed using 0.5 g/kg body weight intravenous glucose (50% 
dextrose solution) administered through the cephalic catheter. Blood glucose concentration was 
measured using a portable glucose meter (Abbott AlphaTRAK) from the ear or paw 
immediately before glucose injection (time 0) and after glucose injection at 2 min and 2 h. 
Relevant research chapters 
Chapter 5- Diagnosis of prediabetes in cats: glucose concentration cut points for impaired 
fasting glucose and impaired glucose tolerance 
81 
 
 
Experiment 3 
 Aims 
• To design the methodology for a blood glucose screening test to be used in a 
clinic environment 
• To determine cutpoints in cats for screening blood glucose concentration 
measured from paw or ear samples with a portable glucose meter  
• To compare these values with those obtained in the traditional way  
• To determine whether there are associations between screening blood glucose and 
weight, body condition score, stress score, diet (amount of carbohydrate eaten in 
previous 6, 12 and 24 h) or breed (Burmese versus non-Burmese)  
Animals 
120 healthy neutered client-owned cats 8 years and over of varying weights and body 
condition scores 
Methods 
 On entering the consultation room, blood glucose concentration was measured using a 
portable glucose meter in blood obtained from the paw or ear via a lancing device. A 
history and clinical examination was performed, followed by collection of a jugular blood 
sample. Blood glucose concentration was measured with the portable meter and at a 
reference laboratory to determine meter accuracy. Data on signalment, health history, 
type of food, amount and timing of eating in the previous 24 h was obtained. Behaviours 
associated with stress at the time of the initial blood collection were scored. 
Relevant research chapters 
Chapter 6- Cutpoints for screening blood glucose concentrations in healthy senior cats   
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Experiment 4 
 
Aim 
• To establish what metabolites are changed with obesity in elderly cats 
• To establish if any individual metabolites are associated with measures of glucose 
metabolism (screening/fasting and 2-hr blood glucose following a glucose tolerance 
test) and diabetes related parameters (insulin, G:I ratio, leptin, triglycerides, 
adiponectin, leptin:adiponectin ratio, fPLi and MCP-1 
Animals 
Cats volunteered by their owner from experiment 2 and 3 and of appropriate demeanour  
Samples from 39 cats were used in this study of metabolomics: 21 lean (BCS4-5/9) non-
Burmese (13 domestic and 8 other breeds) and 18 obese (BCS 8-9/9) non-Burmese (15 
domestic and 3 other breeds). 
 
Methods 
• A jugular venous blood sample was collected from cats fasted for the glucose 
tolerance test in experiment 2 
• Serum and plasma was separated into aliquots for hormonal, enzymatic and 
metabolomic (GC-MS) analysis and stored at -80°Cuntil analysis  
Relevant research chapter 
Chapter 7- Metabolomic differences between lean and obese neutered senior cats and 
associations with glucose tolerance 
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Experiment 5 
 
 
Aim 
• To compare the metabolites between healthy Burmese and non-Burmese cats 8  
years and older 
• To compare these significant metabolomic variables with fasted insulin, G:I ratio, 
triglycerides, leptin, adiponectin, leptin:adiponectin ratio, fPLi and MCP-1 and with 
measures of glucose intolerance (fasting blood glucose and 2-h blood glucose 
following a glucose tolerance test) in senior Burmese and non-Burmese cats.  
Animals 
Cats used in this study were from experiment 2 and 3, volunteered by their owner and of 
appropriate demeanour. 
Samples from cats (n=49) classified as non-Burmese (n=30) or Burmese (n=19) were used in 
this study. Body condition scores for non-Burmese were 12 lean (BCS 4-5), 5 overweight 
(BCS 6-7) and 13 obese (BCS 8-9) (mean 6.1, range 4-9) and for Burmese were 6 lean, 11 
overweight and 2 obese (mean 6.1, range 4-8).  
 
Methods 
• A jugular venous blood sample was collected from cats fasted for the glucose 
tolerance test in experiment 2 
• EDTA plasma and serum were separated into aliquots for hormonal and  
metabolomic analysis and stored at -80 degrees until analysis until analysis  
Relevant research chapter 
Chapter 8- Metabolite differences between healthy senior Burmese and non-Burmese cats, 
and associations between metabolites and measures of glucose metabolism 
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Abstract 
The primary objective was to investigate whether dosing glucose by body weight results in 
spurious effects on measures of glucose tolerance in obese cats, because volume of 
distribution does not increase linearly with body weight. Healthy research cats (n = 16; 6 
castrated males, 10 spayed females) were used. A retrospective study was performed using 
glucose concentration data from glucose tolerance and insulin sensitivity tests before and 
after cats were fed ad libitum for 9 to 12 mo to promote weight gain. The higher dose of 
glucose (0.5 versus 0.3 g/kg body weight) in the glucose tolerance tests increased 2-min 
glucose concentrations (P <0.001), and there was a positive correlation between 2-min and 2-
h glucose (r = 0.65, P = 0.006).  Two-min (P = 0.016 and 0.019, respectively), and 2-h (P = 
0.057 and 0.003, respectively) glucose concentrations and glucose half-life (T ½) (P = 0.034 
and <0.001 respectively) were positively associated with body weight and body condition 
score. Glucose dose should be decreased by 0.05 g for every kg above ideal body weight.  
Alternatively, for every unit of BCS above 5 on a 9- point scale, observed 2-h glucose 
concentration should be adjusted down by 0.1 mmol/L. Dosing glucose based on body weight 
spuriously increases glucose concentrations at 2 h in obese cats and could lead to cats being 
incorrectly classified as having impaired glucose tolerance. This has important implications 
for clinical studies assessing the effect of interventions on glucose tolerance when lean and 
obese cats are compared. 
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Introduction 
The IVGTT was introduced in human medicine in 1923 to assess glucose homestasis1 and 
measures an individual’s ability to clear glucose from circulation after a bolus dose of 
glucose. People with impaired glucose tolerance are considered prediabetic and at high risk of 
developing type 2 diabetes2-4. Measures of glucose tolerance include T ½ and rate of glucose 
clearance, but these require multiple blood samples and complex mathematical calculations. 
In clinical practice, blood glucose concentration two hours after a standardized oral glucose 
dose (75g/adult person) is currently used to identify humans with impaired glucose 
tolerance5,6.  
Approximately 1 in 200-400 domestic cats and 1 in 50 Burmese cats of European origin 
develop diabetes analogous to human type 2 diabetes6-10. As in humans, if diagnosed in the 
prediabetic state, clinical disease can likely be averted or minimized through diet and weight 
loss11. However, tests for prediabetes are not well characterised or commonly utilized in 
clinical veterinary practice, and cats are usually not diagnosed until overt diabetes is evident8.   
A number of criteria for classification of glucose tolerance in cats have been published9,12,13. 
The “gold standard” test is tedious, requires multiple blood samples, and interpretation can be 
difficult because of the complex calculations required, such as glucose T ½, rate of glucose 
clearance, and area under the curve14,15. For many cat owners, the procedure is unacceptably 
expensive and invasive. A routine screening test equivalent to the test in human medicine, 
based on absolute glucose concentrations and requiring two blood samples, was reported in 
1998 but has not been widely implemented for cats14. Although there are inherent problems 
associated with interpreting absolute glucose values16, these measures form the basis of a 
satisfactory primary screening test for prediabetes in humans3 and could be similarly used for 
cats.  
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In humans, oral administration of glucose has replaced intravenous administration, due to its 
ease and practicality3. Oral glucose administration has been reported in cats and, as in 
humans, results in greater insulin stimulation through an incretin effect17. However, cats are 
very susceptible to stress hyperglycaemia and may be stressed by oral administration which 
would confound the assessment of glucose tolerance18. Stress, particularly if it results in 
struggling, can increase blood glucose concentrations by as much as 10 mmol/L and take 3 h 
to resolve18, and therefore needs to be avoided. Placing a cephalic catheter for glucose 
injection 3 h before the test start likely assists in preventing struggling and stress-induced 
hyperglycaemia during the test. 
A recent study in dogs reported a spurious effect on evaluation of glucose tolerance when 
glucose was dosed on a body weight basis in obese dogs, resulting in higher peak glucose 
concentrations and higher area under the glucose curve, incorrectly implying impaired 
glucose tolerance19. For the analysis of glucose tolerance, this was resolved by adjusting the 
measured glucose concentrations, based on peak glucose concentration. The observation that 
peak glucose concentration was higher in obese dogs compared to lean dogs when dosing 
glucose based on body weight is not surprising. For a substance injected intravenously, the 
volume of distribution (and circulating blood volume), expressed as a percentage of body 
weight, is reduced in obese individuals, because it does not increase linearly with increasing 
fat mass19-21. Therefore, when administering glucose at a dose based on body weight, obese 
cats are potentially overdosed in comparison with cats in ideal body condition, which could 
lead to a false assessment of impaired glucose tolerance. No studies investigating clearance of 
anaesthetic agents or sedatives or allometric scaling in cats have been identified22. 
The purpose of this study was to investigate effects of changes induced by obesity on 
absolute glucose concentrations measured at various times after a bolus dose of intravenous 
glucose. We then determined the effect of these obesity-induced changes on assessment of 
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glucose homeostasis, in particular, diagnosis of glucose intolerance, and investigated whether 
adjustment for glucose dose was indicated in obese cats. Such information is important for 
the development of reference values for a simple clinical test for glucose intolerance in cats 
that requires only a fasting and a 2-h blood sample.  
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Materials and Methods 
A retrospective study was conducted using data from a previous study that investigated the 
effect of obesity on various glucose variables. That study was approved by the Animal 
Experimentation and Ethics Committee of the University of Queensland.  In the current 
study, we examined the effects of body weight and body condition on variables including 
peak and 2-min glucose after glucose administration, fasting glucose, glucose dose (0.3 and 
0.5 g/kg), and measures of glucose tolerance such as T ½ and 2-h glucose concentration. We 
utilized blood glucose concentration data from glucose tolerance tests and the first 2 min 
from insulin sensitivity test previously performed at our laboratory in 16 cats before and after 
weight gain15,23. In the original study, 16 (10 spayed females, 6 castrated males) clinically 
healthy research cats between 1 and 5 yr of age (most in ideal body condition) underwent 
glucose tolerance and insulin sensitivity tests to provide baseline data prior to weight gain23. 
The cats were offered a combination of 2 commercially available extruded foods, with 
metabolizable energy consisting of 33% protein, 22.3% fat, 30.2% carbohydrate and 40% 
protein, 26.6% fat and 17.2 % carbohydrate, respectively23. The tests were repeated after a 
weight gain period, when cats were fed ad libitum for an average (± standard deviation) of 
10.5 (± 1.1 mo) (range, 9 to 12 mo)24. Based on dual energy x-ray absorptiometry, after the 
weight gain period, all cats had more than 30% body fat (range 34.2 – 48.7%)23. 
Body condition score was originally measured on a 5-point scale25. For the current study, 
these scores were converted to a 9-point scoring system, where scores of 1, 2, 3, 4, and 5 on 
the 5-point scale were converted to 1, 3, 5, 7, and 9, respectively, on the 9-point scale to 
allow better comparison with other data sets26. All body condition scores were measured by 
the same person. 
In the original study, glucose tolerance and insulin sensitivity tests were performed on 
separate days15. For the glucose tolerance test, glucose was administered at 0.5 g/kg as a 
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bolus dose over 30 s, via a jugular vein catheter. Blood samples were collected before 
glucose administration (four samples at -15, -10, -5, and -1 min) and after (at 2, 5, 10, 15, 30, 
45, 60, 90, and 120 min). For the insulin sensitivity test, glucose was administered at 0.3 g/kg 
as a bolus dose over 30 s, via a jugular vein catheter and insulin was injected 20 min later.  
Glucose concentration data before and 2 min after glucose injection in the insulin sensitivity 
test was used to compare the effect of glucose dose on 2-min blood glucose concentration 
after injection of 0.3 g/kg glucose and 0.5 g/kg from glucose tolerance test. Data from blood 
samples collected after insulin administration could not be used due to effects of insulin on 
glucose concentrations, precluding the calculation of T ½ and time to return to baseline for 
the 0.3g/kg dose rate. In both tests, the timer was started halfway through infusion. Glucose 
was measured in plasma using an automated glucose analyser which had a precision for 
replicate analyses of < 2% (YSI 2300 Stat Plus; Yellow Springs Instrument Co.)15.  
 
 Statistical analyses 
The statistical analyses assessed a) the effects of weight gain on 2-min and peak blood 
glucose concentration by comparisons before and after the 9 to 12 mo ad libitum feeding 
period, b) the effects of glucose dose (0.3 g/kg versus 0.5 g/kg) on 2-min glucose, and c) 
selected associations between fasting blood glucose concentration, 2-min and peak blood 
glucose concentrations, body weight, body condition score, and key measures of glucose 
tolerance, namely T ½ and 2-h blood glucose concentration. Linear regression and correlation 
coefficients were used. Statistical analyses were performed using specialist software (Stata 
version 12, StataCorp, College Station, Texas, USA). T ½ for glucose was estimated for each 
cat using glucose values from 15 to 90 min. Between these time points, the glucose 
disappearance curve is most rectilinear27. Loge (glucose) was regressed on time (in min) and 
T1/2 was calculated using the resulting ß-coefficient (ie. the slope coefficient) as follows: T1/2 
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= loge (2)/|ß-coefficient|. This was equivalent to fitting the model: Gt = G0*e
(-k*t), where Gt is 
the serum glucose concentration at time t, and G0 is the initial serum glucose concentration 
based on extrapolation from the period from 15 to 90 min to time 027. 
 
For most analyses, data from before and after the ad libitum feeding period were pooled for 
linear regression analyses. Thus the ‘cat-period’ was the unit of analysis where each cat 
provided 2 'cat-periods', 1 before and 1 after it was fed ad libitum. Cat was fitted as a random 
effect (to account for clustering of cat-period within cat), using maximum likelihood 
estimation. R-square values overall and within cat were estimated using models fitted using 
the generalized least squares estimator. Additionally, confounding by sex of relationships 
assessed using linear regression was explored by comparing regression coefficients after 
refitting the models with sex included as a covariate; interactions with cat sex were also 
assessed in subsequent models. Regression coefficients changed minimally after adjustment 
for sex, and P- values for all interaction terms were above 0.26, so results of these additional 
analyses were not reported. For correlation coefficients, 95% confidence intervals were 
calculated using Fisher's transformation. 
 
Following an intravenous injection of glucose at time 0, the direct causal effect of 2-min 
glucose concentration on 2-h glucose concentration was estimated by regressing 2-h glucose 
concentration on 2-min glucose concentration with BCS fitted as a continuous covariate. The 
rationale for this analysis was that 2-h glucose concentration could be affected by 2-min 
glucose concentration via a 'direct' causal effect, if there was no (or insufficient) increase in 
rate of glucose clearance with higher 2-min glucose concentrations (Figure 4.1). Hence, 
higher 2-min glucose concentrations would result in higher 2-h glucose concentrations. This 
is supported by the observation that T ½ of glucose (a measure of glucose clearance) was not 
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closely related to peak glucose concentration (Figure 4.2). The rationale for fitting BCS was 
that BCS may affect 2-min glucose concentration if glucose dose is calculated on a body 
weight basis. This occurs because the volume of distribution does not increase linearly with 
increases in body weight due to accumulation of body fat28. There may also be effects of 
obesity on 2-h glucose concentration mediated other than through higher 2-min glucose 
concentration. These effects could include increases in insulin resistance with obesity, which 
in turn, could increase 2-h glucose concentration. If so, BCS would confound the observed 
association between 2-min glucose concentration and 2-h glucose concentration, when 
glucose is dosed on a body weight basis. Associations between fasting blood glucose and 
each of 2-min and 2-h blood glucose concentrations were also assessed using linear 
regression. Because we postulated a priori that these relationships involving fasting blood 
glucose may have differed between before and after the 9 to 12 mo ad libitum feeding period, 
separate linear regression models were fitted for each period. Variances of 2-h glucose were 
compared between before and after the ad libitum feeding period using Levene's test for the 
equality of variances between groups; this did not account for pairing of results within cat. 
Reference intervals for 2-h glucose concentration were calculated using published 
methods29,30 that were incorporated into a spreadsheet (Microsoft Excel spreadsheet, 
Reference Interval Draft Version, Copyright 2005, University of Cincinnati). Data were 
transformed to approximate a normal distribution using the Box-Cox transformation, and 
outliers identified for exclusion from subsequent calculations. Associated 90% confidence 
intervals for the upper 95% limits of the reference intervals for 2-h glucose concentrations 
before and after the ad libitum feeding period were estimated using bootstrapping with 1000 
replications. Only cats with body condition scores of 8 or 9 (n = 10) were used to calculate 
the reference interval after the ad libitum feeding period. 
 
93 
 
Results  
After the ad libitum feeding period, the average proportional body weight increase was 44% 
compared to the initial body weight (before weight gain mean ± SD of 4.4 ± 0.8 kg to after 
weight gain 6.3 ± 1.3 kg)20. Most cats were initially in ideal body condition (BCS 5 n=14; 
BCS 3 n=1; BCS 7 n=1). Body condition scores on the 9-point scale increased from a mean ± 
SD of 5.0 ± 0.7 to 8.1 ± 1.1. After weight gain, 10 of the 16 cats were classed as obese (BCS 
8 or 9) and 6 as overweight (BCS 6 or 7). All results were based on a glucose dose of 0.5 
g/kg body weight IV unless otherwise stated. 
 Effects of weight gain on 2-min and peak blood glucose concentrations 
When glucose dose was based on body weight (ie. 0.5 g/kg body weight), both 2-min and 
peak blood glucose concentrations were significantly increased by weight gain (ie. from 
before to after the weight gain period; P ≤ 0.001; Figure 4.3). Peak blood glucose 
concentrations occurred at 2 min for 14 of the 16 cats and at 5 min in 2 cats, both before and 
after the ad libitum feeding period. Peak glucose concentration was closely correlated with 2-
min glucose both before and after the ad libitum feeding period (r = 0.96; 95% CI 0.88 to 
0.99; P < 0.001 and r = 0.98; 95% CI 0.95 to 1.00; P < 0.001, respectively).  
 
Two-min glucose increased with each of body weight and body condition score (Table 4.1). 
Body weight explained 15% of the total variation, and 26% of the within-cat variation for 2- 
min glucose concentrations. Body condition score explained 15% and 18% of the total and 
within-cat variations, respectively, for 2-min glucose concentration. 
 
 Associations between peak and 2-min blood glucose concentrations and measures of glucose 
tolerance 
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Before the ad libitum feeding period, both peak and 2-min glucose concentrations were 
positively correlated with 2-h blood glucose concentration (peak: r = 0.61; 95% CI 0.17 to 
0.85; P = 0.012; 2-min: r = 0.65; 95% CI 0.23 to 0.87; P = 0.006) (Figure 4.4). Using pooled 
data from before and after the ad libitum feeding period, for every 1 mmol/L increase in 2-
min glucose concentration, 2-h glucose concentration increased by 0.09 mmol/L (95% CI -
0.01 to 0.18 mmol/L; P = 0.067). 
 
 Associations between body weight and BCS and measures of glucose tolerance  
Using pooled data from before and after the ad libitum feeding period, 2-h glucose was 
associated with body weight (estimated increase for each extra kg body weight 0.33 mmol/L; 
95% CI -0.01 to 0.67; P = 0.057) and BCS (estimated increase for each extra unit of BCS 
0.32 mmol/L; 95% CI 0.11 to 0.53; P = 0.003) (Table 4.1, Figure 4.5). Body weight and BCS 
explained 7% and 15%, respectively, of the total variation in 2-h glucose concentrations, and 
30% and 38%, respectively, of the within-cat variation. The variance of 2-h glucose was 
significantly larger (P = 0.013) after the ad libitum feeding period; standard deviations were 
0.9 mmol/L and 1.6 mmol/L before and after the ad libitum feeding period, respectively. 
 The upper limit for the 95% reference interval for 2-h glucose concentration using cats 
before the ad libitum feeding period was 6.0 mmol/L (90% CI 5.1 to 6.6 mmol/L) and using 
cats after the ad libitum feeding period was 8.9 mmol/L (90% CI 7.1 to 9.3 mmol/L).  
 
Increasing body weight and body condition score were associated with increasing T ½ (Table 
1). Body weight and BCS explained 9% and 19%, respectively, of the total variation in T ½, 
and 27% and 45%, respectively, of the within-cat variation. 
 
 Association between fasting glucose and each of 2-min and 2-h glucose concentrations  
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Both 2-min and 2-h blood glucose concentrations were positively associated with fasting 
blood glucose concentrations both before and after the ad libitum feeding period (P ≤ 0.018). 
 
 Effect of glucose dose rate (0.3 versus 0.5 g/kg) on 2-min blood glucose concentrations 
The dose rate of glucose (0.3 versus 0.5 g/kg body weight) affected 2-min glucose 
concentrations. 2-min glucose concentration increased from a mean ± SEM of 18.0 ± 0.8 
mmol/L to 22.7 ± 1.3 mmol/L (P < 0.001) when glucose dose was increased from 0.3 to 0.5 
g/kg body weight. 2-min glucose increased by 4.7 mmol/L (95% CI 2.1 to 7.2 mmol/L) when 
the dose increased from 0.3 to 0.5 g/kg, equating to an increase in 2-min glucose 
concentration of 23.3 mmol/L for every 1g/kg increase in glucose dose. Effects of dose on T 
½ and 2-h blood glucose concentrations could not be calculated because insulin was 
administered 20 min after the 0.3 g/kg dose of glucose was given and prevented valid 
measurement of these variables. 
 
Accounting for effects of obesity on 2-h glucose concentrations when using glucose tolerance 
tests  
To account for the spurious effects of obesity on 2-h glucose concentrations when dosing 
glucose by body weight, a number of simple theoretical options were investigated. These 
options were designed to allow results from cats with body condition scores varying from 
lean to obese to all be interpreted using the upper limit of the reference interval for 2-h 
glucose concentration calculated for lean cats. Two approaches were investigated: adjustment 
of glucose dose and adjustment of measured 2-h glucose concentration. 
 
Adjustment of glucose dose:  
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For every extra unit of BCS above 5 on a 9-point scale, the glucose dose of 0.5 g/kg glucose 
should be reduced by 0.05 g/kg. This was calculated by the following equations: 
Adjusted glucose dose = Actual glucose dose - X, where X = A divided by B 
Where X = Adjustment of glucose dose; A = Increase in 2-min blood glucose 
concentration/unit BCS = 1.14 mmol/L (Table 4.1) and, B = Increase in 2-min glucose 
concentration/each 1g/kg increase in glucose dose = 23.3 mmol/L. 
 
Similarly, if using body weight as a measure, for every kg increase in body weight above the 
cat’s ideal body weight (its body weight if it were BCS 5), the dose should be decreased by X 
= 0.064 g/kg, where  
A = increase in 2-min blood glucose per kg increase in body weight=1.48 mmol/L (Table 
4.1); B=23.3. 
 
Adjustment of measured 2-h glucose concentration following a dose of 0.5 g/kg body weight. 
This was calculated as follows:  
Adjusted 2-h glucose concentration = actual 2-h glucose concentration – correction for obesity.  
The correction of 2-h glucose concentration for obesity was calculated in 3 ways, based on 
associations between 2-h glucose concentrations and each of 2-min glucose concentrations, 
BCS, and body weight from this study. These 3 methods are for use in cats with a BCS 
greater than 5 (method a), or when body weight is greater than ideal (ie body weight is higher 
than if cat were BCS 5; method b), or cats with a 2-min glucose concentration > 17.8 mmol/L 
(method c). 
Method a: Correction for obesity based on the effects of BCS on 2-min glucose 
concentration:  
 (Cat’s actual BCS – 5) x 0.10 mmol/L. 
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This calculation assumes that 5 is an ideal BCS on a 1 to 9 scale, and 0.10 mmol/L is the 
direct causal amount by which 2-h glucose concentration increases for each unit increase in 
BCS via an effect on 2-min blood glucose concentration. This was estimated by multiplying 
the amount by which the 2-min glucose concentration increased per unit increase in BCS 
(1.14 mmol/L; Table 4.1) by the estimated direct causal effect of 2-min glucose concentration 
on 2-h glucose concentration (0.09 mmol/L). For example, one study cat had a BCS of 9 and 
a 2-h blood glucose concentration of 6.2 mmol/L. As this is 0.2 mmol/L above the upper limit 
of the calculated 95% reference interval of 6.0 mmol/L,without adjustment, this cat would 
have been classified as having impaired glucose tolerance. Using this method of adjustment 
(0.01 mmol/L for each unit of BCS), this cat would have an adjusted 2-h glucose 
concentration of 5.8 mmol/L (Table 4.2) and so be classified as having normal glucose 
tolerance. In contrast, another study cat with a BCS of 7 and a 2-h glucose concentration of 
7.4 mmol/L would have an adjusted 2-h glucose concentration of 7.2 mmol/L, and so would 
still be considered to have impaired glucose tolerance.  
Method b: Correction for obesity based on the effects of body weight on 2-min glucose 
concentration:  
 (Cat’s actual weight – Cat’s ideal body weight) x 0.13 mmol/L,  
In this calculation, the amount by which the 2-min glucose concentration increased per kg 
increase in body weight (1.48 mmol/L; Table 4.1) was multiplied by the estimated direct 
causal effect of 2-min glucose concentration on 2-h glucose concentration (0.09 mmol/L) 
resulting in an adjustment of 2-h blood glucose by 0.13mmol/L per kg of weight increase 
from ideal body weight (Table 4.2).  
 Method c: Correction for obesity based on the mean 2-min glucose concentration in cats of 
ideal BCS (BCS 5) 
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(Cat’s actual 2-min glucose concentration – 17.8) x 0.09 in mmol/L. 
In this calculation, 17.8 mmol/L was used as this was the mean 2-min glucose concentration 
for cats with ideal BCS (BCS 5; n=14 cats prior to the ad libitum feeding period), and 0.09 is 
the estimated direct causal effect of 2-min glucose concentration on 2-h glucose 
concentration. This method assumes that the 2-min glucose concentration for cats in ideal 
BCS (5) is always 17.8 mmol/L. For the cat in the previous example with a BCS of 9, the 2-
min glucose concentration was 29.2 and the recalculated 2-h glucose concentration was 5.3 
mmol/L. Similarly, for the cat with a BCS of 7, the 2-min glucose concentration was 21.7 
mmol/L, and the recalculated value of 7 mmol/L would still be considered indicative of 
impaired glucose tolerance (Table 4.2). 
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Discussion  
Glucose clearance after an intravenous glucose challenge, and therefore measured glucose 
concentrations, are influenced by complex mechanisms involving insulin and non-insulin 
dependent glucose uptake into tissues, as well as suppression of glucose output via 
gluconeogenesis in the liver31. Obesity affects both receptor and post-receptor processes 
involved in glucose uptake into tissues, and inhibits suppression of hepatic gluconeogenesis. 
Obesity also adversely affects beta cell function and insulin secretion32. These effects on 
glucose clearance are mediated by insulin resistance as well as other direct effects including 
inflammatory mediators associated with obesity16.  
Glucose tolerance is assessed by measures of glucose clearance such as glucose half-life (T 
½), and absolute glucose concentrations at a given time after a glucose challenge, for 
example, 2 h33. In cats, glucose is most commonly administered intravenously and dosed on a 
body weight basis12,16. However, the volume of distribution of glucose does not increase 
linearly with increasing fat mass, potentially resulting in a relative glucose overdose in obese 
cats. Our study is the first study to examine whether dosing glucose on a per kg basis in an 
intravenous glucose tolerance test has a spurious effect on the results when testing 
overweight and obese cats. There were several important findings from this study that clinical 
researchers should be aware of when comparing glucose tolerance between lean and obese 
cats. 
Firstly, glucose concentration measured at 2 min is positively associated with glucose dose. 
Secondly, the 2-min glucose concentration has a direct causal effect on the 2-h glucose 
concentration. Thirdly, both body condition score and body weight were positively associated 
with 2-min and peak glucose concentrations, 2-h glucose concentration, and T ½. These 
findings corroborate those of others12,16 and have implications for interpreting measures of 
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glucose tolerance, especially glucose concentrations at 2 h after glucose administration. There 
is the potential to erroneously classify an obese cat as having impaired glucose tolerance 
because of the effect of a standard glucose dose on peak or 2-min glucose, and subsequently 
on 2-h glucose concentration. 
Peak (and 2-min) glucose concentration are a reflection of the volume of distribution, as no 
substantial clearance of glucose from the blood occurs in the short timeframe16,21. The 
volume of distribution, that is the circulating blood volume, does not increase linearly with 
body weight in obesity34,35. The important finding in our study is that there is relative 
overdosing of glucose in obese cats when glucose dosing is based on body weight. Further 
investigation would be required to examine if dosing on ideal body weight or using a fixed 
dose regardless of body weight, as used in human medicine, was advantageous in glucose 
tolerance tests in obese cats. Both of these methodologies incorrectly assume that volume of 
distribution (circulating blood volume) do not increase concomitant with increasing fat mass. 
However, blood volume indeed does increase with increasing fat mass, but at a proportionally 
lower rate compared to if the weight increase was muscle24. The second limitation with 
dosing based on ideal body is the inherent imprecision of estimating ideal body weight in 
obese cats using morphometric or other measures available in clinical practice.  
 
In human3,4,36 and veterinary8 medicine, fasting glucose concentration is also used as a 
measure of glucose homeostasis, and patients with increased concentrations are classified as 
either having impaired fasting glucose or diabetes, depending on the magnitude of the 
increase. Fasting glucose concentration is less sensitive for detecting abnormalities of glucose 
homeostasis than measurement of glucose concentrations after a glucose challenge, as occurs 
in the glucose tolerance test2,37,38. T ½ is based on 4 glucose measurements from 15-90 min 
and there was no evidence that T ½ was affected substantially by peak values.  Whether it is a 
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better tool to assess glucose tolerance status in obese cats, or is a less sensitive measure of 
glucose tolerance than absolute glucose concentrations, is unclear. However, it is technically 
more difficult to calculate and not suitable as a simple measure of glucose tolerance status for 
use in clinical research or veterinary practice. In clinical practice in humans, the 2-h glucose 
concentration has replaced T1/2 as a measure to identify individuals with impaired glucose 
tolerance and diabetes.   
It is important to separate the dosage effect of obesity from the pathological effect of obesity 
on the 2-h glucose concentration. The pathological effect is associated with impaired glucose 
clearance from the circulating blood as a result of peripheral insulin resistance secondary to 
obesity and a number of other factors affecting glucose uptake into tissues and insulin 
secretion11. In our study, the combined dosage and pathological effects increased the 2-h 
glucose concentration by 0.32 mmol/L for every unit increase in body condition score. The 
calculated spurious effect of dosing on body weight was 0.10 mmol/L/unit increase in BCS, 
or approximately 30% of the overall increase in 2-h blood glucose induced by obesity. Our 
results showed a significant difference between the upper 95% reference interval for 2-h 
glucose concentrations in lean and obese cats (6 and 8.9 mmol/L), indicating that one 
reference limit for all cats was inappropriate. However, employing different reference limits 
for different body condition scores or body weights could cause confusion and be less 
practical. Based on our results, a simplified test for assessment of glucose tolerance—relying 
on a 2-h blood glucose measurement and a single reference range for normal cats—would 
need to account for the dosage effects of obesity. This could be achieved in overweight and 
obese cats by adjusting down either the dose of glucose administered, or the 2-h glucose 
value before interpretation with standardised reference limits. 
Based on the associations found, we propose two ways to adjust the measured 2-h glucose 
value, to account for the dosage effects of obesity. Both methods attempt to account for the 
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effects of dose alone, and therefore involve the relationships between body weight or 
condition, 2-min, and 2-h glucose concentrations. The direct causal effect (spurious effect) of 
2-min glucose concentration on 2-h glucose concentration was estimated by regressing 2-h 
glucose concentration on 2-min glucose concentration adjusted for BCS. Thus, our estimates 
of this relationship are independent of any decrease in insulin sensitivity in the obese cats. 
Adjustment using measured 2-min glucose is considered less ideal than using BCS because it 
relies on comparison with the calculated mean 2-min glucose concentration for lean cats, 
which may cause inaccuracies given that the standard deviation for the 2-min glucose 
concentration was relatively large. Also, this method requires a third blood sample, which 
would decrease the simplicity of the test, and would be more technically difficult than 
measurement of the fasting and 2-h samples because of the small leeway with timing. 
The preferred option is using BCS to adjust 2-h glucose based on the observed effect of BCS 
on 2-min glucose (method a), because it is likely to provide a reasonably accurate adjustment 
for 2-h glucose concentrations. Although there is some error in measuring BCS, an error of 1-
2 BCS units would only affect the adjusted 2-h glucose concentration by 0.10-0.2 mmol/L. 
Body weight is a more quantitative measure of the size of the cat than body condition score, 
however, the latter provides a better estimate of the extent of obesity, and had a bigger effect 
on many of the measured associations. Adjustments based on body weight would require 
knowledge of the cat’s previous ideal weight, or subjective assessment of each obese cat’s 
ideal weight, and this might be less accurate than an assessment of body condition score. 
However, adjustment on body weight could be useful in research or clinical practice where 
the actual increase in body weight above normal was known, or morphometric measures were 
used to calculate ideal body weight39,40. The alternative strategy proposed is to adjust the dose 
rate, with the aim of reducing the peak glucose concentration in obese cats to the same or 
similar to that in lean cats. This theoretical approach to calculation of the reduced dose rate 
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needs to be confirmed through an empirical study to identify the correct dose rate for 
different body condition scores in cats. The calculations used were theoretical and several 
assumptions were made, but regardless of these limitations, the spurious effect is likely small, 
particularly in relation to the magnitude of the precision error, and only of concern in an 
obese cat that is close to the cutpoint. 
Our study has provided an important foundation for the development of a feline equivalent to 
the human GTT for identifying glucose intolerance in cats. The feline test includes glucose 
being administered intravenously, but would require only 2 blood samples, and would 
provide clinical researchers and veterinary practitioners with a practical screening tool for 
prediabetes in cats. We propose that a standard reference range for 2-h glucose be developed 
to interpret GTT results for cats of all body condition scores, and this range should be 
determined from cats with ideal BCS (4 and 5). Testing of overweight and obese cats would 
then require an adjustment to compensate for the ‘dosage’ effects of obesity, following 
guidelines outlined in this research. 
The main limitations in this study are related to the fact that the study population was young 
adult cats less than 4 years of age, whereas glucose tolerance testing to identify prediabetic 
cats will have most use in senior cats because of the age predisposition to diabetes in this 
species. It is recommended that a longer fasting period before testing be used if cats are fed 
once a day with a high carbohydrate diet (50% of energy), because blood glucose 
concentrations may take 24 h to return to baseline in some cats41. Withholding food for 14 h 
is sufficient for 75% of cats fed twice daily a high carbohydrate diet42. Another limitation is 
that data was adjusted based on assumptions rather than actual measurements and the data 
quality could be improved by using real data in future studies such as by titrating the initial 
glucose concentrations during the GTT to the same levels of glycaemia in obese and lean 
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cats. These data was collected retrospectively and thus validation of the assumptions was not 
possible. However, this is a potential area for future studies. 
In conclusion, dosing obese cats based on body weight spuriously affects some measures of 
glucose tolerance in a glucose tolerance test, and could lead to cats being incorrectly 
classified as having impaired glucose tolerance. For an individual cat, the dosing effect is 
relatively small, and only of concern if 2-h blood glucose concentration is just above the 
upper cutpoint of the reference range – the maximum expected increase in 2-h glucose 
concentration is 0.4 mmol/L for obese cats (BCS 9 on a 1 - 9 scale). However, it has 
important implications for clinical studies assessing the effect of interventions such as diet or 
medication on glucose tolerance, if glucose concentrations are compared between lean and 
obese cats. This dosing effect may be accounted for in overweight and obese cats by 
adjusting down either the dose of glucose administered by 0.05 g for every kg increase above 
ideal weight, or the measured 2-h glucose value by 0.1 mmol/L for every unit of BCS 
increase above 5 on a 9- point scale, before interpretation with standardised reference limits.  
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Tables 
Table 4.1 Regression coefficients, 95% confidence intervals and P- values for the 
associations between body weight and body condition score and peak, 2-min, and 2-h blood 
glucose concentrations, and half- life (T ½) following glucose bolus of 0.5 g/kg body weight 
for 16 healthy cats assessed before and after a 9 to 12 mo ad libitum feeding period. 
Variables Peak blood 
glucose 
2-min blood 
glucose 
T ½  2-h blood 
glucose 
Body weight For every extra 
kg body weight, 
the estimated 
increase was 
1.50 mmol/L 
(95% CI 0.40 to 
2.61; P = 0.008). 
For every extra 
kg body weight, 
the estimated 
increase was 
1.48 mmol/L 
(95% CI 0.27 to 
2.69; P = 0.016) 
For every extra 
kg of body 
weight, T ½ 
increases by 5.5 
mins (95% CI 
0.4 to 10.6; P = 
0.034). 
For every extra 
kg body weight, 
the estimated 
increase was 
0.33 mmol/L 
(95% CI -0.01 to 
0.67; P = 0.057) 
Body condition 
score (BCS) 
For every extra 
unit of BCS, the 
estimated 
increase was 
1.06 mmol/L   
(95% CI 0.18 to 
1.94; P = 0.018) 
For every extra 
unit of BCS the 
estimated 
increase was 
1.14 mmol/L 
(95% CI 0.19 to 
2.09; P = 0.019). 
For every extra 
unit of BCS, T 
½ increases by 
5.6 mins (95% 
CI 2.5 to 8.8; P 
< 0.001) 
For every extra 
unit of BCS, the 
estimated 
increase was 
0.32 mmol/L  
(95% CI 0.11 to 
0.53; P = 0.003). 
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Table 4.2: Body condition scores (BCS), fasting blood glucose concentrations, T ½ values, 
and measured and adjusted 2-h blood glucose concentrations after a 9 to 12 mo ad libitum 
feeding period in 16 cats. Cats with suspected glucose intolerance based on T ½ values are 
bolded.  
Cat BCS 
Fasting blood 
glucose 
concentration 
mmol/L 
T ½ after 
weight gain 
(upper limit 
of normal 
reported as 
74[15] and 
95[7] min) 
Measured 
2-h blood 
glucose 
mmol/L  
Upper 
limit 6.0 
mmol/L  
Adjusted  
2-h blood 
glucose 
mmol/L  
using 
method a*  
Adjusted 
2-h blood 
glucose 
mmol/L  
using 
method 
b*  
Adjusted 
2-h blood 
glucose 
mmol/L  
using 
method 
c*  
1 9 5.0  105.67 5.7  5.3  5.4 3.6  
2 9 3  60.11 4.0  3.6  3.6 4  
3 9 4.4  40.31 3.2  2.9  2.9 2.4  
4 9 4.1 46.94 3.8  3.5  3.6 3.2  
5 6 3.9  54.57 3.1  3.1  3.1 2  
6 9 3.9  77.14 6.7  6.4  6.3 5.7  
7 9 4.6  57.63 2.7  2.4  2.5 2.7  
8 7 2.2  46.17 3.2  3.0  2.9 2.5  
9 7 3.9  116.78 7.4  7.2  7.3 7  
10 8 4.3  96.08 6.0  5.7  5.7 6.4  
11 7 3.5  69.2 4.4  4.2  4.2 4.1  
12 7 4.8  93.78 6.5  6.3  6.4 5.8  
13 7 4.6  70.41 4.1  3.9  3.8 3.6  
14 9 4.5  88.99 6.2  5.8  6.0 5.6  
15 9 5.0 62.16 4.5  4.1  4.1 4.6  
16 8 4.6  59.79 2.5  2.2  2.2 2.8  
 
a*(Cat’s actual BCS – 5) x 0.10 mmol/L. 
b* (Cat’s actual weight – Cat’s ideal weight) x 0.13 mmol/L 
c*(Cat’s actual 2-min glucose concentration – 17.8) x 0.09 mmol/L 
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Figures 
Figure 4.1: Causal diagram showing interrelationships between obesity and 2-min and 2-h 
blood glucose concentrations in cats undergoing a glucose tolerance test.  
 
 
 
 
 
 
 
Figure 4.2: Association between T ½ for glucose disappearance following an intravenous 
glucose infusion (dosed at 0.5 g/kg body weight) and each of 2-min blood glucose (A) (r = 
0.17; 95% CI -0.35 to 0.62; P = 0.518) and peak blood glucose (B) (r = 0.18; 95% CI -0.34 to 
0.62; P = 0.498) concentrations in 16 healthy lean cats. Lines are least squares lines of best 
fit. 
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effect of 2-min 
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based on 
body weight 
regardless of 
body 
condition 
score. 
Indirect effect of obesity on 2-h 
glucose concentration due to dosing 
based on body weight regardless of body 
condition score. 
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Figure 4.3: Associations between 2-min blood glucose concentration following an 
intravenous glucose infusion (dosed at 0.5 g/kg body weight) and each of body weight (A) 
(estimated increase for each extra kg body weight 0.14 mmol/L; 95% CI 0.27 to 2.69; P = 
0.016) and body condition score (B) (estimated increase for each extra unit of BCS 0.14 
mmol/L; 95% CI 0.19 to 2.09; P = 0.019) in 16 healthy cats assessed before (circles) and 
after (triangles) approximately 10 mo of ad lib feeding. Lines are least squares lines of best 
fit. 
A                                                                 B        
 
 
 
 
 
 
 
 
 
109 
 
Figure 4.4: Association between 2-h blood glucose concentration following an intravenous 
glucose infusion (dosed at 0.5 g/kg body weight) and each of 2-min blood glucose (A) (r = 
0.65; 95% CI 0.23 to 0.87; P = 0.006) and peak blood glucose (B) (r = 0.61; 95% CI 0.17 to 
0.85; P = 0.012) concentrations in 16 healthy lean cats. Lines are least squares lines of best 
fit. 
A                                                                   B      
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Figure 4.5: Association between 2-h blood glucose concentration following an intravenous 
glucose infusion (dosed at 0.5 g/kg body weight) and each of body weight (A) (estimated 
increase for each extra kg body weight 0.33 mmol/L; 95% CI -0.01 to 0.67; P = 0.057) and 
body condition score (B) (estimated increase for each extra unit of BCS 0.32 mmol/L; 95% 
CI 0.1 to 0.5; P = 0.003) in 16 healthy lean cats assessed before (circles) and after (triangles) 
approximately 10 mo of ad libitum feeding. Lines are least squares lines of best fit.  
A                                                                           B 
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Abstract 
Diabetes is typically diagnosed in cats once clinical signs are evident. Diagnostic criteria for 
prediabetes in cats have not been defined. The objective of the study was to establish 
methodology and cutpoints for fasting and 2-h blood glucose concentrations in healthy client-
owned senior cats (> 8 yrs) using ear/ paw samples and a portable glucose meter calibrated 
for feline blood. Of the 78 cats, 27 were ideal (body condition score (BCS) 4 or 5 out of 9), 
31 overweight (BCS 6 or 7) and 20 obese (BCS 8 or 9); 19 were Burmese and 59 non-
Burmese. Following an 18 - 24 h fast and an ear/paw blood glucose measurement using a 
portable glucose meter, glucose (0.5 g/kg bodyweight) was administered IV and blood 
glucose measured at 2 min and 2 h. Cutpoints for fasting and 2-h glucose concentrations were 
defined as the upper limits of 95% reference intervals using cats with BCS 4 or 5. The upper 
cutpoint for fasting glucose was 6.5 mmol/L. Of the overweight and obese cats, one (BCS 7) 
was above this cutpoint indicating evidence of impaired fasting glucose. The cutpoint for 2-h 
glucose was 9.8 mmol/L. A total of 7 cats (4 with BCS 8 or 9 including 1 Burmese; 3 with 
BCS 6 or 7, non-Burmese) were above this cutpoint and thus had evidence of impaired 
glucose tolerance. In conclusion, the methodology and cutpoints for diagnosis of prediabetes 
are defined for use in healthy cats 8 yr and older with a range of body condition scores.  
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Introduction 
In cats, 0.2% to 1%1-3 are reported to be diabetic compared to 44 to 10%4,5 of humans. 
Humans with blood glucose concentrations above normal but below diabetic for fasting or at 
2-h in a glucose tolerance test are classed as having impaired fasting glucose or impaired 
glucose tolerance respectively. They are considered prediabetic and develop diabetes at a rate 
of 5 - 10% per yr6,7.  It is estimated that over 50% of humans in the USA with diabetes are 
undiagnosed8, and the number with undiagnosed prediabetes is 3 to 4 times greater than with 
undiagnosed diabetes8. There are no corresponding data for cats in the veterinary literature. 
As in humans, there is a genetic predisposition for feline diabetes. Burmese cats from the 
United Kingdom and Oceania are approximately 4 times more likely to develop diabetes than 
other breeds9, with one in 50 affected2. 
Diagnostic criteria for subclinical and prediabetes in cats have not been defined, and cats are 
not typically diagnosed until clinical diabetes is evident. In obese cats, mild fasting or 
postprandial hyperglycaemia is reported to be the only early sign of diabetes, prior to onset of 
classical signs of diabetes such as polyuria10. Reported upper limits for normal fasting blood 
glucose in cats vary from 6.1 mmol/L11 to 9 mmol/L12-14; this variability is due at least in part 
to a lack of standardization of the test protocol.  
Intravenous (IV) glucose tolerance tests are used to assess glucose tolerance in cats15. The 
‘gold standard’ test requires multiple samples and interpretation can be difficult because of 
the complex calculations required to generate the necessary statistics such as glucose half- 
life, glucose clearance time and area under the curve. Veterinarians need screening tests for 
impaired fasting glucose and impaired glucose tolerance that are inexpensive, non-invasive, 
and easy to perform and interpret in a clinical setting. A standardized IV glucose tolerance 
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test would need a standardised glucose dose rate, fasting period, sampling times, and an 
established reference range applicable to all cats, lean, overweight and obese. 
Numerous portable blood glucose meters calibrated for human blood are used for glucose 
monitoring in cats16-18. Although precise, they are less accurate, typically measuring 0.5 to 
2.2 mmol/L lower than a serum chemistry analyses19. A meter validated for feline blood, 
requiring a 0.3 uL blood sample is now commercially available20, facilitating successful 
blood sampling from the ear or foot pad and more accurate measurements. A simplified 
protocol for IV glucose tolerance testing in cats using this glucose meter has been reported 
using a glucose dose of 1g/kg7, but from a practitioner’s perspective, the volume to be 
infused can be problematic. A glucose dose of 0.5 g/kg is typically used in cats for assessing 
glucose tolerance whereas 1 g/kg is used for assessing maximal insulin secretory capacity. 
Administering an IV glucose dose to overweight and obese cats based on bodyweight 
spuriously affects some measures of glucose tolerance21. This is presumed to occur because 
blood volume does not increase linearly with the increase in body weight due to obesity22. As 
a result, peak (2-min) glucose concentration is higher in obese cats, which subsequently 
increases 2-h glucose concentration when glucose is dosed on bodyweight21. This can be 
overcome by adjusting either the glucose dose or measured 2–h blood glucose concentration 
based on body condition score, so that one reference interval can be used for lean, overweight 
and obese cats. To the authors’ knowledge, these adjustments have not been applied to cats in 
the age group at risk of diabetes (≥ 8 yrs). 
The aims of this study were to establish methodology and cutpoints for fasting and 2–h blood 
glucose concentration in healthy client-owned, senior cats of varying body condition using 
ear/ paw samples and a portable glucose meter calibrated for feline blood, to compare these 
120 
 
between Burmese and non-Burmese cats, to apply adjustment equations to 2–h blood glucose 
concentrations in overweight and obese cats. 
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Materials and Method 
 Study overview: 
The protocol for these studies and the care and handling of these animals were approved by 
the Animal Experimentation Ethics Committee of the University of Queensland approval 
number SVS/040/10/NC/ABBOTT. In 78 client-owned cats, fasting blood glucose was 
measured from a paw or ear sample using a portable glucose meter then an IV glucose 
tolerance test performed using a glucose dose of 0.5g/kg. This was repeated in 8 of these cats 
23 to 57 d later to determine variability over time. An IV glucose tolerance test using the 
same protocol but a glucose dose rate of 1g/kg was also subsequently performed in 11 of the 
78 cats.  
 Animals:  
Clinically healthy client-owned cats ≥ 8 yrs (n = 90) were recruited though veterinary clinics, 
advertisements and radio interviews between May 2011 and November 2012. Cats were 
tested at the University of Queensland Small Animal Clinic and a private specialist cat clinic. 
All cats included in the study appeared clinically healthy during examination. The cats were 
not on any medications except routine flea and worming control. Exclusions were based on 
haematological and biochemical panels, body condition score (BCS) of ≤ 3 out of a 9- point 
scale23 and behaviour of the cats. Exclusions (n = 12) were for stress/ aggressive behaviour (n 
= 3), suspected pancreatitis based on increased fPLi of > 3.5 ug/L in line with the general 
interpretive guidelines of our reference laboratory (n = 2), hyperthyroidism (n = 3), ongoing 
health issues (n = 2), pancreatic cancer (n = 1) and BCS ≤ 3 out of 9 (n = 1). Remaining cats 
(n = 78) were classified as non-Burmese (n = 59) or Burmese (n = 19). Body condition scores 
of the cats (out of 9)23 included in the study were all assessed by one person (MRJ), and were 
4 (8 cats), 5 (19 cats), 6 (14 cats), 7 (17 cats), 8 (14 cats) and 9 (6 cats). Data was collected on 
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diets of the study cats and consisted of a variety of supermarket, premium and home cooked 
dry and tinned food. 
Protocol: 
Cats were admitted to the hospital the d before the glucose tolerance tests and all cats stayed 
overnight. On admission, a 5-mL venous blood sample was collected for a routine health 
screen performed by a commercial veterinary diagnostic laboratory (Idexx Laboratories, 
Brisbane Australia). The following morning, after food was withheld for 18 to 24 h, a jugular 
venous blood sample (4 mL) was collected for hormone assays and then a 22 - gauge catheter 
(Surflo 22G x1” intravenous catheter, Terumo Europe, Belgium) was placed in the cephalic 
vein and flushed (2 mL 0.9% sodium chloride (Baxter)). To allow for resolution of stress 
hyperglycemia, fasting blood glucose was measured 3 h after catheter placement24. A 
portable glucose meter calibrated for feline blood (AlphaTRAK) was used and the sample 
obtained from the paw or ear. Glucose (undiluted 50% glucose injection BP; Astra 
Pharmaceutical) (0.5g/kg) was then administered IV over 30 s via the catheter. A timer was 
started halfway through the infusion and blood samples were taken at 2 min, 2 h and then 
hourly until glucose returned to below our laboratory’s upper limit of normal fasting glucose 
concentration of 6.5 mmol/L25. On completion, the catheter was removed, cats were fed and 
discharged. 
 
Blood samples from syringes from 3 cats were analysed 20 times with 2 different portable 
glucose meters of the same brand within 1 h of collection to assess intra and inter-meter 
variability. The interassay CV for the glucose meter was 2 % and the intra-assay 3.3 %. To 
determine repeatability, fasting blood glucose assessments and glucose tolerance tests were 
repeated in 8 cats 23 to 57 d after their first admission (median 42 d). To compare the 
previously-derived adjustment equations with those derived from this population of cats, a 
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glucose tolerance test using the same protocol but a glucose dose rate of 1g/kg was also 
performed in 11 of the 78 cats (BCS 4 n = 3; 5 n = 3; 7 n = 4; 8 n = 1) 38 to 365 d later 
(median 60 d), depending on client availability, after their first glucose tolerance test. 
 
Statistical analyses: 
Reference intervals for fasting and 2-h glucose concentration were calculated using published 
method used in humans, whereby data are transformed as necessary and outliers identified 
and excluded from analysis26. This methodology results on average in a 10 % narrower 
reference interval than if outlier detection was not used27. Data were entered into a spreadheet 
(Microsoft Excel, Reference Interval Draft Version, Copyright 2005, University of 
Cincinnati), transformed to approximate a normal distribution using the Box-Cox 
transformation, and outliers excluded from subsequent calculations. Diagnostic cutpoints 
were defined as the upper limits of the 95% reference intervals. Associated 90% confidence 
intervals (CI) for the upper limits of the reference intervals were estimated using 
bootstrapping with 1000 replications. Based on a priori knowledge that some overweight and 
obese cats have abnormal glucose tolerance15, only lean cats (BCS of 4 or 5) were used for 
estimating fasting and 2–h reference intervals. Data from Burmese were pooled with non-
Burmese to determine reference intervals for fasting and 2-h glucose concentrations as the 
median glucose concentrations and interquartile ranges were similar (median fasting Burmese 
and non-Burmese 4.6 and 4.7 mmol/L, respectively, and 0.7 and 1.1 mmol/L respectively; 
median 2-h Burmese and non-Burmese 6.2 and 5.7 mmol/L respectively, and interquartile 
range 2.6 and 3.1 mmol/L, respectively. 
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Repeatability was established using repeatability coefficients calculated using specialized 
software (the Pairs etc module (version 3.57) of the WinPepi software (version 11.62; 
www.brixtonhealth.com)). 
 Repeatability coefficients were calculated:  
based on the within-cat variance. Approximate 95% CIs were obtained by substituting 
confidence limits for the within- cat variance, estimated by the method described by Zar28 
(formula 7.16). 
Associations between breed (Burmese or non-Burmese) and each of 2-min and 2-h glucose 
concentrations were assessed using linear regression with body condition score, age (both 
fitted as continuous variables) and sex (fitted as covariates). Associations between body 
condition score and 2-min glucose concentration, 2-min and 2-h glucose concentration and 
fasting and 2-h glucose concentrations were each assessed using univariable linear regression. 
Homoscedasticity of residuals were assessed using plots of residual versus fitted values. The 
effects of glucose dose on 2-h glucose concentration were also assessed using linear 
regression, with cat-time as the unit of analysis, with cat fitted as a random effect; maximum 
likelihood estimation was used. Interactions between dose and each of breed (Burmese or 
non-Burmese) and body condition score (fitted as a continuous variable) were also assessed. 
Regression analyses were performed using a commercial software program (Stata (version 
12, StataCorp, College Station, Texas, USA)).  
 Adjustments of measured 2-h glucose: 
We used two previously developed algorithms (Reeve-Johnson et al, unpublished data), to 
compensate for the spurious effect on 2-h glucose concentration that arises from dosing on a 
bodyweight basis (rather than using total blood volume), as previously demonstrated in obese 
dogs22. Using one algorithm, observed 2-h glucose concentration was adjusted downward by 
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0.1 mmol/L for every unit of BCS above 5. Using the other algorithm, the difference between 
the observed 2-min blood glucose concentration and the mean 2-min blood glucose 
concentration of lean cats (17.5 mmol/L) was calculated, and multiplied by 0.09. The 
measured 2-h blood glucose concentrations were then adjusted downwards by subtracting the 
calculated product; this was done for all cats with values above the upper cutpoint.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
126 
 
Results 
 Fasting blood glucose concentrations 
The upper cutpoint for fasting blood glucose concentration in cats with BCS 4 and 5 (n = 27) 
was 6.5 mmol/L based on the upper limit of the 95% reference interval (Table 5.1). When the 
statistical power was increased by including all 78 study cats (BCS varied from 4 to 9), the 
upper cutpoint was 6.3 mmol/L and the 90% CI 6.0 to 6.5 mmol/L. Only 1 of the 51 cats 
(2%) with BCS 6 to 9 was classed as having impaired fasting glucose (> 6.5 mmol/L) based 
on this cutpoint (BCS 7; non-Burmese), as well as one of the lean cats (BCS 5; non-
Burmese). The lower limit of the 95% reference interval for cats with BCS 4 and 5 was 3.9 
mmol/L (90% CI 3.6 to 4.2 mmol/L), and when all 78 cats were included, was 3.4 mmol/L 
(90% CI 3.2 to 3.5 mmol/L).   
  
When 8 lean cats were retested 23 to 57 d later, the repeatability coefficient for fasting blood 
glucose concentration was 1.1 mmol/L (95% CI 0.7 to 2.2 mmol/L) when data from 7 of the 8 
cats were used. One cat had an initial value of 4.6 mmol/L, and a value of 12.3 mmol/L after 
a further 43 d. At the first and second tests, fasting blood glucose concentrations for the other 
7 cats ranged from 3.6 to 5.6 mmol/L and 4.1 to 5.7 mmol/L, respectively. When this cat was 
included in the data, the repeatability coefficient was 5.4 mmol/L (95% CI 3.7 to 10.4 
mmol/L). As the 95% CI for these repeatability coefficients was wide, this estimate should be 
interpreted with caution. The second value for this latter cat was inconsistent with fasting 
concentrations in healthy cats and may have been the result of stress hyperglycaemia or 
laboratory error such as a bubble in the blood sample. These results indicate that when cats 
are tested twice 23 to 57 d apart, glucose concentrations differ within cats by up to about 1.1 
mmol/L for most cats.  
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 2-h blood glucose concentrations 
 
The cutpoint for 2-h blood glucose concentration in an IV glucose tolerance test using 0.5 
g/kg glucose estimated from cats with BCS 4 or 5 (n = 27) was 9.8 mmol/L. This was the 
upper limit of the 95% reference interval (90% CI 8.5 to 10.7 mmol/L) (Table 5.1). The 
repeatability coefficient for 2-h blood glucose concentration was 3.8 mmol/L (95% CI 2.6 to 
7.2 mmol/L). 
 Adjustment for effect of BCS on interpretation of glucose tolerance test results  
The measured 2-h blood glucose concentration for cats in the present study was adjusted in 
overweight and obese cats (BCS > 5) using 2 previously established algorithms (Reeve-
Johnson et al, unpublished data), and the adjusted values compared to the upper cutpoints 
established in the present study. A total of 7 cats had 2-h glucose concentrations above the 
diagnostic cutpoint reported above of 9.8 mmol/L (4 obese (BCS 8 or 9), 3 overweight (BCS 
6 or 7); 5 domestic, 1 Burmese and 1 British Blue). Adjusted 2-h blood glucose 
concentrations from both algorithms for these 7 cats were all above the upper limit of the 
reference range, and thus all were considered to be glucose intolerant (Appendix tables 5.3 
and 5.4).  
 
 Effect of breed on fasting and 2-h blood glucose concentration 
Although Burmese cats are overrepresented amongst diabetic cats, after adjusting for BCS, 
sex and age, Burmese cats (n = 19) did not have significantly differing fasting and 2-h 
glucose concentrations compared to non-Burmese (n = 59) cats. After adjusting for BCS, sex 
and age, the estimated difference in mean 2-h blood glucose concentrations (Burmese minus 
non-Burmese) was -0.6 mmol/L (95% CI of difference -1.4 to 0.2; P = 0.140). After adjusting 
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for BCS, sex and age, the estimated difference in mean 2-h blood glucose concentrations 
(Burmese minus non-Burmese) was 0.1 mmol/L (95% CI of difference -1.1 to 1.3; P = 
0.856). 
 
 Associations between body condition score and 2-min glucose concentration, and 2-min 
glucose and 2-h glucose concentrations 
There tended to be a positive association between 2-min glucose concentration and body 
condition score; for every 1unit increase in body condition score, 2-min glucose 
concentration increased by 0.8 mmol/L (95% CI -0.1 to -1.7mmol/L; P = 0.078). There was 
no significant association between 2-min and 2-h glucose concentrations (P = 0.396) but the 
point estimate was consistent with a positive relationship; for every 1 mmol/L increase in 2-
min glucose concentration, 2-h glucose concentration increased by 0.04 mmol/L (95% CI -
0.054 to -0.14). Although, these point estimates were not significantly associated, they were 
of similar magnitude to previously determined adjustments in another cohort of cats (Reeve-
Johnson et al, unpublished data). 
 
 Effect of glucose dose rate on 2-h blood glucose concentrations 
We evaluated the effect of glucose dose (0.5 versus 1.0 g/kg bodyweight) on 2-h blood 
glucose concentrations in lean, overweight and obese cats (n = 11; BCS 4 n = 3; 5 n = 3; 7 n 
= 4; 8 n = 1). Increasing the dose rate from 0.5 g/kg to 1 g/kg increased 2-h glucose in non-
Burmese cats by an estimated 1.4 mmol/L (95% CI -0.1 to 2.8; P = 0.031). However, in 
Burmese, relative to 0.5 g/kg, 1 g/kg had a much larger effect; 2-h glucose was 6.4 mmol/L 
higher than for the lower glucose dose (95% CI 4.6 to 8.1; P < 0.001; P for interaction 0.001). 
Mean 2-h glucose concentration for Burmese was estimated to be 0.7 mmol/L lower than for 
non-Burmese (95% CI 1.2 lower to 2.6 higher; P = 0.483) at 0.5 g/kg but 5.6 mmol/L higher 
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(95% CI 3.7 to 7.5; P < 0.001) at 1 g/kg. No significant interaction was detected between 
dose and BCS (P for interaction 0.334). Increasing the dose rate from 0.5 g/kg to 1 g/kg 
increased 2-h glucose by an estimated 2.2 mmol/L (95% CI -0.4 to 4.9; P = 0.098) where 
BCS was 4, and by an estimated 4.5 mmol/L (95% CI 1.4 to 7.7; P = 0.005) where BCS was 
8. 
 
 Associations between fasting glucose concentration and 2-h glucose concentrations 
We assessed whether there was an association between fasting glucose and glucose 
concentrations at 2-h in an IV glucose tolerance test, because cats with impaired fasting 
glucose might be expected to also have impaired glucose tolerance. For every unit increase in 
fasting glucose, 2-h glucose increased by 0.5 mmol/L (P = 0.0064; 95% CI 0.2 to 0.9). Two 
cats of BCS 5 and 7 had high fasting glucose concentrations (>10 mmol/L) and this positive 
relationship between fasting and 2-h glucose was almost entirely due to these cats.  
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Discussion 
In this study of cats 8 yr or older, we established a standardized clinical protocol for 
diagnosing impaired fasting glucose and glucose tolerance using a portable glucose meter. 
The upper cutpoint for normal fasting glucose concentration was 6.5 mmol/L and for 2-h 
glucose concentration following a simplified IV glucose tolerance test (delivering 0.5 g/kg 
glucose dose) was 9.8 mmol/L. When applied to cats with a range of body condition scores, 
3% were classed as having impaired fasting glucose and 9% as glucose intolerant.  In 
contrast, 12 to 26 %29 of human populations in USA, Europe and Australia have impaired 
fasting glucose and 7 to 28% are reported to be glucose intolerant30,31.  However, reported 
rates of overweight and obesity are typically higher in these human populations (66-75%) 
than are reported from feline studies (1432 - 63%33), although the rate in cats varies with the 
population studied, and how body condition was measured33,34.  In the absence of more 
accurate data on the frequency of prediabetes in the feline population 8 yrs of age or older, it 
is unknown if more stringent cutpoints should be applied, for example, 90% reference 
intervals or lower. For fasting glucose, the 90% interval would result in an upper cutpoint of 
6.2 mmol/L.  In humans, a link between microvascular disease such as retinopathy and 
glucose concentrations35 is well accepted. As this link has not been established in cats, we 
have chosen to use the 95% reference intervals.  
 
Currently, there is no accepted cutpoint between impaired fasting glucose and diabetes in cats 
and various values have been suggested ranging from 9.536 to 16 mmol/L, with the latter 
approximately representing the renal threshold14. In humans, cutpoints were established in 
part based on the association with renal and microvascular complications6. There is an urgent 
need for these cutpoints to be established in cats, especially for fasting glucose, because this 
measurement is easily evaluated in clinical practice. The prevalence of undiagnosed diabetes 
131 
 
in adults in a U.S. population was 2.8%, increasing to 5.8% by the age of 60 yrs37. It is 
unknown how many cats have undiagnosed diabetes. Until the cutpoint for diabetes is 
established, the authors suggest using 6.5 mmol/L as the upper cutpoint for impaired fasting 
glucose, and unstressed cats with glucose concentrations of >10 mmol/L that are confirmed 
with repeated measurements be considered diabetic38. 
 
Humans with impaired fasting glucose or impaired glucose tolerance are considered 
prediabetic6,29,30, because they are at high risk of developing diabetes, with 5-10% of 
individuals progressing to diabetes per yr35.   Evidence-based cutpoints are important for 
diagnosing prediabetes in at risk cats, such as obese and Burmese cats. Because cats with 
impaired fasting glucose or glucose intolerance are at increased risk of diabetes7, prediabetic 
cats need to be identified, and management regimes implemented including weight loss and 
dietary intervention. 
 
 Repeatability of fasting blood glucose concentrations 
Repeatability coefficients describe repeatability from a clinical perspective, ie. if the same 
animal is sampled on different day, how much variation is likely between two results. This 
incorporates both the within lab precision plus the biological variation within the same 
animal. Repeatability studies showed that fasting glucose concentrations differed within cats 
over 3-7 weeks by approximately 1.0 mmol/L for most cats. The group size, the 
heterogeneity and the lack of acclimatization would have contributed to the relatively large 
variation. Diagnosis of impaired fasting glucose or impaired glucose tolerance in humans is 
based on the mean of two values measured no more than 3 months apart6,30, and a similar 
recommendation would be prudent for cats. 
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 Reference values for 2-h blood glucose concentrations 
Our upper cutpoint for 2-h glucose concentration of 9.8 mmol/L was similar to 9.5 mmol/L 
established previously by Link et al14 , but higher than 6.0 mmol/L calculated from 
Appleton’s raw data39 (data not shown), and likely higher than estimated from Hoenig’s15 
lean cats (mean concentration estimated from graph was 5.6 mmol/L. The latter two studies 
used acclimatized research cats, and inserted jugular catheters under general anesthesia prior 
to obtaining blood samples, decreasing the probability for stress hyperglycaemia.  They also 
used automated analysers which delayed sample analysis and might have contributed to lower 
glucose concentrations. Link et al14 used human portable glucose meters calibrated for whole 
blood which are biased to lower readings than meters calibrated for cat blood that provide 
plasma-equivalent measurements20. Appleton’s cats were much younger (1-5 yrs old) and 
there is some evidence glucose tolerance decreases with age in cats40.  
 
 Results from an IV glucose tolerance test is more sensitive (but slightly less specific) than 
fasting blood glucose for identifying people at high risk of diabetes30. Reflecting this higher 
test sensitivity, impaired glucose tolerance is more prevalent than impaired fasting glucose in 
human populations30. Similarly, in our study, 9% of all cats and 20% of obese cats had 
impaired glucose tolerance, whereas only 3% of overweight cats (BCS 6–7), and no obese 
cats had impaired fasting glucose. We tested only cats ≥ 8 yr old and recruited a large 
proportion (65%) that were overweight or obese, because this age group and body condition 
are at greatest risk of developing diabetes. Also, glucose tolerance decreases with age and 
increasing body condition15,41. The prevalence of abnormal glucose homeostasis would be 
expected to be lower if all ages or more lean cats had been included. 
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Repeatability for 2-h blood glucose concentrations 
Based on our results, there is a 95% expectation that two measurements would differ within 
cats by less than 3.8 mmol/L but by as much as 7.2 mmol/L.  Caution is necessary when 
interpreting a single test result in client-owned cats because compared to acclimatized cats, 
non-acclimatized cats have a longer glucose half-life, attributed to stress42. Struggling 10 min 
prior to blood sampling is reported to increase blood glucose by as much as 10 mmol/L in 
cats24. We recommend retesting cats with glucose concentrations above the cutpoints, based 
on the variability of glucose tolerance test results in humans43-45 and cats42, although owner 
compliance may limit retesting for client-owned cats.   
  
 Effect of breed on fasting and 2-h blood glucose concentrations and dose 
Neither fasting nor 2-h blood glucose concentrations were higher in Burmese compared to 
non-Burmese cats. Despite this, Burmese are 3 to 4 times more likely to develop diabetes 
than non-Burmese cats46. Because Burmese had significantly higher 2-h blood glucose 
concentrations at the higher dose rate, it could suggest relative intolerance to glucose at 
higher doses and this warrants further investigation.  
 Protocol standardization  
The glucose dose rate used for a glucose tolerance test depend on the measurements of 
interest. In cats, 1 g/kg is more sensitive than 0.5 g/kg for determining abnormalities in 
insulin secretory patterns and maximum insulin secretory capacity15.  However, a lower 
glucose dose rate (i.e. 0.5 g/kg) is used when investigating insulin action14,39. Our study used 
a glucose dose rate of 0.5 g/kg. The higher dose of 1 g/kg was observed to cause nausea and 
distress in some cats (personal observations Reeve-Johnson and Gottlieb) and the lower dose 
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rate (and therefore volume of injection) was considered more user-friendly for practitioners. 
However, at 1 g/kg, the significantly higher 2-h glucose concentrations in Burmese compared 
to non-Burmese cats raises the question whether a higher glucose dose can better differentiate 
cats with impaired glucose tolerance. 
Our aim was to establish reference intervals for use in veterinary practice. Our protocol 
decreases technical and laboratory variability reported to affect measured blood glucose 
concentrations15. The same type of portable glucose meter can be used in each veterinary 
practice to measure glucose immediately after blood collection, avoiding the variable time 
delay in measuring glucose using a variety of serum chemistry analysers in external 
laboratories. Postprandial glucose concentrations can be strongly influenced by diet47 and 
thus blood glucose should be measured in fasted cats.  This requires a 14-h fast if less than 
50% of the daily energy requirement is consumed, and a 24-h fast after 100% of the daily 
energy requirement is consumed48. In our study, cats were fasted for 18-24 h and hospitalized 
overnight to avoid owner non-compliance and to minimize confounding of blood glucose 
measurement by stress. 
 
Associations of 2-min and 2-h glucose concentrations and adjustment for obesity 
Adjustment for the spurious effects of obesity on glucose measurements following glucose 
dosing based on body weight was further evaluated in this study. While the associations 
between 2-min and 2-h glucose concentrations were not significant in the present study 
compared to our previous study (Reeve-Johnson et al, unpublished data), the calculated 
values for adjustment were very similar to those previously reported (0.05 versus 0.09 
mmol/L per unit of body condition above 5; P = 0.282 versus P = 0.006 respectively). Hence, 
any cat with a BCS ≥ 6 which is persistently just above the cutpoint at 2 h should have the 
observed glucose concentration adjusted downward by 0.1 mmol/L per unit of BCS above 5. 
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The 2-min blood sample following the glucose injection was difficult to obtain with accurate 
timing using a lancing device on the ear using one veterinarian and one handler. Adjusting on 
BCS is more precise (Reeve-Johnson et al, unpublished data), and it is therefore 
recommended.  
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Conclusion 
We have established the methodology and cutpoints for fasting glucose and glucose tolerance 
in a simplified intravenous glucose tolerance test for identifying prediabetic cats in clinical 
practice with lean or obese body condition. We recommend 6.5 mmol/L for the cutpoint 
between normal and impaired fasting glucose, and 9.8 mmol/L for the 2-h glucose cutpoint 
between normal and impaired glucose tolerance when using a glucose dose of 0.5g/kg with 
blood glucose measured from ear or pad samples using a portable glucose meter calibrated 
for feline blood and performed after an overnight fast and hospitalization. Impaired fasting 
glucose and glucose intolerance should be confirmed by repeat measurements, to minimize 
the probability of incorrectly diagnosing a cat with stress hyperglycaemia as prediabetic. 
Using the criteria established, 20 % of obese cats 8 yr of age or older are glucose intolerant. 
Prospective studies are required to determine the relative risk of diabetes in cats with glucose 
concentrations above these cutpoints.  It is recommended that measured 2-h glucose 
concentration be adjusted downward by 0.1 mmol/L for every BCS above 5, and tests be 
repeated to confirm abnormal glucose tolerance. 
 
 
 
 
Table 5.1: Descriptive statistics and upper limits of 95 % reference intervals (90 % 
confidence intervals) in mmol/L after fasting, and 2 min and 2 h after a glucose infusion of 
0.5 g/kg bodyweight iv for all cats (n = 78) and various sub-groups; BCS was assessed using 
a 9-point scale. 
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Sub-group of cats 
Variables  
Fasting blood 
glucose 
(mmol/L) 
2-min blood 
glucose 
(mmol/L) 
2-h blood 
glucose 
(mmol/L) 
BCS 4 or 5 n=         27          27         27 
  Mean 5.1 23.3 5.8 
  Median  4.9 23.4 5.4 
  SEM 0.3   1.2 0.3 
  SD 1.6   6.2 1.5 
  Range        2.4-12.3         12.8-35.9       3.4-9.6 
  95% reference interval upper limit 6.5  36.7 9.8 
  Upper limit 90% CI       6.0-6.7         33.7-38.6         8.5-10.7 
BCS 4 or 5; Burmese 
only n=           6           6           6 
  Mean 4.5 20.7 6.1 
  Median  4.7          23           6 
  SEM 0.4   2.6 0.9 
  SD 1.1   6.4 2.2 
  Range       2.4-5.4         12.8-28.7       3.4-9.6 
  95% reference interval upper limit 1 1 1 
  Upper limit 90% CI 1 1 1 
 BCS 6 or 7 n= 31 31 31 
  Mean 4.9 24.6 6.4 
  Median  4.4 25.1 5.7 
  SEM 0.3            1 0.5 
  SD           1.5   5.7 2.6 
  Range        3.6-12.4         13.7-35.9 3.4-15.7 
  95% reference interval upper limit 9.1 36.4 13.3 
  Upper limit 90% CI         6.0-10.8         33.3-38.9 10.4-15.6 
 BCS 8 or 9 n= 20 20 20 
  Mean 4.6 25.4 7.9 
  Median  4.6 24.8 7.9 
  SEM 0.2   1.2 0.6 
  SD 0.9   5.5 2.7 
  Range       3.2-6.3         17.3-38.7 3-12.9 
  95% reference interval upper limit 6.6  39.1 14.1 
  Upper limit 90% CI       6.0-7.1          33.8-42.9 12.1-15.8 
All cats (BCS 4-9) n=         78           78 78 
  Mean 4.9   24.4 6.6 
  Median  4.7   24.7 5.8 
  SEM 0.2     0.7 0.3 
  SD 1.4     5.8 2.4 
  Range         2.4-12.4          12.8-38.7 3.0-15.7 
  95% reference interval upper limit 6.3  36.3 12.8 
  Upper limit 90% CI      6.1-6.5          34.4-37.9 11.5-13.9 
    1 Number of cats was insufficient to estimate reference interval 
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Abstract 
The aim was to determine the reference interval for screening blood glucose in senior cats, to 
apply this to a population of obese senior cats, to compare screening and fasting blood 
glucose, to assess whether screening blood glucose is predicted by breed, bodyweight, body 
condition score (BCS), behaviour score, fasting blood glucose and/or recent carbohydrate 
intake, and to assess its robustness to changes in methodology. 120 clinically healthy client-
owned cats aged 8 years and older of varying breeds and body condition scores. Blood 
glucose was measured at the beginning of the consultation from an ear/ paw sample using a 
portable glucose meter calibrated for cats, and again after physical examination from a 
jugular sample. Fasting blood glucose was measured after overnight hospitalization and 
fasting for 18-24 hours. The reference interval upper limit for screening blood glucose was 
189 mg/dL (10.5 mmol/L). Mean screening blood glucose was greater than mean fasting 
glucose. Breed, bodyweight, BCS, behaviour score, fasting blood glucose concentration, and 
amount of carbohydrate consumed 2 to 24 hours before sampling collectively explained only 
a small proportion of the variability in screening blood glucose.: Screening blood glucose 
measurement represents a simple test, and cats with values from 117 mg/dL to 189 mg/dL 
(6.5 mmol/L to 10.5 mmol/L) should be retested several hours later. Cats with initial 
screening blood glucose >189 mg/dL (10.5 mmol/L), or a second screening blood glucose 
>116 mg/dL (6.4mmol/L) several hours after the first, should have fasting glucose and 
glucose tolerance measured after overnight hospitalization.  
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Introduction 
Diabetes occurs in 1 in 50 to 1 in 400 cats, depending on the population studied, and risk 
factors include age, male sex, obesity and breed. Burmese cats are overrepresented in Europe 
and Australasia 1,2 and Russian Blue, Maine Coon and Siamese in the USA3. The terms 
impaired glucose tolerance and impaired fasting glucose refer to an intermediate stage 
between normal glucose homeostasis and diabetes, now referred to as prediabetes4,5.   At least 
60 % of humans who develop diabetes have either impaired glucose tolerance or impaired 
fasting glucose identified in the previous 5 years6, and up to 33% of people with impaired 
glucose tolerance develop diabetes over a two year period7.  If identified before progression 
to diabetes, these individuals usually return to reasonable glycaemic control with weight loss, 
dietary management, and exercise. As in humans, progression from impaired fasting glucose 
and impaired glucose tolerance to diabetes also occurs in cats. Of cats in diabetic remission 
with moderate impaired fasting glucose (≥135- ≤ 151 mg/dL; ≥7.5- ≤ 8.4 mmol/L) or 
moderate glucose intolerance (n=21), 75% and 38%, respectively, developed diabetes within 
9 months of testing8. Impaired fasting glucose is rarely diagnosed in cats, and mild increases 
in blood glucose are mostly attributed to stress hyperglycaemia associated with the veterinary 
visit or with illness6,9. As in humans, it is likely advantageous to differentiate cats with 
transient hyperglycaemia associated with stress or eating, from cats with persistent mild 
increases in glucose (prediabetic), so appropriate therapy can be implemented to prevent 
progression to overt diabetes. Measurement of fasting glucose concentration is the gold 
standard in human medicine used to diagnose impaired fasting glucose. However, fasting can 
be problematic in client-owned cats because the postprandial period in some cats fed twice 
daily can exceed 14 h, and 24 h in some cats fed once daily10. Although owners can fast cats 
at home, it does not resolve the effect of stress of travel to the clinic on blood glucose 
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concentrations. Therefore, measurement of fasting blood glucose at home or in the clinic may 
not be a practical screening test for some pet cats. 
Casual blood glucose, defined as blood glucose measured unrelated to time of eating or type 
of food, is used as a screening test to diagnose diabetes in humans11.  In humans, the lower 
cutpoint for diabetes for casual blood glucose is higher4,11 than for fasting glucose (>200 
mg/dL;11.1 mmol/L versus >126 mg/dL; 7.0 mmol/L), and requires the presence of classical 
signs for definitive diagnosis. It is recommended that casual blood glucose concentrations 
above fasting values, but unaccompanied by diabetic signs, are confirmed by measurement of 
fasting blood glucose and glucose tolerance testing because of the potential for confounding 
factors to increase blood glucose4, such as “white coat” hyperglycaemia associated with 
stress12,13. 
In cats, stress hyperglycaemia is a major factor confusing diagnosis of diabetes, and 
struggling can increase blood glucose by as much as 180 mg/dL (10 mmol/L)6. Cats without 
clinical signs of diabetes but blood glucose concentrations above the upper cutpoint for 
normal could have prediabetes or subclinical diabetes, or a response to stress or eating. 
Where other risk factors are present, such as senior age and obesity, it would be prudent to 
determine if the hyperglycaemia is persistent and consistent with abnormal glucose 
homeostasis, or transient and consistent with stress-induced hyperglycaemia or eating.  
Measurement of blood glucose in capillary blood from the ear or pad using a portable glucose 
meter requires less restraint than for venipuncture, which may help reduce the effect of stress 
on measurement of blood glucose14-16. Numerous portable blood glucose meters calibrated for 
human blood have been used in cats17-19 and although precise, have lower accuracy than 
meters calibrated for feline blood, and typically under-report blood glucose by 8-18 mg/dL 
(0.4-1.0 mmol/L)20. The availability of a portable glucose meter calibrated for feline blood 
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(AlphaTRAK Glucose Monitoring System, Zoetis) and requiring only a small sample volume 
(0.3 uL)21, facilitates more accurate measurement of blood glucose in cats.  
The aims of this study were i. to establish the reference interval for a screening blood glucose 
test in client-owned cats aged 8 years and older, measured on entry to the clinic from a pad or 
paw sample using a glucose meter calibrated for cat blood (screening blood glucose), ii to 
apply this in a population of obese cats, iii to determine if selected variables account for 
variability in screening blood glucose (breed, bodyweight, body condition score, behaviour 
score, fasting blood glucose, recent carbohydrate intake) and iv to determine if blood glucose 
is affected by changes in screening blood glucose methodology that could be expected in 
veterinary practice, such as using a jugular sample or external laboratory.   
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Materials and Methods 
The protocol for these studies and the care and handling of these animals were approved by 
the Animal Experimentation Ethics Committee of the University of Queensland approval 
number SVS/040/10/NC/ABBOTT. 
Animals 
Client-owned, neutered cats 8 years and older (mean 10.9 years, range 8-18 years; n=134, 
Table 6.1) presenting for a routine health check at local veterinary clinics in Brisbane were 
assessed. Other than for excess body condition in some cats, cats enrolled in the study were 
assessed as healthy based on results of a clinical examination, patient history, haematological 
and biochemical assays, total thyroxine, and fPLi. Body condition score (BCS) was recorded 
on scale of 1 to 9, and cats between 4 and 9 were included22. Exclusions (n=14) were due to 
chronic renal failure (n=2), hyperthyroidism (n=6), suspected pancreatitis based on increased 
fPLI (> 3.5 ug/L) (n=1), gastrointestinal neoplasia detected at initial examination (n=1), 
inability to sample from an ear or paw pad (n=1), and BCS was ≤3/9 (n=2) or not recorded 
(n=1). Reference intervals were established using cats with ideal body condition scores (4-
5/9, n=49), and then applied in a population of otherwise healthy overweight (6-7/9, n=45), 
and obese (8-9/9, n=26) cats. The mean bodyweight of the 120 cats was 5.5 kg (range 2.9-
10.0 kg, Table 6.1). 
The following definitions for blood glucose measurement methods were used: ‘screening’ 
(measurement any time after eating and on entry to the consultation room prior to history 
taking and physical examination, from an ear or paw pad blood sample, using a portable 
glucose meter calibrated for cat blood), and ‘fasting’ (after overnight hospitalisation and 
withholding food for 18-24hr, from ear or paw pad blood sample, and measurement by 
glucose meter).  To determine the robustness of screening blood glucose to some variations in 
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sampling and measurement that could be expected in a busy veterinary practice, blood 
glucose was also measured using a glucose meter from a venepuncture sample obtained any 
time after eating and after history taking and physical exam, with blood dropped directly 
from the syringe after removal of the needle (traditional-meter). It was then placed in a tube 
containing the anticoagulant sodium fluoride/potassium oxalate (FO) and measured by meter 
(traditional-meter-FO) and by an external laboratory in plasma (traditional-laboratory-FO).  
Experimental protocol 
After entry of the client and their cat into the consulting room for screening blood glucose 
measurement, a drop of blood was obtained from the pinna margin (n=106) or edge of the 
pisiform pad (n=11) using a lancet (AlphaTRAK lancing device, Zoetis). The method of 
sampling (pinna or pad) was not recorded for 3 cats. Whenever possible, the cat was 
positioned with minimal restraint with its fore-paws on the shoulder of the client. To increase 
perfusion, the ear/ paw was warmed by holding a cotton wool ball soaked in warm water and 
squeezed dry to the area for approximately 10 seconds. The drop of blood was analysed 
immediately using the portable glucose meter using glucose oxidase methodology 
(AlphaTRAK, Zoetis) (screening blood glucose). Behaviour in cats were assessed by the 
clinician at the time of the screening blood glucose measurement and an integer score from 0 
to 4 allocated based on previously determined criteria6, where 0 indicates no behaviours 
suggesting stress and 4 indicates behaviours suggesting extreme stress. Behaviours assessed 
to determine each cat’s score were escape attempts including struggling, vocalization, 
hypersalivation, mouth breathing, aggression and immobility. 
The medical history, indoor or outdoor access, body weight (in kg), body condition score, and 
feeding (timing, and type and amount of food fed) were recorded, and a physical examination 
was performed. For 105 of the 120 study cats, a venous blood sample was taken at the end of 
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the consultation and measured with the meter (traditional-meter). For 48 of these, the sample 
was then placed into a tube containing the anticoagulant sodium fluoride/potassium oxalate 
and blood glucose concentration measured with the meter after using a syringe to aspirate a 
droplet (traditional-meter-FO), and the same tube was then sent to a commercial veterinary 
laboratory (Idexx Laboratories, Brisbane Australia) for blood glucose analysis with an 
automated serum chemistry analyser (Beckman Coulter AU 600) which used the hexokinase 
reaction (traditional-laboratory FO). For the portable glucose meter, the previously 
established inter-assay precision was 2% (coefficient of variation) and intra-assay 3.3%23. For 
the laboratory method, within-run precision was <3% and total precision <3%. 
Study cats that were compliant and whose owner gave consent (n=74) were subsequently 
hospitalised overnight, and samples collected for fasting blood glucose and a simplified 
glucose tolerance test conducted. This was done on the day after the cat's first study visit for 
51 cats and fasting values from only these cats were used in statistical analyses. Cats were 
fasted and glucose was measured at 0 h (fasting blood glucose) and again 2 h after receiving 
0.5g/kg glucose iv, using the same pinna/ pad technique and portable glucose meter. Results 
from these samples are reported in a separate publication23 but comparisons between 
screening blood glucose and fasting blood glucose, and some individual glucose tolerance 
test results are reported here. 
Dietary carbohydrate calculations 
Carbohydrate consumption 2-24 h and 2-12 h prior to the screening blood glucose 
measurement was estimated. Carbohydrate consumed in the last two hours before sampling 
was not included in the calculations as blood glucose concentration would have been 
minimally affected by this24. Owners were informed that dietary data would be collected from 
them and when possible, they were emailed the data capture form prior to the consultation. 
Owners recorded food, amount fed and timing of feedings. Dietary composition data supplied 
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by the various food manufacturers were used to calculate the amount of carbohydrate 
(nitrogen-free extract) in grams consumed. Estimates were not generated for those cats whose 
owners provided incomplete or unreliable data on the food, amounts and timing of foods 
given/eaten by the cat (n=55 of the 120 study cats).  
 
The nitrogen-free extract consumption of cats fed ad libitum (defined as food always or 
nearly always present, and in excess of what could be consumed) (n=39 cats) was calculated 
using estimated daily metabolizable energy requirements. Two methods were used: 
a. Daily consumption was estimated at 60 kcal/kg/24 hours or 30 kcal/ kg/12 hr.  
b. Using the following formula24,25: Daily energy requirement = 151.8 X 
(bodyweight (kg))0.4 - 87.5. The exponent of 0.4 and the constants 151.8 and 87.5 
are reported to provide an accurate estimate of daily energy requirements/ kg 
bodyweight in cats of various body conditions from lean to obese 25,26.  
 
Carbohydrate intake for the period (i.e. for 12 or 24 h) was then calculated for each cat as 
estimated daily energy intake for the period multiplied by the percentage of the dietary 
energy that was supplied by carbohydrate. For cats meal-fed once daily (n=26 cats), time 
when food was replenished was used to calculate the cats’ estimated consumption, assuming 
that 50% of daily energy provided was eaten in the 12 h following feeding, and 100% of daily 
energy provided was eaten in 24 hours, if bowls were replenished once daily.  For cats fed 
twice or more times daily, amount fed (data provided by the owner) was used for calculation 
of carbohydrate intake in 12 and 24 h. These owners accurately kept a record of how much 
the cats were fed and at what time. 
Statistical analyses 
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Reference intervals were determined after Box-Cox transformation and exclusion of outliers 
(Reference Interval Draft Version, Copyright 2005, University of Cincinnati). Confidence 
intervals for each reference interval limit were calculated using 1000 bootstrap resamplings. 
The upper cutpoints were defined as the upper limits of the 95% reference intervals. Medians 
and interquartile ranges were compared between Burmese and non-Burmese cats, and where 
absolute differences between the medians and interquartile ranges were <50% and <100% of 
the lowest median and interquartile range, respectively, the sub-groups of cats (ie. Burmese 
and non-Burmese) were pooled, an approach that has been used previously27. 
 
All other analyses were performed using a statistical software program (Stata (version 14, 
StataCorp, College Station, Texas, USA). Means were compared between screening and 
fasting samples using cats with BCS 4 or 5 whose fasting blood glucose was assessed on the 
day after their first study visit, using the paired t-test, calculated using Stata's -ttest- 
command.  
The amount of variability in screening blood glucose that was accounted for by potential 
determinants of screening blood glucose concentration was assessed using multivariable 
linear regression models, simultaneously fitting breed (Burmese/Burmese cross or non-
Burmese), bodyweight, BCS, behaviour score during screening blood sampling, fasting blood 
glucose concentration (as assessed at the cat's subsequent hospitalisation, using only those 
cats whose fasting blood glucose was assessed on the day after their first study visit), and 
amount of carbohydrate consumed in either the 2 to 24 h or 2 to 12 h before screening 
sampling. Behaviour score was fitted as a categorical variable with four categories (0, 1, 2, 3 
and 4 combined). All six variables were recorded for only 29 of the 120 study cats but breed, 
BCS, behaviour score and fasting blood glucose concentration were all recorded for 49 cats.  
Models were fitted both including and not including bodyweight and amount of carbohydrate 
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consumed. The overall P-values for behaviour score were assessed using the multiple Wald 
test. One cat had elevated screening and fasting blood glucose concentrations (238 and 221 
mg/dL; 13.2 and 12.3 mmol/L, respectively). A further cat had lower screening but elevated 
fasting blood glucose concentrations (155 and 223 mg/dL; 8.6 and 12.4 mmol/L, 
respectively). Regression analyses were performed with and without these cats. As results 
were similar, only those with these cats included are reported. With preliminary univariable 
linear regression analyses, histograms of residuals were used to identify whether the residuals 
had a normal distribution. Residual-versus-predictor plots were used to assess 
homoscedasticity of residuals. Residuals were not normally distributed and/or were 
heteroscedastic in models that included the cat with elevated screening and fasting blood 
glucose concentrations, so the bootstrap method with 1000 replications was used for 
multivariable regression analyses. Normal-based confidence intervals were used.  
To determine the robustness of the screening blood glucose to some changes in methodology 
that could be expected in veterinary practice, we compared screening blood glucose 
concentrations with those obtained following some changes in sampling and measurement. 
Agreement was assessed using Lin's concordance correlation coefficient with 95% 
confidence intervals based on the z-transformation, Pearson's correlation coefficient with 
95% confidence intervals based on Fisher's transformation, comparison between the reduced 
major axis line and the line of perfect concordance, and 95% limits of agreement, using 
Stata's -concord- and -ci2- commands. Mean glucose concentrations were also compared, 
using paired t-tests, calculated with Stata's -ttest- command. 
Means and standard deviations are reported, unless otherwise indicated, and P <0.05 was 
considered significant.  
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Results 
Reference intervals for screening and fasting blood glucose 
Distributions of screening, traditional and fasting blood glucose concentrations for the 71 cats 
with all three measures are shown in Figure 6.1. In this study of senior cats, using those with 
ideal body condition score (4 to 5/9; n=49), the reference interval for screening blood glucose 
was 67 to 189 mg/dL (3.7 to 10.5 mmol/L; 90% confidence interval for upper limit 164 to 
212 mg/dL; 9.1 to 11.8 mmol/L). This upper limit for screening blood glucose was 73 mg/dL 
(4.1 mmol/L) higher than for fasting blood glucose (116 mg/dL; 6.4 mmol/L; 90% 
confidence interval for upper limit 107 to 120 mg/dL; 5.9 to 6.7 mmol/L) calculated using the 
28 of these cats that had fasting values. For 35% (17/49) of the study cats with ideal body 
condition score, screening blood glucose concentration was above that upper limit for fasting 
blood glucose. Using only the 20 cats with ideal body condition score and whose fasting 
blood glucose was assessed on the day after their first study visit, mean blood glucose 
concentrations were significantly higher (P=0.001) for screening samples (121 ± 39 mg/dL 
(6.7 ± 2.1 mmol/L)) than fasting samples (96 ± 32 mg/dL (5.3 ± 1.8 mmol/L)), with a 
difference of 25 mg/dL (95% CI 12 to 39 mg/dL) (1.4 mmol/L; 95% CI 0.7 to 2.2 mmol/L). 
Behaviour scores were low (63% of cats scored 0 or 1 and a further 25% scored 2), and no 
cats were observed to struggle (Table 6.1). 
Determinants of screening blood glucose concentration 
We investigated the extent to which screening blood glucose concentration was accounted for 
by breed, bodyweight, BCS, behaviour score during screening blood sampling, fasting blood 
glucose concentration and carbohydrate intake before sampling. These six variables 
collectively explained only a small proportion of the variability in the screening blood 
glucose (R2 36%, adjusted R2 10%). This model was not significantly better than the null 
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model (P=0.893), and none of these variables was significantly associated with screening 
blood glucose after adjustment for the other five variables (Table 6.2). Results were similar 
when amounts of carbohydrate consumed from 2 to 12 h were used instead of 2 to 24 h 
before sampling. From the four-variable model with breed, BCS, behaviour score and fasting 
blood glucose concentration fitted, screening blood glucose concentration was also not 
significantly associated with fasting blood glucose concentration (Table 6.2). 
The reference interval upper limit for screening blood glucose obtained from cats with ideal 
body condition scores (189 mg/dL or 10.5 mmol/L) was applied to the population of obese 
cats (range 8-9/9; n=26). No obese cats were above the upper limit. One cat (with a BCS of 
5/9) had both a screening blood glucose and fasting blood glucose above the screening blood 
glucose cutpoint (screening blood glucose was 238 mg/dL; 13.2 mmol/L and fasting blood 
glucose was 221 mg/dL; 12.3 mmol/L, respectively). However, the traditional blood glucose 
measured 20 minutes after screening was normal (117 mg/dL;6.5 mmol/L) and glucose 
tolerance the following day was normal with a blood glucose value at 2 h of 140 mg/dL;7.8 
mmol/L, which was below the upper cutpoint for our laboratory (178mg/dL, 9.9 mmol/l)23. 
Robustness of screening blood glucose to variations in methodology  
Because veterinarians in practice usually take a jugular blood sample after history taking and 
physical examination ('traditional sampling') rather than using a screening sample, and 
measure blood glucose either directly from the syringe by meter (traditional-meter), or place 
the sample in a tube with anticoagulant (in our study, sodium fluoride/potassium oxalate) and 
measure with meter (traditional-meter-FO) prior to sending it to an external laboratory 
(traditional-laboratory-FO), we investigated how well screening blood glucose concentrations 
agreed with measurements of blood glucose after some changes in methods of sampling and 
measurement that could be expected in a busy veterinary practice (Table 6.3). Agreement 
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between results from screening and the three other methods was low as indicated by low Lin's 
concordance correlation coefficients (0.51 to 0.55) because they were not closely correlated 
(Pearson's correlation coefficients 0.56 to 0.58), but accuracy was high; that is, on average, 
results from each method from the same cat were close to each other. Differences in 
concentrations between screening and the three other methods were widely spread. For 
example, for screening versus traditional-meter, the 95% limits of agreement were -60 to +44 
mg/dl (-3.4 to +2.4 mmol/L); these results indicate that for 95% of cats, the difference would 
fall between these values. Agreement was only a little better for each of traditional-meter and 
traditional-meter-FO versus traditional-lab-FO (Lin's concordance correlation coefficients 
(0.73 and 0.77). Concentrations were closely correlated (Pearson's correlation coefficients 
0.95 and 0.96) but accuracy was poor because laboratory results were generally higher than 
glucose meter results. Mean differences were 17 and 14 mg/dl (0.9 and 0.8 mmol/L) lower 
for laboratory results compared to traditional-meter and traditional-meter-FO, respectively. 
Of note, when blood was dropped from the syringe with the needle attached, inconsistent and 
spurious results for blood glucose measurement were obtained, resulting from inconsistent 
mixing of red blood cells in plasma in the needle (per comm L Cozzi, Abbott Animal Health).  
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Discussion  
In this study of healthy, client-owned, senior cats, we standardized measurement of screening 
blood glucose and established the upper cutpoint of 189 mg/dL (10.5 mmol/L) for ideal body 
condition cats using a portable glucose meter validated for feline blood (AlphaTRAK, 
Zoetis).  Screening blood glucose was defined in our study as measurement any time after 
eating and on entry to the consulting room, with blood sampling from an ear or paw pad, and 
measurement with a portable glucose meter calibrated for cats.  
The upper cutpoint for screening blood glucose was higher (73 mg/dL or 4.1 mmol/L higher) 
than that for fasting glucose concentration.  In humans, inadequate fasting, for example less 
than 10 hours, can increase glucose concentrations above fasting values28. In cats consuming 
a high carbohydrate diet (50% of metabolizable energy, 12.8 g per 100 kcal), blood glucose 
increased on average by 61 mg/dL (3.4 mmol/L) after a meal of 100% of daily energy 
requirements29.  Measurement of fasting blood glucose requires food to be withheld at least 
for 14 hours after a meal of 50% of daily energy requirements, and for 24 hours after a meal 
of 100% daily energy requirements10, which may be not practical in client-owned cats.  In our 
study, carbohydrate intake accounted for little of the variation in screening glucose, possibly 
because cats in our study consumed diets with moderate carbohydrate content (mean ± SD; 
7.5 ± 2.4g per 100kcal) and most were fed ad libitum or twice daily. However, there were 
many limitations in this calculation of carbohydrate consumed. More detailed understanding 
of the timing of carbohydrate consumption, along with a more detailed knowledge of the 
amount and nature of the carbohydrate would be required to fully evaluate effects of 
carbohydrate consumption. These constraints limit confidence in the findings relating to the 
effect of carbohydrate intake on blood glucose, and this dietary effect should be further 
investigated in a future study.  
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 At the time of blood sampling, overt behaviours that may be associated with stress also did 
not account for the much of the variation in screening blood glucose concentrations. In a 
study of stress hyperglycaemia associated with a 5-min spray bath, struggling was the only 
behaviour associated with increased blood glucose concentration. In that study, glucose 
concentration increased on average by 74 mg/dL (4.1 mmol/L) within 10 minutes, and as 
much as 194 mg/dL (10.8mmol/L) in some cats, and the mean change was the same 
magnitude to the difference between fasting and screening blood glucose in our study. The 
increase was associated with increased plasma lactate and norepinephrine concentrations, and 
resolved within 90 minutes in most cats6. However, there were limitations in our study when 
assessing the effect on blood glucose of behaviours previously shown to be associated with 
stress hyperglycaemia. Behaviour scores were low compared to cats being spray bathed, no 
cats were observed to struggle, our stressor was shorter and milder than in the five- minute 
spray bath, and in our study, non-compliant cats were excluded to facilitate successful blood 
collection. Because neither carbohydrate consumed nor the behavioural scores in the 
consulting room explained much of the variation in screening blood glucose, it is likely that 
this variation was, in part, the result of stress prior to entry into the consulting room, for 
example, stress associated with travel to the clinic. Based on continuing research in our 
laboratory using a continuous glucose monitor to identify when stress hyperglycaemia occurs, 
it is clear that travel to the clinic in some cats’ results in marked hyperglycaemia. However, 
not all cats in the current study had higher values for screening compared to fasting blood 
glucose, suggesting not all cats develop stress hyperglycaemia associated with a veterinary 
clinic visit, and further research is required to understand the triggers for stress 
hyperglycaemia. 
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There was no significant association between either body weight or BCS and screening blood 
glucose concentration, consistent with previous findings that although obesity is associated 
with impaired glucose tolerance, fasting blood glucose concentrations are not typically 
increased30,31.  This suggests that simply measuring fasting or screening blood glucose may 
not be sensitive in identifying cats with milder disturbances of glucose metabolism, and a 
glucose tolerance test should be considered if multiple risk factors for diabetes are present.  
 
Importantly, the cutpoints were not robust to changes in methodology, and if the cutpoints 
determined in our study are to be used, the methodology for screening blood glucose needs to 
be adhered to. Compared to screening blood glucose, agreement was poor when blood 
glucose was measured after physical examination and jugular blood sampling using the meter 
with blood either dropped from the syringe or preserved with sodium fluoride/potassium 
oxalate then tested. There was also poor agreement with screening when glucose was 
measured in blood from the jugular sample several hours later by an external laboratory. 
There were a number of differences in methodology between screening blood glucose and 
these traditional sampling methods, and the relative contribution of these differences is 
unknown. However, they highlight the importance of adhering to the methodology described. 
The glycolysis inhibitor, sodium fluoride/potassium oxalate, does not completely inhibit 
glycolysis, and it artifactually decreases plasma glucose concentration because of movement 
of water from erythrocytes, resulting in plasma dilution and erythrocyte shrinkage32,33. 
Therefore, if the cutpoints identified in our study are being used, the methodology needs to be 
the same, including collection of the sample from the ear or foot pad on entry to the clinic 
and before physical examination, and blood glucose measured using a portable glucose meter 
calibrated for feline blood immediately after collection. 
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A range of blood glucose cutpoints are used for diagnosing diabetes in cats, varying from 171 
to 290 mg/dL (9.534 to 16 mmol/L), the latter being the renal threshold35. In humans, the 
cutpoint for diabetes (126 mg/dl, 7 mmol/L) was established, in part, based on the 
associations with renal and microvascular complications11. Individuals below this cutpoint 
but above fasting (100 mg/dl, 5.6 mmol/L) are considered prediabetic and at high risk of 
developing clinical diabetes11. Approximately 30% of adult humans have undiagnosed 
diabetes, increasing to 62% by the age of 65 years36.  It is likely that many cats have 
undiagnosed subclinical diabetes, and most cats with prediabetes are undiagnosed. The blood 
glucose concentration cutpoint for diabetes in cats urgently needs to be established.  
Based on the increased incidence of diabetes in cats 8 years of age or older37, we recommend 
all senior cats have a screening blood glucose measured at each health check. This is 
especially important in cats with one or more additional risk factors for diabetes such as 
obesity, Burmese breed, male sex or glucocorticoid therapy. Measuring blood glucose in 
capillary blood from the ear or paw is easy and rapid to perform14,15,18,38, and is less labour 
intensive and better tolerated than traditional methods of venous sampling (personal 
observation of author, Reeve-Johnson). In our study of 134 cats, a screening blood sample 
was easily obtained in all but 1 cat and, for that cat, sampling from an ear or paw pad was 
successfully performed at a later date.  
If blood glucose during the screening test is higher than the upper cutpoint for fasting (116 
mg/dL; 6.5 mmol/L) but lower than the upper cutpoint for screening (189 mg/dL; 10.5 
mmol/L), we recommend the cat is retested 3-4 hours later to determine if the 
hyperglycaemia has normalized and was likely associated with stress or eating. If 
hyperglycaemia is persistent, the cat should be retested at home or after overnight fasting and 
hospitalisation, ideally with a glucose tolerance test.  In one study, stress hyperglycaemia 
resolved within 90 minutes after the end of the stressor in the majority of cats, although in 
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8/20 cats, glucose concentrations were above baseline (range > 83 mg/dL; 4.6 mmol/L - 258 
mg/dL (14.3 mmol/L), and in general, these cats had higher peak glucose concentrations 
during the spay bath6. In the author’s (JR) experience, 3-4 hours is sufficient for stress 
hyperglycaemia to resolve in the majority of cats if they are quietly housed, and the second 
sample from the ear or pad is collected with the cat in the cage or carry basket. There is lack 
of definitive research in this area, but stress hyperglycaemia is likely affected by the nature 
and duration of the stressor(s) and the individual cat. 
Senior cats with an initial screening blood glucose > 189 mg/dL (10.5 mmol/L) should have 
fasting blood glucose and glucose tolerance measured after an 18-24 hr fast and overnight 
hospitalisation.  Based on data in humans11, senior cats with persistent mild hyperglycaemia 
or glucose intolerance could be considered prediabetic and at risk of developing diabetes, 
especially if other risk factors are present. Cats in diabetic remission with persistent fasting 
blood glucose between 135 mg/dL (7.5 mmol/L) and 151 mg/dL (8.4 mmol/L) have an 
estimated 14 times higher odds of development of diabetes compared to those whose glucose 
is less than 135 mg/dL (7.5 mmol/L). Mild persistently increased fasting blood glucose is 
therefore likely to be an indicator or risk factor for diabetes in other groups of predisposed 
cats, such as senior obese or Burmese cats8. A longitudinal study would be required to 
identify the percentage of cats with impaired fasting glucose or glucose intolerance which 
develop clinical diabetes within 1 to 3 years. 
One study cat had conflicting blood glucose data with screening 238 mg/dL (13.2 mmol/L) 
and a behaviour score of 2; traditional-meter 117 mg/dL (6.5 mmol/L); fasting 221 mg/dL 
(12.3 mmol/L) and a normal glucose tolerance test.  In humans and cats, glucose tolerance 
testing is more sensitive at detecting abnormalities of glucose metabolism than measurement 
of fasting glucose8. While occasionally some humans have mild impaired fasting glucose and 
normal glucose tolerance, this is unusual39.  In this cat, screening and fasting blood glucose 
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were in the diabetic range40 and but traditional blood glucose measured approximately 20 
minutes after screening glucose was normal, and glucose tolerance was normal measured the 
next day, suggesting both screening and fasting samples were stress affected. No clinical 
signs of diabetes developed in the ensuing 4 years after testing, supporting this interpretation 
of results. When fasting glucose is increased, but glucose tolerance is normal, stress 
hyperglycaemia should be suspected and measurement of blood glucose at home be 
considered.  
In prediabetic humans, changes in lifestyle which increase physical activity and decrease 
bodyweight can mitigate the risk of developing diabetes41.  In senior cats with impaired 
fasting glucose or impaired glucose tolerance, especially if other risk factors are present, it 
would also be prudent to implement strategies to reduce risk. For example, implementing a 
weight loss protocol and increasing physical activity in obese cats, changing from a high 
carbohydrate to a low carbohydrate diet, and reducing or eliminating steroid administration42.  
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Conclusions 
 We established cutpoints for screening blood glucose concentrations in a population of 
healthy cats aged ≥ 8 years and demonstrated that cutpoints are not robust to changes in 
methodology. We recommend that screening blood glucose, as described in our study, be 
included in the health examination for all senior cats. It is simple to perform, is well tolerated, 
and has the benefit of only needing 0.3 uL of blood. Cats with risk factors for diabetes and 
abnormal results should be retested to confirm they are persistent. For cats with persistently 
increased fasting glucose (impaired fasting glucose) or impaired glucose tolerance, it would 
be prudent to implement management strategies to reduce risk of future diabetes, especially 
in cats with reversible risk factors such as obesity and corticosteroid administration. In cats 
where stress hyperglycaemia is suspected, it may be advisable to measure blood glucose at 
home. Future studies are needed to determine the relative risk for diabetes of blood glucose 
concentrations persistently above the cutpoints identified in this study, and to better 
understand transient hyperglycaemia in cats associated with stress and eating. 
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Table 6.1:  Table 1 Means, standard deviations (SD) and ranges for body condition score (BCS), bodyweight, and age, and distributions of sex, 1 
breed, and behaviour score during screening blood sampling for healthy cats ≥8 years of age 2 
 BCS/9 
(mean±SD) 
(range) 
Bodyweight 
(kg)  
mean±SD 
(range) 
Age (years) 
mean±SD 
(range) 
Sex 
(F/M) 
Burmese and 
Burmese cross/non-
Burmese (B/NB) 
Behaviour score 
% ≥2 
(range)1 
All cats 
n=1202 
6.2±1.5 
(4-9) 
5.5±1.6 
(2.9-10.0) 
10.9±2.4 
(8-18) 
62F 
58M 
29B 
91 NB 
34% 
(0-4) 
Ideal body 
condition cats 
(body condition 
scores 4 or 5) 
n=492 
4.7±0.5 
(4-5) 
4.3±0.7 
(2.9-5.5) 
11.4±2.6 
(8-18) 
22F 
27M 
12B 
37NB 
35% 
(0-4) 
Overweight cats 
(body condition 
scores 6 or 7) 
n=452 
6.6±0.5 
(6-7) 
5.5±1.0 
(4.1-7.3) 
10.8±2.3 
(8-17) 
24F 
21M 
15B 
30NB 
26% 
(0-3) 
Obese cats (body 
condition scores 8 
or 9) 
n=262 
8.3±0.5 
(8-9) 
7.4±1.2 
(5.6-10.0) 
10.2±2.2 
(8-16) 
16F 
10M 
2B 
24NB 
46% 
(0-3) 
1For all groups, the median score was 1 3 
2For bodyweights, ages, and behaviour scores, numbers of cats are less than shown for some groups as these data were not recorded for all cats4 
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Table 6.2 Regression coefficients (estimated changes in screening blood glucose in mg/dL 5 
(mmol/L)), 95% confidence intervals for estimates and p-values for the associations between 6 
screening blood glucose and each of breed, bodyweight, body condition score, behaviour 7 
score during screening blood sampling, fasting blood glucose concentration and carbohydrate 8 
intake from 2 to 24 hr before sampling for healthy cats ≥8 years of age 9 
Variable and category Adjusted regression 
coefficient1 
95% confidence 
interval 
P 
Breed 
(Burmese/Burmese cross relative to 
non-Burmese) 
-8.02 
(-0.4) 
-58.0 to 42.0 
(-3.2 to 2.3) 
0.754 
Bodyweight (kg) -7.13 
(-0.4) 
-31.4 to 17.3 
(-1.7 to 1.0) 
0.570 
Body condition score 9.9 
(0.6) 
-15.8 to 35.7 
(-0.9 to 2.0) 
0.450 
Behaviour score:   0.2604 
1 relative to 0 31.1 
(1.7) 
-7.7 to 69.8 
(-0.4 to 3.9) 
0.116 
2 relative to 0 15.1 
(0.8) 
-25.2 to 55.5 
(-1.4 to 3.1) 
0.463 
3 or 4 relative to 0 50.6 
(2.8) 
-8.9 to 110.1 
(-0.5 to 6.1) 
0.095 
Fasting blood glucose concentration 
(mmol/L) 
11.85,6 
(0.7) 
-13.3 to 37.0 
(-0.7 to 2.1) 
0.355 
Carbohydrate intake from 2 to 24 hr 
before sampling (g) 
-0.27 
(0.0) 
-4.8 to 4.4 
(-0.3 to 0.2) 
0.925 
 
1Adjusted for the other five variables in the model 
2Screening blood glucose concentration was estimated to be 8 mg/dL (0.4 mmol/L) lower in 
Burmese/Burmese cross relative to non-Burmese (95% confidence interval 58.0 mg/dL (3.2 
mmol/L) lower to 42.0 mg/dL (2.3 mmol/L) higher; P=0.754) 
3For each additional kg bodyweight, screening blood glucose concentration was estimated to be 7.1 
mg/dL (0.4 mmol/L) lower (95% confidence interval 31.4 mg/dL (1.7 mmol/L) lower to 17.3 
mg/dL (1.0 mmol/L) higher; P=0.570) 
4Overall P-value for behaviour score 
5For each 18 mg/dL (1 mmol/L) increase in fasting blood glucose concentration, screening blood 
glucose concentration was estimated to be 11.8 mg/dL (0.7 mmol/L) higher (95% confidence 
interval 13.3 mg/dL (0.7 mmol/L) lower to 37.0 mg/dL (2.1 mmol/L) higher; P=0.355) 
6After adjusting only for breed, body condition score and behaviour score, for each 18 mg/dL (1 
mmol/L) increase in fasting blood glucose concentration, screening blood glucose concentration 
was estimated to be 10.1 mg/dL (0.6 mmol/L) higher (95% confidence interval 7.4 mg/dL (0.4 
mmol/L) lower to 27.6 mg/dL (1.5 mmol/L) higher; P=0.259) 
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7For each 1 g increase in carbohydrate intake, screening blood glucose concentration was estimated 
to be 0.2 mg/dL (0.0 mmol/L) lower (95% confidence interval 4.8 mg/dL (0.3 mmol/L) lower to 
4.4 mg/dL (0.2 mmol/L) higher; P=0.925) 
10 
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Table 6.3. Agreement (and comparisons of means) between screening blood glucose concentrations after various changes in methodology for 
sampling and measurement that could be expected in a busy veterinary practice. Screening blood glucose: pinna or paw sample on entry to the 
consulting room measured with a portable glucose meter) was compared with traditional sampling (jugular blood sample after history taking and 
physical examination) and blood glucose measured either directly from the syringe by meter (traditional-meter), or placed in tube with 
anticoagulant (sodium fluoride/potassium oxalate (FO) and measured with meter (traditional-meter-FO) and at an external laboratory 
(traditional-lab-FO). 
Methodologies 
compared 
N Lin’s concordance 
correlation 
coefficient (95% 
confidence interval) 
Pearson’s 
correlation 
coefficient (95% 
confidence 
interval) 
95% limits of 
agreement mg/dL 
(mmol/L)1 
Mean ±SD mg/dL 
(mmol/L) 
 
Difference 
mg/dL 
(mmol/L)1 
 
95% confidence interval of 
difference mg/dL (mmol/L) 
and p-value for difference 
Screening versus 
Traditional-meter 
105 0.54 
(0.40 to 0.66) 
0.57 
(0.43 to 0.69) 
-60 to 44 
(-3.4 to 2.4) 
106 ± 30 (5.9 ± 1.7) 
115 ± 27 (6.4 ± 1.5)  
-8 (-0.5)  -13 to -3 (-0.7 to -0.2) 
P=0.002 
Screening versus 
Traditional-meter-FO 
50 0.55 
(0.33 to 0.71) 
0.56 
(0.33 to 0.72) 
-57 to 53 
(-3.2 to 2.9) 
112 ± 32 (6.2 ± 1.8) 
114 ± 27 (6.3 ± 1.5)  
-2 (-0.1)  -10 to 6 (-0.6 to 0.3) 
P=0.551 
Screening versus 
Traditional-lab-FO 
91 0.51 
(0.36 to 0.63) 
0.58 
(0.42 to 0.70) 
-42 to 60 
(-2.3 to 3.4) 
106 ± 32 (5.9 ± 1.8)  
 97 ± 22 (5.4 ± 1.2) 
9 (0.5) 4 to 15 (0.2 to 0.8) 
P=0.001 
Traditional-meter 
Traditional-meter-FO 
49 0.98 
(0.96 to 0.99) 
0.98 
(0.97 to 0.99) 
-9 to 12 
(-0.5 to 0.7) 
115 ± 28 (6.4 ± 1.5) 
114 ± 27 (6.3 ± 1.5) 
1 (0.1) 0 to 3 (0.0 to 0.2) 
P=0.086 
Traditional-meter 
Traditional-lab-FO 
86 0.73 
(0.66 to 0.80) 
0.95 
(0.92 to 0.96) 
-2 to 36 
(-0.1 to 2.0) 
114 ± 26 (6.3 ± 1.5) 
95 ± 21 (5.3 ± 1.2) 
17 (0.9) 15 to 19 (0.8 to 1.0) 
P<0.001 
Traditional-meter-FO 
Traditional-lab-FO 
48 0.79 
(0.70 to 0.85) 
0.96 
(0.93 to 0.98) 
-1 to 30 
(0 to 1.6) 
112 ± 25 (6.2 ± 1.4) 
97 ± 21 (5.4 ± 1.2)  
14 (0.8) 12 to 17 (0.7 to 0.9) 
P<0.001 
1First listed methodology minus second listed methodology 
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Figures 
Figure 6.1: Box and whiskers plot showing blood glucose concentrations in screening 
samples (collected immediately after entry to the consultation room from pinna or pad) from 
the cat's first study visit, traditional method (jugular venous sample collected after history and 
taking and physical exam) and after fasting (sampled from pinna or pad after overnight 
hospitalisation) from 71 cats 8 years of age or older that had all three samples collected. All 
samples were tested using a portable glucose meter. (Medians are shown as thick horizontal 
lines; interquartile ranges and 25th and 75th percentiles are shown by boxes; values more than 
1.5 interquartile ranges above the 75th percentile or below the 25th percentiles are each shown 
as diamonds; error bars show ranges for all less extreme values.) 
 
 
 
 
 
 170 
 
References 
1. Baral RM, Rand J, Catt MJ, et al. Prevalence of Feline Diabetes Mellitus in a Feline 
private practice. Journal of Veterinary Internal Medicine 2003;17:434. 
2. Panciera DL, Thomas CB, Eicker SW, et al. Epizootiological patterns of diabetes-mellitus 
in cats - 333 cases (1980-1986). Journal of the American Veterinary Medical Association 
1990;197:1504-1508. 
3. Lund EM, Armstrong PJ, Kirk CA, et al. Prevalence and risk factors for obesity in adult 
cats from private US veterinary practices. International Journal of Applied Research in 
Veterinary Medicine 2005;3:88-96. 
4. Gavin JR, Alberti K, Davidson MB, et al. Report of the expert committee on the diagnosis 
and classification of diabetes mellitus. Diabetes Care 2009;32:S62-S67. 
5. Inzucchi S, Bergenstal R, Fonseca V, et al. Diagnosis and Classification of Diabetes 
Mellitus. Diabetes Care 2010;33:S62-S69. 
6. Rand JS, Kinnaird E, Baglioni A, et al. Acute stress hyperglycemia in cats is associated 
with struggling and increased concentrations of lactate and norepinephrine. Journal of 
Veterinary Internal Medicine 2002;16:123-132. 
7. Heine RJ, Mooy JM. Impaired glucose tolerance and unidentified diabetes. Postgraduate 
Medical Journal 1996;72:67-71. 
8. Gottlieb S, Rand J, Marshall R, et al. Glycemic status and predictors of relapse for diabetic 
cats in remission. Journal of Veterinary Internal Medicine 2015;29:184-192. 
9. Laluha P, Gerber B, Laluhova D, et al. Stress hyperglycemia in sick cats: a retrospective 
study over 4 years. Schweizer Archiv Fur Tierheilkunde 2004;146:375-383. 
10. Coradini M, Rand JS, Morton JM, et al. Delayed gastric emptying may contribute to 
prolonged postprandial hyperglycemia in meal-fed cats. Journal of Veterinary Internal 
Medicine 2006;20:726-727. 
 171 
 
11. Amer Diabet A. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 
2009;32:S62-S67. 
12. Reeve-Johnson MK, Rand JS, Anderson S, et al. Human white coat hypertension: a 
community based feline model. Journal of Veterinary Pharmacology and Therapeutics 
2012;35:176-177. 
13. Lardinois C. White coat hyperglycemia. Archives of Family Medicine 1994;3:461-464. 
14. Casella M, Wess G, Reusch CE. Measurement of capillary blood glucose concentrations 
by pet owners: A new tool in the management of diabetes mellitus. Journal of the American 
Animal Hospital Association 2002;38:239-245. 
15. Sieber-Ruckstuhl NS, Alt N, Reusch CE. Measurement of blood sugar levels using 
capillary blood from the ear in diabetic dogs and cats - Comment on the GST-VETLINE 
discussion of November 2003. Schweizer Archiv Fur Tierheilkunde 2004;146:92-93. 
16. Thompson MD, Taylor SM, Adams VJ, et al. Comparison of glucose concentrations in 
blood samples obtained with a marginal ear vein nick technique versus from a peripheral vein 
in healthy cats and cats with diabetes mellitus. Journal of the American Veterinary Medical 
Association 2002;221:389-392. 
17. Casella M, Hassig M, Reusch CE. Home-monitoring of blood glucose in cats with 
diabetes mellitus: evaluation over a 4-month period. Journal of Feline Medicine and Surgery 
2005;7:163-171. 
18. Wess G, Reusch C. Capillary blood sampling from the ear of dogs and cats and use of 
portable meters to measure glucose concentration. Journal of Small Animal Practice 
2000;41:60-66. 
19. Zeugswetter F, Benesch T, Pagitz M. Validation of the portable blood glucose meter 
FreeStyle Freedom (TM) for the use in cats. Wiener Tierarztliche Monatsschrift 2007;94:143-
148. 
 172 
 
20. Wess G, Reusch C. Assessment of five portable blood glucose meters for use in cats. 
American Journal of Veterinary Research 2000;61:1587-1592. 
21. Zini E, Moretti S, Tschuor F, et al. Evaluation of a new portable glucose meter designed 
for the use in cats. Schweizer Archiv Fur Tierheilkunde 2009;151:448-451. 
22. Laflamme D. Development and validation of a body condition score system for cats: A 
clinical tool. Feline Practice 1997;25:13-18. 
23. Reeve-Johnson M, Rand J, Vankan D, et al. Diagnosis of prediabetes in cats: glucose 
concentration cut points for impaired fasting glucose and impaired glucose tolerance. 
Domestic Animal Endocrinology 2016;57:55-62. 
24. Coradini M, Rand JS, Morton JM, et al. Effects of two commercially available feline diets 
on glucose and insulin concentrations, insulin sensitivity and energetic efficiency of weight 
gain. British Journal of Nutrition 2011;106:S64-S77. 
25. Earle KE, Smith PM. Digestible energy-requirements of adult cats at maintenance. 
Journal of Nutrition 1991;121:S45-S46. 
26. Coradini M, Rand JS, Morton JM, et al. Effects of two commercially available feline diets 
on glucose and insulin concentrations, insulin sensitivity and energetic efficiency of weight 
gain (vol 106, pg S64, 2011). British Journal of Nutrition 2012;107:1402-1402. 
27. Flint M, Morton JM, Limpus CJ, et al. Development and application of biochemical and 
haematological reference intervals to identify unhealthy green sea turtles (Chelonia mydas). 
Veterinary Journal 2010;185:299-304. 
28. Harris M. Classification and diagnosis of diabetes-mellitus and other categories of 
glucose-intolerance. Diabetes 1979;28:1039-1057. 
29. Farrow H, Rand J, Morton JM, et al. Effect of dietary carbohydrate, fat and protein on 
postprandial glycemia and energy intake in cats  Journal of Veterinary Internal Medicine 
2013. 
 173 
 
30. Appleton DJ, Rand JS, Priest J, et al. Determination of reference values for glucose 
tolerance, insulin tolerance, and insulin sensitivity tests in clinically normal cats. American 
Journal of Veterinary Research 2001;62:630-636. 
31. Hoenig M. The cat as a model for human nutrition and disease. Current Opinion in 
Clinical Nutrition and Metabolic Care 2006;9:584-588. 
32. Waring WS, Evans LE, Kirkpatrick CT. Glycolysis inhibitors negatively bias blood 
glucose measurements: potential impact on the reported prevalence of diabetes mellitus. 
Journal of Clinical Pathology 2007;60:820-823. 
33. Ceron JJ, Martinez-Subiela S, Hennemann C, et al. The effects of different anticoagulants 
on routine canine plasma biochemistry. Veterinary Journal 2004;167:294-301. 
34. Rios L, Ward C. Feline Diabetes Mellitus: Diagnosis,Treatment, and Monitoring. 
Compendium-Continuing Education for Veterinarians 2008;30:626-639. 
35. Kruth S, Cowgill L. Renal glucose transport in the cat. (Abstract). In: American College 
of Veterinary Internal Medicine Forum 1982;78 
36. Cowie CC, Engelgau MM, Rust KF, et al. Prevalence of diabetes and impaired fasting 
glucose in adults in the US population - National Health and Nutrition Examination Survey 
1999-2002. Diabetes Care 2006;29:1263-1268.  
37. Rand JS, Marshall RD. Diabetes mellitus in cats. Veterinary Clinics of North America-
Small Animal Practice 2005;35:211-224. 
38. Zini E. An update on the pathogenesis of diabetes mellitus in cats and on the methods 
used to monitor glucose levels. Veterinaria 2009;23:51-60. 
39. Gavin JR, Alberti K, Davidson MB, et al. Report of the Expert Committee on the 
Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197. 
 174 
 
40. Crenshaw KL, Peterson ME. Pretreatment clinical and laboratory evaluation of cats with 
diabetes mellitus: 104 cases (1992-1994). Journal of the American Veterinary Medical 
Association 1996;209:943-949. 
41. Kopelman PG. Obesity as a medical problem. Nature 2000;404:635-643. 
42. Rand JS, Fleeman LM, Farrow HA, et al. Canine and feline diabetes mellitus: nature or 
nurture? Journal of Nutrition 2004;134:2072S-2080S. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 175 
 
Chapter 7: Metabolomic differences between lean and obese neutered senior cats and 
associations with glucose tolerance 
MK Reeve-Johnson1, ST Anderson2, JS Rand 1,3, DM Vankan1, DA Dias4, B Boughton5, AM 
De Livera6, K Ishioka7 and U Roessner5 
1 The School of Veterinary Science, The University of Queensland, Gatton, Australia                                                                             
2The School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, St 
Lucia, Australia 
3 Australian Pet Welfare Foundation, Kenmore, Queensland 
4School of Health and Biomedical Sciences, Discipline of Laboratory Medicine, RMIT 
University, 3083 Bundoora, Victoria, Australia 
5Metabolomics Australia, School of BioSciences, The University of Melbourne, 3010 
Victoria, Australia 
6 Centre for Molecular, Environmental, Genetic & Analytic (MEGA) Epidemiology, 
Melbourne School of Population and Global Health, The University of Melbourne, Parkville, 
Victoria, Australia  
 7 School of Veterinary Nursing & Technology, Faculty of Veterinary Science, Nippon 
Veterinary and Life Science University, Tokyo, Japan 
Short title: Metabolomics in obese cats 
Key words: obesity, diabetes, fatty acids; glycolic acid 
 
Presented in poster form at the American College of Veterinary Internal Medicine Annual 
Forum, Nashville, Tennessee, June 2014. 
 
 
 
 176 
 
 
Abstract 
Type 2 diabetes is the most common form of diabetes in humans and cats, and obesity is a 
major risk factor. Metabolomic markers of obesity and predictors of diabetes have been 
identified in humans, but not in cats. The objectives of the study were to identify metabolite 
changes with obesity in senior neutered cats, and to establish if changed metabolites were 
associated with abnormal glucose metabolism and diabetes. Blood samples from 39 cats were 
analysed: 21 lean (BCS 4-5/9) and 18 obese (BCS 8-9/9). Food was withheld 18 - 24 h and a 
venous blood sample was collected for GC-MS analysis, and biochemical measures 
associated with abnormal glucose metabolism and diabetes. Metabolomic analysis identified 
that 9Z-hexadecenoic acid, tetradecenoic acid, glycerol, and glycolic acid were all increased 
(P<0.05).  Alanine was decreased (P=0.05) and phenylalanine tended to be increased 
(P=0.09) in obese senior cats. Obesity was characterised by normal screening and fasting 
blood glucose concentrations, but increased 2 h blood glucose in a glucose tolerance test 
(GTT) (p<0.01), decreased glucose:insulin ratio (P<0.05), increased plasma leptin (P<0.001), 
decreased adiponectin (P<0.01), and increased triglyceride (P<0.01) concentrations. There 
was no significant effect of BCS on FPLi or MCP-1 concentrations. 9Z-hexadecenoic was 
positively and alanine negatively correlated (P<0.05) with leptin concentrations, and glycolic 
acid and glycerol were positively associated (P<0.05) with insulin concentrations. This study 
is the first to report on metabolomic markers of obesity in senior neutered cats, and the 
identified metabolites need further investigation to determine if they are useful for diagnosing 
prediabetes in this species. 
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Introduction 
In humans and cats, obesity is often associated with a state of chronic, low grade 
inflammation, with responses originating primarily in adipose tissue1-5. This inflammation 
plays a role in the link between obesity and disease, but the disease mechanisms in complex 
metabolic systems have not yet been fully determined6. Inflammatory signals associated with 
obesity contribute to metabolic dysfunction of carbohydrate, lipid and protein metabolism7-9. 
In adipose tissue, inflammatory mediators cause adipocyte insulin resistance and changes in 
adipocyte gene expression, including decreased adiponectin concentrations10 which in turn 
can lead to systemic insulin resistance2,3,11,12. 
Predisposing factors for diabetes in cats, like humans13, are age14,15, obesity16-18 and physical 
inactivity19 and further in cats, neutering20,21 and male gender14,20 and breed15,22 increase risk. 
Obese cats are 3.9 times as likely to develop diabetes mellitus than lean cats of matched 
ages23. Clinical signs of diabetes in cats are subtle and progressive over months to years24. A 
major confounding influence on diagnosis in cats are stress effects on blood glucose 
concentrations at the time of blood sampling (stress hyperglycaemia). Diagnosis of diabetes 
in cats is usually only be made late in disease progression when overt clinical signs are 
evident, such as a persistent hyperglycaemia and glucosuria25. Approximately 80% of cats 
with newly-diagnosed diabetes have clinical characteristics and abnormalities consistent with 
human type 2 diabetes1,26,27. The typical onset for diabetes in cats and humans appears to be 
in middle age or later23,28, with over 50% of diabetic cats 10 years or older8. As in humans29-
31, obesity in cats is associated with increased mortality7.  
Type 2 diabetes in humans occurs as the result of the failure of multiple organ systems: 
impaired insulin action in muscles and adipose32,33, poor control of gluconeogenesis by the 
liver9, and insulin deficiency as a result of dysfunction of beta- cells in the endocrine 
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pancreas34-37. Similar disease characteristics have been found in cats11,26,38-40. A better 
understanding of the pathophysiological events that contribute to the development of the 
disease is the key to early diagnosis.  
As alterations in metabolic profiles often present much earlier in the course of disease than 
histopathological changes, metabolomics can be used as a sensitive, early indicator of a 
disease process, potentially providing a powerful investigative tool for investigating diseases 
such as diabetes28,41. Candidate biomarkers for insulin resistance have been identified in 
mice28, and numerous studies have identified the metabolite profiles of insulin resistance and 
diabetes in humans. These include alterations in essential amino acid metabolism that mark 
the obese, insulin resistant phenotype29-31. Branched chain amino acids and related 
metabolites are more strongly associated with insulin resistance than lipids7,30. For example, 
isoleucine, leucine, valine, tyrosine, and phenylalanine are together associated with a greater 
than fivefold higher risk of diabetes42, and have been shown to be predictive of development 
of diabetes in adults up to 12 years in advance, well before alterations in insulin action is 
detectable by gold standard methods31 of insulin sensitivity testing.  
There is scant information on metabolomic changes with obesity in animals, despite obesity 
being common in dogs and cats, as humans. Increased pyruvate and mannose, some long 
chain fatty acids and lysophospholipids, homocysteine, cysteine, cystine and decreased citrate 
α- ketoglutarate and anhydrogluticol have been reported to be associated with weight gain in 
dogs43, but these changes have not been reported in cats. 
Impaired glucose tolerance and impaired fasting glucose are used to diagnose prediabetes in 
humans, which is an intermediate stage between normal glucose metabolism and clinical 
diabetes44. Obese humans are four times more likely to have impaired glucose tolerance than 
normal-weight humans45.  We have recently established clinically practical screening tests for 
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IFG and IGT in high risk cats aged 8 years and older46,47, and found the no obese cats had 
IFG but 18% had IGT.  Furthermore, changes in adipokines (adiponectin and leptin)48-52, 
fPLi53, triglycerides54,55 and inflammatory mediators56 have all been associated with obesity 
and abnormal glucose metabolism in cats, suggesting a role in the development of diabetes. 
Monocyte chemoattractant protein-1, a chemokine first identified in monocytes, has been 
found to be significantly increased in humans with obesity and type 2 diabetes57,58,59 but no 
such reports have yet been made in cats. However, MCP-1 mRNA was detected in 
subcutaneous and visceral fat, but not in skeletal muscle in cats60 and the expression of MCP-
1 was quantified in isolated islets of healthy cats using feline-specific real-time PCR primers 
nested within the mRNA sequences61. 
The primary purpose of this study in cats was to identify metabolic profiles induced by 
spontaneous obesity in senior animals. Secondly, we determined associations between 
identified metabolites and measures of abnormal glucose metabolism and diabetes, including 
insulin, triglyceride, leptin, adiponectin, fPLi and MCP-1 and our glucose screening test 
based on screening glucose62, fasting glucose, and the 2-hour glucose concentration following 
a simplified glucose tolerance test46. 
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Materials and Methods 
The protocol for these studies and the care and handling of these animals were approved by 
the Animal Experimentation Ethics Committee of the University of Queensland.  
Animals: Client-owned cats ≥8 years (n=91) were recruited through veterinary clinics, 
advertisements and radio interviews between May 2011 and November 2012. Other than for 
excess body condition in some cats, cats enrolled in the study were assessed as healthy based 
on results of a clinical examination, patient history, haematological and biochemical assays, 
total thyroxine, and fPLi. Of the remaining 79 cats, 60 were classified as non-Burmese. Of 
these cats, samples from 39 cats were used in this study of metabolomics, selected on the 
basis of client availability/compliance and GC-MS analysis success: 21 lean (BCS 4-5/9; 13 
domestic and 8 other breeds; mean age 11.4 years, range 8-18 years; 9 males, 12 females) and 
18 obese (BCS 8-9/9; 15 domestic and 3 other breeds; mean age 10.6 years, range 8-16 years; 
8 males, 10 females). Additionally, 12 overweight (BCS 6-7/9) cats were used in the analyses 
of various measures associated with abnormal glucose metabolism and diabetes. All cats used 
in this study non-Burmese. Incomplete diet histories were available for cats; reliable diet data 
was only available for 9 of 21 lean and 5 of 18 obese cats. Dietary protein content as a 
percentage of fed metabolizable energy in lean cats was 24 % ME (all of these cats n=9 were 
housed together and fed the same diet) whilst in obese cats (n=5) ranged between 24% to 
35% (mean ± SEM 27.5 ± 2.3 %). Dietary fat in lean cats was 34% and ranged from 9% to 
44% in obese cats (mean ± SEM 27.2 ± 6.5 %). Dietary carbohydrate in lean cats was 36% 
and ranged from 27% to 45% in obese cats (mean ± SEM 34.0 ± 3.5 %). 
 
Protocol: 
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On admission, a 5 ml venous blood sample was collected for haematological, biochemical, 
fPLi and T4 analyses. Fasting blood glucose was measured from a paw or ear sample using a 
portable glucose meter calibrated for feline blood a then an IVGTT was performed using a 
glucose dose of 0.5 g/kg47. Samples were analysed by a commercial veterinary laboratoryb. 
After food was withheld for 18 to 24 h47 a venous blood sample (2 mL) was collected for 
metabolomic assays. Immediately after collection, the blood was placed into clotted red top 
tubes. Approximately 20 minutes from collection, all samples were centrifuged (8 minutes at 
1500 g), serum was separated and stored at -80°C prior to transport on dry ice for GC-MS 
metabolomic analysis.  
 
GC-MS Metabolite analysis: 
Serum was assessed for metabolites using gas chromatography- mass spectrometry. A serum 
sample of 50 µL was transferred into a 1.5 mL Eppendorf® tube. A mix of 150 μL of cold 
methanol (100 %, 4°C) with 1 μL of a quantitative internal standardg added to each sample. 
The serum mixture was then vortexed for 30 s and then placed on ice for 10 min to precipitate 
protein. The extracted serum samples were then centrifuged at 13,000 rpm for 10 min at room 
temperature (23°C). A (30 μL) aliquot of the supernatant was transferred into a glass insert and 
dried in vacuo for subsequent polar metabolite derivatisation. 
 
The extracted serum samples were re-dissolved in 10 μL of 30 mg mL-1 methoxyamine 
hydrochloride in pyridine and derivatised at 37°C for 120 min with mixing at 500 rpm. The 
serum samples were then treated for 30 min with 20 μL N,O-bis-
(trimethylsilyl)trifluoroacetamide with 1% trimethylchlorosilane (BSTFA + 1% TMCS) and 
the addition of a retention time standard mixtureh (2.0 µL) with mixing at 500 rpm. Each 
derivatised sample was allowed to rest for 60 min prior to injection. 
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Samples (1 μL) were injected using a hot needle technique into a GC-MS systemi. The MS was 
adjusted according to the manufacturer’s recommendations using tris-(perfluorobutyl)-amine 
(CF43). The GC was performed on a 30 m VF-5MS column with 0.2 μm film thickness and a 
10 m Integra guard columnj. The injection temperature was set at 250°C, the MS transfer line 
at 280°C, the ion source adjusted to 250°C and the quadrupole at 150ºC. Helium was used as 
the carrier gas at a flow rate of 1.0 mL min-1. For the polar metabolite analysis, the following 
temperature program was used; start at injection 35°C, a hold for 2 min, followed by a 15°C 
min-1 oven temperature, ramp to 325°C and a final 3 min heating at 325°C. Both 
chromatograms and mass spectra were evaluated using specialist softwarek. Mass spectra of 
eluting compounds were identified using a public domain mass spectra libraryl and the in-house 
Metabolomics Australia mass spectral library. All matching mass spectra were additionally 
verified by determination of the retention time with authentic standard substances. Resulting 
relative response ratios (area of analyte divided by area of internal standard, 13C6-sorbitol) per 
volume of serum for each metabolite was carried out. If a specific metabolite had multiple TMS 
derivatives, the metabolite with the greater detector response and improved peak shape within 
the dynamic range of the instrument was selected. 
 
Details of the instrumentation, instrument setting and chromatographic conditions are 
included in Appendix 7.1. 
 
Hormones and other analytes: 
Plasma leptin concentration was measured using a commercially available radioimmunoassay 
kitc, which has been validated for the detection of feline leptin63. Intra-assay coefficients of 
variation (CVs) were 12.3% and 3.9% at mean serum leptin concentrations of 2.3 ng/mL and 
 183 
 
11.4 ng/mL, respectively, and the inter-assay CVs were 11.3% and 6.3% at mean leptin 
concentrations of 2.6 ng/mL and 11.4 ng/mL, respectively.  
 
Serum total adiponectin concentration was determined by a commercially available 
murine/rat adiponectin ELISA kitd. The assay was validated for the detection of feline 
adiponectin64. Intra-assay CV was 3.2% and 3.7% for adiponectin concentrations of 21.7 
µg/mL and 4.2 µg/mL, respectively. 
 
Feline pancreatic lipase concentrations were determined at a commercial laboratoryb by 
radioimmunoassay validated for use in the cat65. The intra-assay coefficients of variation of 4 
different serum samples ranged from 2.2 to 10.1%. 
 
Serum triglyceride concentrations were determined using an autoanalyser (Hitachi-7180) 
using manufacturer’s reagents.  The intra-assay coefficient of variation was 2.2% and the 
inter-assay coefficient was 2.2 and 5.7%. 
 
Serum insulin concentrations were measured at a research laboratorye using a commercial 
ELISA kit validated for feline insulinf. Intra- and inter-assay reproducibility of feline insulin 
ELISA kit are less than 10%. 
 
MCP-1 concentrations were determined at a research laboratorye using the canine MCP-1 
ELISA kit. This was validated by assaying two feline serum samples: MCP-1 concentrations 
were 163.8 and 316.9 pg/ml, CV were 3.8% and 3.5% (intra-assay), correlation coefficients 
of the diluted samples were 0.998 and 1.00, respectively.  Recovery of the applied 
recombinant MCP-1 at varied concentrations ranged from 92% through 100%.   
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Statistical analyses: 
As metabolites in a data matrix are often heteroscedastic and have a right skewed 
distribution, the data were log transformed. Using the metabolomics package of Rn, 
metabolite data were normalized using a single internal standard method where a normalized 
data matrix is obtained by subtracting the log metabolite abundance of a single internal 
standard from the log abundances of the metabolites in each sample66. The normalized data 
was visualized using a RLA plot66 where the median of each metabolite in the data matrix, 
and then subtracted this median from each metabolite. Ideally the medians would be as close 
to zero as possible, but this may vary if there are numerous significantly abundant 
metabolites. Principal component analysis plots of the normalized log transformed data were 
used to aid in visualizing possible variation, clustering tendencies, trends and outliers.  
 
A linear regression model (adjusting for the covariances of body condition, sex and age) was 
used to identify significant metabolites and fold changes were calculated to rank the 
metabolites of significance in the pairwise comparisons.  P-values are presented as 
unadjusted, and adjusted using the Benjamini-Hochberg step-up false discovery rate 
method68. Adjusted P-values <0.05 were considered significant and <0.1 were considered 
trending towards significance.  
 
The effect of BCS on measures associated with abnormal glucose metabolism and diabetes 
(screening, fasting and 2-h blood glucose following a glucose tolerance test, leptin, 
adiponectin, L:A ratio, fPLi, Insulin, G:I ratio, triglyceride, and MCP-1) was analysed by 
one-way ANOVA. A post-hoc Tukey’s multiple comparison test was used to determine 
significant differences between lean, overweight and obese cats.  Pearson correlations were 
used to examine relationships between significant metabolites identified from metabolomics 
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analysis and measures associated with abnormal glucose metabolism and diabetes for lean 
and obese cats. 
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Results 
 
Metabolic characterization of cats 
Glucose variables for both lean and obese cats have been reported previously46,47. Fasting 
blood glucose concentrations (mean ± SEM) were not different between lean and obese cats 
(5.2 ± 0.4 mmol/L lean; 4.6 ± 0.2 mmol/L obese cats). Glucose concentrations 2 hr following 
a GTT were significantly higher (P<0.01) in obese cats (5.8 ± 0.3 mmol/L lean;7.9 ± 0.6 
mmol/L obese), and 18% (3/17) obese cats but no lean cats had impaired glucose tolerance 
(glucose > 9.8 mmol/L at 2 hr).  Mean fasting insulin concentrations were 50% higher in 
obese cats (0.6 ± 0.1 ng/ml lean; 0.9 ± 0.2 ng/ml obese) but the difference was not 
statistically significant (P=0.1). Mean fasting glucose:insulin ratio in obese cats was only 
1/3rd of lean cats (22.0 ± 8.2 lean; 7.5 ± 1.1 obese; P <0.05). Triglyceride concentrations were 
2.5 times higher in obese than lean cats (18.9 ± 2.4 lean; 54.2 ± 19.1 obese, P< 0.01)  (Table 
7.1).  Leptin concentrations were higher (P<0.05), whilst adiponectin concentrations were 
lower (P<0.05) than lean cats, but MCP -1 was not different between lean and obese cats 
(Table 7.1). 
 
Metabolomic differences between lean and obese cats 
GC-MS analyses identified 173 metabolites (55 identified by the metabolomics libraries and 
118 unknown) in this study of lean and obese senior cats.  Relative log abundance (RLA) plot 
across all cats exhibited medians close to zero and acceptable variation (Figure 7.1). Principal 
component analysis (PCA) plots identified distinct clustering of metabolites between the lean 
and obese cats (Figure 7.2).  Thirteen metabolites were found to be significantly different 
between lean and obese cats, and of these 6 metabolites were identified (Table 7.2). Identified 
non-significant metabolites are listed in Appendix 7.2. Obese cats exhibited a 1.8 to 2.0-fold 
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increase (P<0.05) in the fatty acids; tetradecenoic (myristoleic) and 9Z- hexadecenoic 
(palmitoleic) acid, together with a 1.4-fold increase (P<0.05) in glycerol. Furthermore, obese 
cats had decreased alanine and increased phenylalanine, although both of these amino acids 
were only approaching significance (corrected P=0.052 and P=0.093, respectively). Other 
amino acids; leucine, isoleucine, valine, tyrosine and tryptophan were not significantly 
different between lean and obese cats. Glycolic acid was increased 1.4- fold (P<0.05) in 
obese cats.  
 
Correlations between significant metabolites and measures of abnormal glucose metabolism 
and diabetes  
Moderate significant correlations were found between metabolites identified by GC-MS 
analysis and measures of abnormal glucose metabolism and diabetes (Table 7.3).  Alanine 
was negatively correlated with 2-h blood glucose and leptin. Phenylalanine was negatively 
correlated with fPLi and positively correlated with insulin, but not correlated with blood 
glucose measures. 9Z-hexadecenoic acid was positively correlated with leptin, whilst 
tetradecenoic acid was negatively correlated with glucose:insulin ratio. Neither fatty acid was 
significantly correlated with triglyceride or insulin. Glycerol was negatively correlated with 
fasting blood glucose and glucose:insulin ratio, and positively correlated with insulin.  
Glycolic acid was negatively associated with adiponectin and positively associated with 
insulin. No significant correlations were found between identified metabolites and MCP-1. 
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Discussion 
Numerous studies have reported alterations in amino acid34,68, and fatty acid metabolism69,70 
in obese humans and identified several metabolites as predictors of insulin resistance71,72 and 
type 2 diabetes 31,73,74. In cats there are fewer reports of such predictive markers55,75,76.  Using 
a metabolomic approach we examined differences between obese and lean senior neutered 
cats, and overall identified 6 metabolites that were significantly altered. Obese cats were 
characterised by altered lipid metabolism with increased triglycerides, tetradecenoic and 9Z- 
hexadecenoic (palmitoleic) fatty acids, together with increased glycerol. For amino acids, 
phenylalanine was increased in obese cats, whilst surprisingly alanine was decreased. Also, 
we identified a novel metabolite glycolic acid (glycolate) as increased in obese cats, 
suggesting that dysregulation of glycolic acid metabolism might be characteristic of obesity 
and prediabetes in cats. Additionally, other metabolites measured in this study were altered 
between our lean and obese study cats, namely leptin and leptin:adiponectin ratio and 
triglyceride concentrations significantly increased and adiponectin and glucose:insulin ratio 
significantly decreased in obese cats. Neither insulin nor MCP-1 were not altered between the 
two groups in our study.  
 
Alterations in fatty acid metabolism 
Obese cats are known to exhibit hyperlipidaemia and dyslipidemia40 with increased 
triglycerides, cholesterol, and lipoproteins (VLDL and HDL)74. In the present study, obese 
cats had increased triglycerides (others were not measured). Similarly, in humans, obesity is 
characterised by dyslipidaemia77 with increased FFA, triglycerides and cholesterol, albeit 
decreased HDL78. Increased FFA concentrations in humans are linked to the onset of insulin 
resistance with increased flux of FFA leading to an overproduction of VLDL3 and the 
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dyslipidaemia is thought to be a crucial link between insulin resistance and beta-cell 
dysfunction79 in type 2 diabetes. In our study obese cats had a significantly lower 
glucose:insulin ratio that the lean cats. 
 
Two fatty acids, palmitoleic and tetradecenoic acids were increased in obese cats when 
compared with lean cats. Studies in humans have reported a relationship between palmitoleic 
acid and obesity74,80 and type 2 diabetes81-83, but our results are novel in cats.  However, in 
humans there is controversy over whether palmitoleic acid improves metabolic parameters in 
obesity and insulin resistance84 or increased circulating palmitoleic acid concentrations are 
associated with increased incidence of diabetes 81,83-85. Palmitoleic acid appears to have many 
complex roles in lipid metabolism, and cannot easily be defined as a predictive marker of 
insulin sensitivity and diabetes86. In diabetic rodent models, administration of palmitoleic 
acid has been noted to improve hyperglycaemia and hypertriglyceridemia reduces insulin 
resistance and hepatic lipid accumulation87,88. Our results showed a positive correlation 
between palmitoleic acid and leptin, but no association with insulin, triglycerides, or any 
other measures associated with abnormal glucose metabolism and diabetes. Although in our 
cats, insulin was not significantly increased with obesity, mean concentrations were nearly 
double those in lean cats, and fasting glucose:insulin ratio was significantly lower in obese 
than lean cats (P<0.05). The other fatty acid identified as increased in obese cats was 
tetradecenoic acid, a saturated fatty acid. Altogether fatty acids have been considered 
independent predictors of progression to diabetes in human studies69,89 by directly impairing 
insulin actions via oxidative stress, inflammation and mitochondrial dysfunction89. Long 
chain fatty acids, such as tetradecenoic acid, are considered markers of oxidative stress90-92. 
Interestingly, there was a negative correlation between myristoleic acid and glucose:insulin 
ratio in cats, supporting the notion that saturated fatty acids potentiate glucose-induced 
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insulin secretion which has been reported pancreatic islets extracted from female NMRI 
mice93. Therefore, myristoleic acid may be a useful indictor of oxidative stress and early beta-
cell dysfunction in cats. Glycerol, the “backbone” of triglycerides was also found to be 
increased in the obese cats. In humans, plasma glycerol is reported to increase in early phase 
of obesity94 and predict a worsening of hyperglycaemia and the development of type 2 
diabetes95. Our study identified a positive correlation between glycerol and insulin, and 
negative correlation between glycerol and both fasting blood glucose and glucose:insulin 
ratio in cats. Although the negative of glycerol and fasting blood glucose was contrary to 
results reported in humans, none of the obese cats in our study had increased fasting glucose 
consistent with IFG and only 18% of obese cats had IGT.  The negative association of 
glycerol with glucose:insulin ratio and positive association with insulin in our cats are 
consistent with findings in humans where fasting levels of glycerol are increased with 
impaired fasting glucose, impaired glucose tolerance and newly diagnosed diabetes95. 
Although circulating FFA and glycerol levels are significantly increased in humans with 
obesity, they are only marginally influenced by insulin resistance and type 2 diabetes96, and 
suggest that glycerol may not be a reliable measure of progression to diabetes in obese 
patients.  
Obesity is characterised by an expansion of white adipose tissue mass and is associated with 
increased leptin and decreased adiponectin plasma concentrations as the obesity 
progresses5,49. Our obese cats were also characterized by increased leptin and decreased 
adiponectin concentrations. The relationship between obesity and adipokines as markers of 
inflammation has been extensively studied in humans97,98, dogs99, and cats5,48,50,100. With 
increasing adiposity, there is a general increase in leptin, and the current results agree with 
previous studies in cats63,101,102. The main physiologic role of leptin is to regulate body fat 
mass through modulating satiety and energy metabolism, although previously in cats we have 
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shown that higher plasma leptin concentrations are associated with insulin resistance, 
independent of the degree of adiposity102. Leptin can act to sensitize the body to insulin by 
increasing fatty acid oxidation and decreases triglyceride content in the liver and other 
tissues5.  In contrast, adiponectin was decreased in our obese cats, consistent with reports that 
circulating adiponectin concentrations are decreased with obesity in humans103 and 
cats5,104,105.  Adiponectin has insulin-sensitizing effects, increasing fatty acid oxidation and 
decreasing triglyceride content in the liver and other tissues5 and reduced adiponectin in 
obesity likely contributes to insulin insensitivity.  
 
Glycolic acid 
Glycolic acid (also known as glycolate) was a novel metabolite identified as increased in our 
cohort of obese cats. It has recently been shown to be increased in obese humans that display 
dyslipidaemia and hyperglycaemia, compared to healthy obese people106. Glycolic acid is a 
metabolite related to mitochondrial and peroxisome function in hepatocytes, and oxalic acid 
(oxalate) metabolism. Glycolic acid can be metabolised to glyoxylic acid (glyoxylate) by 
glycolate oxidase in peroxisomes, and then to oxalate by lactate dehydrogenase 
predominantly in the cytoplasm. Oxalate and glycolate can be excreted in urine, or the 
oxalate can be retro-converted to glycolate107 or glyoxylic acid108.  Whilst the underlying 
cause for an increase in glycolic acid in obese cats and humans remains to be determined, 
studies have linked increased glyoxylate to prediabetes in humans, it is hypothesized that 
glyoxylate metabolism contributes to fat-induced hepatic insulin resistance and associated 
hyperglycemia109,110. The obese cats in our study had reduced glucose tolerance compared to 
lean cats based on significantly increased 2 hr glucose concentrations in a GTT, and 16% of 
obese cats had impaired glucose tolerance and were considered prediabetic . Furthermore, 
glyoxylate has been identified as a unique marker of prediabetic metabolism, with increased 
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glyoxylate being detected in subjects up to 3 years prior to diagnosis of diabetes mellitus111.  
Also in a diabetic animal model (db mouse) increased plasma glyoxylate concentrations have 
been reported, but interestingly glycolic acid concentrations were normal 109. Unfortunately, 
in our study, glyoxylate was not detectable by GC-MS.  
 
An increase in circulating glycolic acid concentrations in obese cats could result in acidosis. 
In ethylene glycol toxicity in cats and dogs the hepatic metabolism of ethylene glycol leads to 
an accumulation of glycolic and oxalic acids and this results in a severe, often lethal, 
metabolic acidosis112. In obese cats in our study, the small (1.4-fold) increase in glycolic acid 
is likely to produce a mild metabolic acidosis, and this could potentially predispose cats to 
diabetes.  In humans, even mild metabolic acidosis is known to produce insulin resistance in 
seemingly healthy adults113, and a link between dietary acid load such as a diet rich in animal 
products, is associated with chronic metabolic acidosis, insulin resistance, metabolic 
syndrome, and an increased risk of type 2 diabetes114.  Similarly, cats being obligate 
carnivores traditionally, consume a particularly acidotic diet, although this has changed 
somewhat during domestication with increased levels of carbohydrate in commercial diets115. 
Obese cats are often converted to prescription diets with higher protein than typical feline 
diets to promote weight loss116-118. In our obese cats, the range of dietary protein intake was 
only 24 to 35% of ME, in those animals with good dietary records. It would therefore appear 
unlikely that high protein/meat acidotic diets per se are the cause of increased glycolic acid in 
our cohort of obese cats.  Rather the increased glycolic acid is likely associated with 
dysregulation of liver metabolism in obesity and a prediabetic state. In support of this notion, 
concentrations of glycolic acid are significantly elevated in the urine of streptozotocin-
induced diabetic rats, regardless of the type of diet fed119. In this rodent model, the source of 
increased glycolic acid was unresolved, but was suggested to relate to either decreased rate of 
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glycolic acid utilization and/or excretion, or increased rate of synthesis119. In our study, it 
should be noted that glycolic acid concentrations in cats were negatively associated with 
adiponectin and positively associated with insulin. Together these results imply increased 
glycolic acid is associated with reduced insulin sensitivity. Further work is required to 
investigate the metabolism of glycolic acid in obesity, and determine whether glycolic acid 
and other related metabolites (glyoxylate and oxalate) may be useful in diagnosing 
prediabetes in cats. 
 
Amino acids  
Obesity and insulin resistance in humans is associated with altered amino acid metabolism, in 
particular, high concentrations of branched chain amino acids (BCAA)9,81. Increases in 
leucine, isoleucine and valine, along with alanine (as a by-product of BCAA metabolism), are 
reported to predict worsening insulin sensitivity in humans89.  However, in our cohort of 
obese cats we did not identify any changes in BCAA metabolism, except a trend towards 
decreased alanine concentrations. Nevertheless, alanine concentrations were negatively 
correlated with 2-h blood glucose following a GTT, suggesting a link between alanine and 
glucose intolerance. Further analysis of results for obese cats showed a positive correlation 
(r=+0.60, p<0.05) between alanine and insulin concentrations, which is in accord with 
findings that alanine has weak insulinotropic effects in adult cats120. Decreased alanine levels 
in obese cats could be indicative of increased gluconeogenesis (alanine to pyruvate to 
glucose), and/or increased glyoxylate detoxification in hepatic peroxisomes (glyoxylate can 
combine with alanine to generate pyruvate). However, neither pyruvate nor glucose 
(screening or fasting or metabolomics) were significantly increased in the obese cats. 
Whether alanine is linked to downstream metabolism of glycolic acid in obese cats needs 
further investigation.  
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Phenylalanine, an essential α-amino acid, was also increased in obese cats. Increased 
phenylalanine levels have been described in obese humans34 and as a marker of insulin 
resistance 30,72,121. In our cats, phenylalanine had a positive association with insulin 
concentrations, similar to metabolomic findings in humans at risk for diabetes73. However, 
our data showed no correlation between phenylalanine and fasting glucose, unlike human 
studies where increased phenylalanine is associated with impaired fasting glucose and type 2 
diabetes122. This may have been because none of our cohort of obese cats had impaired fasting 
glucose. Phenylalanine is a glucogenic amino acid and as such is deaminated in the liver to 
produce glucose. Interestingly the natural diets of cats are essentially carbohydrate-free123 and 
in general, cat metabolism is directed towards deriving energy more from dietary proteins and 
fats. Deng et al92 studied the diets of cats and identified increased phenylalanine as a marker 
of high protein diets (50% ME). In contrast, Silva and Mercer124 suggested that the amount of 
amino acid gluconeogenic precursors was unaffected in isolated feline hepatocytes by dietary 
protein intake when comparing diets containing 18% and 70% ME protein. In our study, the 
diets of the cats were variable and they were frequently fed a combination of diets, as cats 
were client owned. Further controlled dietary studies with obese cats are needed to validate 
our results.  
MCP-1 
Surprisingly in our study, MCP-1 was not significantly increased in obese cats. This is 
contrary to findings in humans, where increased MCP-1 concentrations occur with obesity 
and are associated with type 2 diabetes125-131, in dogs with obesity132, and in mice133,134, 
MCP-1 induces inflammation in adipose tissue. In cats, MCP-1 mRNA has been detected in 
subcutaneous and visceral fat but not in skeletal muscle135 and in humans, MCP-1 protein 
expression was higher in omental fat than in subcutaneous fat in severely obese patients136. 
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One possible explanation for the lack of MCP-1 expression is the distribution of fat in obese 
domestic cats. In contrast to humans, obese cats had abdominal fat equally distributed 
subcutaneously and intra-abdominally137. Further studies are needed to determine whether 
MCP-1 plays a role in the development of diabetes in cats. 
 
Limitations 
In this study, there are a few noteworthy limitations. Firstly, our cats were all client-owned 
cats, not research cats, so the number of subjects is small and a period of acclimatization was 
not possible. It was assumed that the cats were spontaneously obese, and given all cats were 
aged (≥8 years), it is presumed that they had been obese for several years. However, no data 
were obtained on the duration of obesity. Secondly, the lack of complete diet records for all 
animals did not enable analysis of the metabolomics results in relation to potential differences 
in dietary composition, although no major differences in diet were noted between animals 
with good records. Further, as the animals were client-owned cats we were unable to 
normalise diets for all animals prior to metabolomics analysis. Thirdly, 7 of the metabolites 
that were significantly different between lean and obese cats could not be identified, and 
would require additional laboratory-based analyses to identify them. In addition, there is a 
limitation of using GC-MS in detecting non-volatile compounds, and these would have been 
better determined using LC-MS. A targeted metabolomic approach in a longitudinal study 
would be useful to determine if changes in metabolites predict the development clinical 
diabetes in the future. As Ferrer et al 138 stated, ‘being obese is not healthy and is even less so 
if insulin resistance and diabetes ensues’, and thus indicators of metabolic derangements of 
obesity and predictors of future diabetes are urgently needed. 
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Conclusion 
We have identified metabolic profiles induced by spontaneous obesity in senior cats. The 
results indicate specific alterations in lipid and amino acid profiles, together altered glycolic 
acid metabolism. These metabolites might prove useful markers of metabolic dysfunction in 
obesity, and improve understanding of the metabolic derangements leading to diabetes in 
cats. 
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a AlphaTRAK (Zoetis) 
b Idexx Laboratories, Brisbane Australia 
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c Linco's Multi-Species Leptin Radioimmunoassay (RIA) Kit, Linco Research Inc, St Charles, 
MO 
d B-Bridge international, Otsuka, Tokyo, Japan 
e Nippon University 
f Morinaga Institute of Biological Science, Kanagawa, Japan  
g 13C6-Sorbitol/
13C5
15N-Valine in methanol, 0.5 mg mL-1 
h 0.029% (v/v) n dodecane, n-pentadecane, n-nonadecane, n-docosane, n-octacosane, n-
dotriacontane, n-hexatriacontane dissolved in pyridine 
i Gerstel 2.5.2 autosampler, a 7890A Agilent gas chromatograph and a 5975C Agilent 
quadrupole MS (Agilent, Santa Clara, USA). 
j Varian, Inc, Victoria, Australia 
k Agilent MassHunter Workstation Software, Quantitative Analysis, Version B.05.00/Build 
5.0.291.0 for GCMS 
l Max-Planck-Institute for Plant Physiology, Golm, Germany (http://csbdb.mpimp-
golm.mpg.de/csbdb/dbma/msri.html)  
m (13C6H4O6 – Sorbitol - (0.5 mg/mL), 13C5-15N-Valine - (0.5 mg/mL), 2-aminoanthracene - 
(0.25 mg/mL) Pentafluorobenzoic acid - (0.25 mg/mL)) 
n R version 3.3.1 (2016-06-21) -- "Bug in Your Hair" Copyright (C) 2016 The R Foundation 
for Statistical Computing. Metabolomics package for R user guide v.02 Last updated 1 
February 2013 
o GraphPad Prism version 7.01. GraphPad Software, Inc. La Jolla, CA, USA. 
 Reference Interval Draft Version, Copyright 2005, University of Cincinnati 
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Tables 
Table 7.1. Measures associated with abnormal glucose metabolism and diabetes for lean, 
overweight and obese senior cats. Values are mean ± SEM. Different superscripts denote 
significant (P<0.05) difference between groups, as determined by post-hoc Tukey multiple 
comparison test.  
    ANOVA 
Variables Lean 
 BCS 4-5/9 
n=18-19 
Overweight 
BCS 6-7/9 
n=12 
Obese 
BCS 8-9/9 
n=17 
P-value 
Screening Blood Glucose 
(mmol/L) 
6.0 ± 0.5 5.4 ± 0.5 6.4 ± 0.5 NS 
Fasting Blood Glucose 
(mmol/L) 
5.2 ± 0.4 4.9 ± 0.2 4.6 ± 0.2 NS 
2-hr Blood Glucose (mmol/L) 5.8 ± 0.3a 6.4 ± 0.5a 7.9 ± 0.6b <0.01 
Leptin (ng/mL) 11.1 ± 1.1a 21.4 ± 3.3b 39.6 ± 5.2c <0.001 
Adiponectin (µg/mL) 6.6 ± 1.1a 4.1 ± 0.9ab 2.5 ± 0.6b <0.01 
Leptin:Adiponectin ratio 
(ng/µg) 
3.9 ± 1.3a 10.4 ± 3.1a 40.2 ± 12.2b <0.01 
fPLi (µg/L) 1.7 ± 0.3 2.7 ± 1.3 2.0 ± 0.5 NS 
Insulin (ng/mL) 0.6 ± 0.1 1.0 ± 0.2 0.9 ± 0.2 NS 
Fasting glucose:insulin ratio 22.0 ± 8.2a 6.5 ± 1.1b 7.5 ± 1.1b <0.05 
Triglyceride (mg/dL) 18.9 ± 2.4a 27.1 ± 6.1a 54.2 ± 19.1b <0.01 
 199 
 
MCP-1 (pg/mL) 64.2 ± 5.3 83.6 ± 19.0 64.6 ± 13.5 NS 
fPLi feline pancreatic lipase 
MCP-1 Monocyte chemoattractant protein-1 
BCS body condition score 
NS not significant (P≥0.05) 
a,b,c Significant differences between lean, overweight and obese cats 
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Table 7.2 Significant identified metabolites from GC-MS analysis of lean and obese senior 
cats. Values are mean ± SEM expressed as fold-change relative to mean for lean (control) 
group. P-values from pair-wise unpaired t-test comparisons are presented as unadjusted, and 
adjusted using the Benjamini-Hochberg step-up false discovery rate method.  
Metabolite 
 
Lean Cats 
n = 21 
Obese Cats 
n = 15 
Unadjusted 
P-value 
Adjusted 
P-value 
Alanine 1.0 ± 0.08 0.6 ± 0.12 0.01 0.09 
Phenylalanine 1.0 ± 0.08 1.6 ± 0.08 0.001 0.05 
Tetradecanoic acid 1.0 ± 0.11 1.8 ± 0.09 0.001 0.03 
9Z- hexadecenoic acid 1.0 ± 0.10 2.0 ± 0.11 0.002 0.04 
Glycerol 1.0 ± 0.09 1.4 ± 0.05 0.001 0.03 
Glycolic acid 1.0 ± 0.08 1.4 ± 0.06 0.001 0.03 
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Table 7.3. Pearson correlation of metabolites identified from GC-MS analysis of lean and 
obese senior cats and measures associated with abnormal glucose metabolism and diabetes 
(n=36).  
Metabolite Measure of glucose metabolism r P 
Amino Acids 
   
Alanine 2-hr blood glucose 
Leptin 
-0.45 
-0.58 
<0.01 
<0.001 
Phenylalanine fPLi 
Insulin 
-0.34 
+0.50 
0.04 
<0.01 
Fatty Acids 
   
9Z- hexadecenoic acid Leptin +0.36 0.03 
Tetradecenoic Acid G:I ratio -0.35 0.03 
Glycerol Fasting blood glucose 
Insulin 
G:I ratio 
-0.33 
+0.35 
-0.35 
0.05 
0.04 
0.03 
Other acids 
   
Glycolic acid Adiponectin 
Insulin 
-0.45 
+0.37 
<0.01 
0.03 
 
 
 
 
Figures 
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Figure 7.1: A relative log abundance (RLA) plot where the median of each metabolite in the data matrix is visualized, and then subtracted this 
median from each metabolite. Blue bars are lean (BCS 4-5/9) and green bars are obese (8-9/9) non-Burmese cats. Red, purple and yellow bars 
are related to chapter 8. 
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Figure 7.2: Principal Component Analysis (PCA) plot of GC-MS data showing distinct 
clustering of metabolic profiles between lean (red) and obese (blue) senior cats discriminated 
based on the thirteen significant metabolites.  
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Abstract 
Burmese cats exhibit dyslipidaemia and are 4 times more likely to develop diabetes than 
other cat breeds. The aim of this study was to identify metabolomic differences between 
healthy senior Burmese (n=19) and non-Burmese (n=30) cats, and to examine correlations 
between significant metabolites and measures known to be associated with abnormal glucose 
metabolism and diabetes. Food was withheld 18 - 24 hr and a venous blood sample collected 
for GC-MS analysis, biochemical and hormonal assays, and a glucose tolerance test was 
performed. Metabolomic analysis (corrected for age, gender and body condition score) 
identified 23 known metabolites significantly (P<0.05) different between Burmese and non-
Burmese cats. Many glucogenic amino acids, together with hydroxyproline and aminobutyric 
acids were all increased, whilst beta-alanine was decreased in Burmese cats.  Fructose and 
glucose, cholesterol and some fatty acids, glycerol-3-phosphate, numerous acids (lactic acid, 
glycolic acid, phosphoric acid, threonic acid, glycerate, and succinate) were all decreased in 
Burmese cats. Urea was increased in Burmese. Biochemical testing revealed that Burmese 
cats exhibited increased (P<0.05) insulin, triglyceride, and MCP-1 concentrations. Positive 
moderate associations were found between 7 amino acids (beta-alanine, cysteine, glutamine, 
hydroxyproline, phenylalanine, proline and tyrosine) identified by metabolomics and insulin. 
No differences were observed in plasma adipokines. This study is the first to report 
metabolite differences between healthy non-Burmese and Burmese cats. The results highlight 
potential markers of metabolic dysfunction in a cat breed at high risk of developing diabetes. 
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Introduction 
Burmese cats from the UK, Sweden, Australia and New Zealand are four times more likely to 
develop diabetes mellitus than non-Burmese1-4, with one in 50 Burmese in the UK and 
Australia being affected2,5. Diabetes in Burmese closely resembles type 2 diabetes in humans, 
based on common pathophysiologic features. These include late age of onset, insulin 
resistance6-11, loss of beta-cell mass12-15, and amyloid deposition in pancreatic islets16-18.  
 
Burmese cats in New Zealand have evidence of an inherited component, involving a major 
locus with a significant risk allele to diabetes3. Formation of the breed occurred in 1957 from 
only a very small number of individuals20,21, and males and females are similarly affected, 
indicating that the gene or genes causing diabetes are autosomal rather than sex-linked3. A 
gene expression study reported that lean Burmese displayed a 3- to 4-fold increase in the very 
low density lipoprotein percentage, double that for obese domestic cats, suggestive of lipid 
(particularly triglyceride) dysregulation22. Approximately, 28% Australian Burmese cats have 
altered lipid metabolism, with an exaggerated postprandial triglyceride response after an oral 
fat tolerance test, indicating possible insulin dysregulation10,23. However, affected Burmese 
cats have normal blood fasting insulin, fructosamine, non-esterified free fatty acids, and 
apolipoprotein concentrations23. 
 
 In Burmese cats, fasting blood glucose concentrations and glucose tolerance test results are 
not different to non-Burmese cats, even when results are adjusted for body condition score, 
age and gender24,25. Therefore, other markers of altered metabolism in Burmese cats need to 
be investigated to identify differences between Burmese and non-Burmese cats that might 
account for their increased risk of developing diabetes.    
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Metabolomics involves measurement of a comprehensive set of metabolites in a body fluid26. 
Alterations in metabolic profiles are often present much earlier in the course of disease than 
histopathological changes, and can therefore be used as a sensitive, early indicator of a 
disease process27. We found metabolomic differences between lean and obese senior non-
Burmese cats (> 8 years of age) (Chapter 7), including changes in lipids, amino acids, and 
glycolic acid metabolism. It is unknown whether the metabolomic characteristics of obese 
non-Burmese cat also occur in senior Burmese cats. Obesity is a risk factor for type 2 
diabetes in both domestic and Burmese cats28, and obesity in domestic cats is associated with 
abnormal glucose metabolism, and changes in circulating levels of adipokines (adiponectin 
and leptin)29-33, fPLi34, triglycerides22,35 and inflammatory disease mediators36 but not with 
MCP-1 (Chapter 7). However, many of these markers have not been examined in Burmese 
cats, and apart from altered lipid metabolism, it is generally unknown if there are other 
characteristic differences in the Burmese metabolome22. 
Therefore, the aims of this study were to compare metabolomics profiles and some other 
indicators of obesity between healthy senior Burmese and non-Burmese cats, adjusted for 
differences in body condition, sex and age. In addition, we determined whether identified 
metabolites were associated with abnormal measures of glucose metabolism, including 
screening24, fasting and the 2-h glucose concentrations25 following a glucose tolerance test. 
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Materials and Methods 
The protocol for these studies and the care and handling of these animals were approved by 
the Animal Experimentation Ethics Committee of the University of Queensland.  
Animals:  
Client-owned cats (n=49) were recruited for this study and were presented for a routine health 
check at local veterinary clinics in Brisbane. Each cat was assessed and classified as either 
Burmese (n=19) or non-Burmese (n=30). All the Burmese cats had a known history of being 
acquired from breeders. Other than for excess body condition in some cats, cats enrolled in 
the study were assessed as healthy based on results of a clinical examination, patient history, 
haematological and biochemical assays, total thyroxine, and fPLi. Body condition score 
(BCS) was recorded on scale of 1 to 9, and cats between 4 and 9 were included23. Body 
condition scores37 for Burmese were 6 lean (BCS 4-5), 11 overweight (BCS 6-7) and 2 obese 
(BCS 8-9) with overall mean 6.1, range 4-8, and for non-Burmese (all domestic cats) were 12 
lean, 5 overweight and 13 obese, with overall mean 6.1 and range 4-9. Ages of the cats 
ranged from 8 to 15 years (mean ± SEM 9.9 ± 0.39 years) for Burmese and 8 to 18 years 
(mean ± SEM 10.7 ± 0.34 years) for non-Burmese. The Burmese consisted of 8 neutered 
females and 11 neutered males, and the non-Burmese had 16 neutered females and 14 
neutered males. Incomplete diet histories were available: 6/19 (32%) of the Burmese and 
16/30 (53%) of the non-Burmese cats in our study had reliable diet information. Dietary 
protein as a percentage of metabolizable energy was 20 % to 31 % ME in Burmese versus 
24% to 35% in non-Burmese (mean ± SEM 26.5 ± 1.7 and 25.1 ± 0.3, respectively). Dietary 
fat in Burmese was 34% to 40% and non-Burmese 15% to 44% (mean ± SEM 37 ± 1.0 and 
33.4 ± 1.6, respectively). Dietary carbohydrate in Burmese was from 34% to 39% and in non-
Burmese 26% to 36% (mean ± SEM 36.5 ± 0.8 and 34.6 ± 0.9, respectively).). P-values using 
an unpaired t-test did not show significant differences (P<0.05) between the subgroups. 
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Protocol: 
On admission after a full physical examination, a 5-ml venous blood sample was collected for 
standard haematology, biochemical profile, feline pancreatic lipase, and total thyroxine 
analyses to determine if animals were suitable for inclusion in the study. Samples were 
analysed by a commercial veterinary pathology laboratorya. 
 
After examination, cats were hospitalized and food was withheld for 18 to 24 hr and jugular 
venous blood samples were collected for hormone (4 mL EDTA plasma and serum) and 
metabolomic (2 mL serum) analyses. Blood for serum was allowed to clot for 20 minutes., 
All samples were centrifuged for 8 minutes at 1500 g then plasma/serum separated and stored 
at -80°C until transport on dry ice and analysis. To allow for resolution of stress 
hyperglycaemia, fasting blood glucose was measured from a paw or ear sample using a 
portable glucose meter calibrated for feline bloodb 3 h after catheter placement and then an 
IV glucose tolerance test performed using a glucose dose of 0.5 g/kg.  A timer was started 
halfway through the infusion and blood samples were taken at 2 min, 2 h and then hourly 
until glucose returned to below our laboratory’s upper limit of normal fasting glucose 
concentration of 6.5 mmol/L26. 
 
Gas chromatography- mass spectrometry metabolomic analysis: 
Serum was assessed for metabolites using gas chromatography/mass spectrometry. Detailed 
methods are described elsewhere (Chapter 7). Briefly, extraction was performed using cold 
methanol and internal standard added. The sample was then placed on ice to precipitate the 
protein, centrifuged, dried and then redissolved for polar derivatisation. Samples were injected 
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using a hot needle technique into a GC-MS system. Chromatograms and mass spectra were 
evaluated using specialist software and metabolites identified using a library. 
 
Hormones and other analytes: 
Plasma leptin and serum total adiponectin concentrations were measured using commercially 
available radioimmunoassayc and ELISAd kits respectively, which have both been previously 
validated for the detection of feline adipokines38,39. Intra-assay and inter-assay coefficients of 
variation (CVs) were <15% and <10% for leptin quality controls of 2.3 ng/mL and 11.4 
ng/mL respectively. For adiponectin, intra-assay CV was <5% for quality controls of 4.2 and 
21.7 µg/mL. 
 
Serum insulin concentrations were measurede using a commercial ELISA kit validated for 
feline insulinf. Intra and inter-assay reproducibility of feline insulin ELISA kit are less than 
10%. Serum triglyceride concentrations were determined using an autoanalyser (Hitachi-
7180) using manufacturer’s reagents.  The intra-assay and inter-assay CV was <5%. Feline 
pancreatic lipase concentrations were determined at a commercial laboratorya by 
radioimmunoassay validated for use in the cat40. Concentrations of  MCP-1 were determinede 
using a canine MCP-1 ELISA kit. Cross-reactivity with feline plasma samples was shown, 
and serial dilution (factors were x1, x2 and x4 ) of two samples at 163.8 and 316.9 pg/ml 
resulted in correlation coefficients of 0.998 and 1.000 respectively. The intra-assay CV was 
<5% for both samples. 
 
Statistical analyses: 
The effect of breed (non-Burmese versus Burmese) on measures associated with abnormal 
glucose metabolism, diabetes, and obesity (screening, fasting and 2 h blood glucose 
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following a glucose tolerance test, leptin, adiponectin, leptin: adiponectin ratio, fPLi, insulin, 
glucose: insulin ratio, triglyceride, and MCP-1) was analysed by unpaired t-test. Data were 
log transformed to remove heterogeneity of variance, as required.  
 
Using the metabolomics package of Rn, metabolite data were normalized using a single 
internal standard method where a normalized data matrix is obtained by subtracting the log 
metabolite abundance of a single internal standard from the log abundances of the 
metabolites in each sample41. A linear regression model (adjusting for the covariances of 
body condition, sex and age) was used to identify and rank significant GC-MS metabolites. 
Pairwise comparisons were made (unpaired t test) and P-values are presented as both 
unadjusted and adjusted using the Benjamini-Hochberg step-up false discovery rate method42. 
P-values <0.05 were considered significant.  
 
Pearson correlations were used to examine the relationships between significant identified 
GC-MS metabolites and measures associated with abnormal glucose metabolism and 
diabetes. These potential markers of diabetic predisposition included blood glucose 
(screening, fasting, and 2 h blood glucose following a glucose tolerance test), insulin, 
triglyceride, adiponectin, leptin, fPLi, and MCP-1 concentrations. Indices such as 
glucose:insulin, and leptin:adiponectin ratios were also calculated.   
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Results 
Metabolomic analytes 
GC-MS analyses identified 173 metabolites, 64 of which were found to be significantly 
different (P<0.05) between Burmese and non-Burmese cats, when adjusted for body 
condition score, age and sex. RLA plot medians were close to zero and had acceptable 
variation (Figure 8.1). Of these 64 metabolites, 23 were identified using the laboratory’s 
metabolomic library and comprised of 10 amino acids, 3 fatty acids and sterols, 6 acids and 2 
sugars. (Figure 8.2, Table 8.1). Identified non-significant metabolites are listed in Appendix 
8.1. 
 
Amino acids constituted the largest proportion of metabolites that were different (P<0.01) 
between Burmese and non-Burmese cats (Table 8.1). Some glucogenic amino acids were 
increased in Burmese cats: alanine, cysteine, arginine, proline, and glutamine. The aromatic, 
glucogenic and ketogenic amino acids phenylalanine and tyrosine were both increased 
(P<0.01). Hydroxyproline and aminobutyric acid were also increased (P<0.01), whilst beta-
alanine was decreased (P<0.00001) in Burmese cats. The branched chain amino acids (valine, 
leucine, isoleucine) and threonine were found to be not significantly different between non-
Burmese and Burmese cats (data not shown). Urea, the breakdown product of protein 
metabolism, was increased (P<0.05) in Burmese cats. 
 
In Burmese cats, the fatty acids monooctadecanoylglycerol and octadecanoic (stearic) acid, 
and cholesterol were decreased (P<0.05) while palmitoleic, palmitic, and tetradecenoic acids 
were not significantly different.  The sugars fructose and glucose, were both decreased 
(P<0.01) in Burmese cats. Many acids were significantly different between the two groups. 
Glycerate, glycolic acid, lactic acid, phosphoric acid, succinate, and threonic acid were all 
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decreased (at least p<0.05) in Burmese cats. Also, glycerol-3-phosphate, the phosphoric ester 
of glycerol, was decreased (p<0.00001) in Burmese cats (Table 8.1).  
 
Insulin, triglyceride, adipokines, MCP-1 and fPLi 
We have previously reported there were no significant differences between Burmese and non-
Burmese cats in measures associated with glucose metabolism determined using a glucose 
meter, including blood glucose (screening, fasting and 2-h blood glucose in GTT) (Thesis 
Chapter 5 and 6) (Figure 8.2). However, in Burmese cats, insulin concentrations were higher, 
and the insulin to glucose ratio lower (P<0.05), which was accentuated by a trend to lower 
fasting glucose concentrations (P=0.09) (Figure 8.2). For the adipokines leptin and 
adiponectin, there were no differences between Burmese and non-Burmese cats, although 
MCP-1 was higher (P<0.05).  However, cholestero1 (by metabolomic analysis) (P<0.05), 
triglyceride (by biochemical assay) (P<0.01), and fPLi (by commercial RIA kit) approached 
being significantly higher (P=0.06) in Burmese cats (Figure 8.2). Triglyceride was higher 
(P<0.01) and total cholesterol was lower (P<0.05) in Burmese, and there was no significant 
sex effect on either (P=0.33 and P=0.72, respectively). There also was no interaction of breed 
by sex (P=0.37) for both total cholesterol and triglyceride. 
 
Associations between GC-MS metabolites and measures of abnormal glucose metabolism and 
diabetes  
Numerous relationships were identified between GC-MS metabolites and measures of 
glucose metabolism when Burmese and non-Burmese cats were pooled (Table 8.2). The 
amino acids cysteine, glutamine, hydroxyproline, phenylalanine and tyrosine, were all 
positively correlated with insulin, whilst B-alanine was negatively correlated with insulin 
(P=0.05). Arginine, phenylalanine, and tyrosine were all positively correlated with 
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triglyceride. Phenylalanine was negatively and lactic acid positively correlated with 
glucose:insulin ratio. Urea was positively and monooctadecanoylglycerol negatively 
associated with fPLi. Alanine and proline had a positive, whilst glycerol-3-phosphate and 
glycolic acid had a negative association with MCP-1 (Table 8.2). Glucose identified in 
metabolomics was positively correlated with fasting blood glucose measured by glucose 
meter.  
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Discussion 
Burmese cats are reported to be 4 times more likely to develop diabetes than domestic cats2,5. 
However, standard measures of glucose homeostasis such as fasting glucose and glucose 
tolerance were not different between Burmese and non-Burmese cats. In this study, we 
compared the metabolomic profiles of healthy senior Burmese and non-Burmese cats, and 
important findings were that 64 metabolites were present in different qualities in Burmese 
cats, of which 23 were known metabolites comprising of 10 amino acids, 3 fatty acids and 
sterols, 6 acids and 2 sugars and 2 other compounds. Monocyte chemoattractant protein was 
also increased and consistent with the literature, triglyceride concentrations in Burmese were 
also increased. 
 
Alterations in fatty acid metabolism 
Consistent with other reports in the literature, Burmese cats in our cohort had increased 
triglyceride concentrations on standard biochemical analysis. Lean Burmese in Australia and 
Europe have increased fasting triglyceride concentrations, decreased ability to clear 
triglycerides after an oral fat challenge or a high fat meal and an exaggerated increase in 
obesity-induced dysregulation of lipid metabolism22,23. These abnormalities may be 
associated with their increased risk of diabetes22,43. In our cohort, there was no effect of sex 
or interaction between breed and sex on triglyceride concentrations, although sample size was 
small. This is in contrast to one study also with small sample size, which reported that only 
lean male Burmese had higher VLDLs (very low-density lipoproteins), which are the main 
triglyceride-carrying component of blood, and females did not show this pattern22.  
 
Total cholesterol represents the sum of the cholesterol carrying components in blood - LDL 
(low-density lipoprotein), HDL (high- density lipoprotein) cholesterol, and VLDL, with LDL 
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carrying the largest proportion of cholesterol44. Although total cholesterol was decreased in 
our cohort of senior Burmese cats, it has been previously reported that total cholesterol is not 
different between Burmese and non-Burmese10,22, and this contrasts with the increased total 
cholesterol in humans with IFG and diabetes45. However, lean male Burmese cats are 
reported to have lower HDL as measured by their cholesterol lipoprotein fraction, albeit 
sample size was small (n=5)22.  The lower total cholesterol concentration in our cohort might 
reflect lower HDL concentrations, or reflect our small sample size. In our cohort of cats, there 
was effect of sex or interaction between breed and sex with total cholesterol, agreeing with a 
study of young cats (age range 1.5-8.6 years)10.  
 
Monooctadecanoylglycerol and stearic (octadecanoic) acid were significantly decreased in 
Burmese cats. These findings are novel in cats and are contrary to findings in humans with 
impaired fasting glucose (prediabetes) and diabetes45,46, where stearic acid is significantly 
increased. In isolated mouse islets, stearic acid increased basal insulin secretion and 
potentiated glucose-induced insulin secretion47. In Burmese cats, stearic acid and insulin 
concentrations were not associated. Stearic acid is either obtained from the diet or synthesised 
by elongation of palmitate. Both palmitate and stearate are the major substrates for the 
enzyme stearoyl-CoA desaturase-1, with stearate being converted to oleate which is the 
preferred substrate for triglyceride synthesis. Lower stearate might reflect increased activity 
of SCD1, and increased formation of triglycerides as we noted in Burmese cats. Indeed, 
SCD1 is an important target for the adipokine hormone leptin, and thought in part to mediate 
the anorexigenic effect of leptin48. We did not find an association between leptin and stearic 
acid (Appendix table 8.2), nor differences in plasma leptin concentrations between Burmese 
and non-Burmese cats. Research on triglyceride synthesis in Burmese cats, including stearic 
acid and the enzyme SCD1 warrants further investigation.   
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Alterations in amino acids and derivatives 
Our study identified 10 metabolites associated with amino acid metabolism which were 
significantly different between Burmese and non-Burmese cats. Eight BCAAs were increased 
in Burmese cats - alanine and phenylalanine, tyrosine, glutamine, proline, hydroxyproline, 
arginine, and cysteine. This is consistent with the finding in non-obese humans with 
increased insulin resistance45,49 where serum BCAAs are increased, and is hypothesized to 
result from increased protein catabolism together with impaired BCAA metabolism in liver 
and adipose tissue associated with insulin resistance45,50.   
 
Tyrosine and phenylalanine 
Phenylalanine a gluconeogenic and ketogenic aromatic amino acid, and tyrosine the precursor 
of phenylalanine were both these amino acids were increased in our cohort of Burmese cats. 
Such increases in phenylalanine and tyrosine concentrations are associated with insulin 
resistance and type 2 diabetes in humans49,51-54. In humans, increased concentrations of 
phenylalanine (males and females) and tyrosine (males only) predicted insulin resistance 
indicated by HOMA at a 6-yr follow-up55. In our cats, we found a positive moderate 
correlation between these amino acids and insulin concentrations, and moreover increased 
fasting insulin is considered an indicator of insulin resistance in cats56.  A study in humans 
reported no correlation between fasting glucose and phenylalanine55, similar to the findings in 
our cohort of cats. The authors concluded that altered amino acid metabolism may be more 
related to insulin resistance before glucose concentrations were affected. In humans, insulin 
resistance and future risk for type 2 diabetes is also predicted by a distinct amino acid pattern 
of increased isoleucine, leucine, and valine55, but these were not significantly different in our 
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Burmese cohort. Further studies are needed to determine whether increases in the aromatic 
amino acids tyrosine and phenylalanine also predict future diabetes in cats. 
 
Alanine and glutamine 
Alanine and glutamine were increased in our cohort of Burmese cats. These gluconeogenic 
amino acids have been associated with insulin resistance57. In our cats, there was a strong 
positive correlation between glutamine (but not alanine) and insulin, and no association of 
either amino acid with fasting glucose. Humans with IFG and untreated diabetes have 
significantly increased glutamine45, and an association between IFG and type 2 diabetes with 
alanine has also been reported45. In cats in diabetic remission these amino acids are reduced 
(Gottleib et al, unpublished data). 
  
Increased concentrations of BCAA lead to increases in by-products of BCAA catabolism 
such as alanine45,51. Alanine is formed from glutamate by the liver enzyme alanine 
aminotransferase (ALT). In patients with type 2, changes in BCAA are hypothesized to 
increase liver enzymes58, and increased ALT levels are a predictor of diabetes in humans. 
Measurement of ALT is recommended to be included in screening panels for diabetes59. Our 
cats all had normal ALT measured on a routine biochemistry panel.  
 
Beta-alanine 
Beta-alanine was the only amino acid significantly decreased in Burmese cats, and exhibited 
a negative correlation with insulin. In humans with type 2 diabetes, beta-alanine 
supplementation has been shown to reduce fasting blood glucose concentrations, and was 
hypothesized to increase insulin secretion and/or improve glucose-uptake60. In our cohort of 
cats, however there was no correlation between beta-alanine and glucose concentrations.  
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Arginine 
Arginine is a gluconeogenic amino acid and often used in insulin stimulation tests in cats 
because arginine is a potent stimulus for insulin secretion61.  Several studies have reported 
that arginine has stronger insulinotropic effects than alanine62,63. Arginine was significantly 
increased in Burmese cats, but there was no correlation with insulin or any measure of 
glucose metabolism. However, there was a strong correlation between arginine and 
triglycerides (P<0.01). L-arginine was reported to enhance the effects of statins in 33 
hypertriglyceridaemic patients by lowering triglycerides but there was no decrease in 
triglycerides when given alone64. L-arginine administration was also reported to decrease 
triglycerides in diabetic rats65 but no similar findings have been reported in cats. 
 
Proline and hydroxyproline 
Proline and hydroxyproline were significantly increased in our cohort of Burmese cats, and 
both were also positively correlated with fasting insulin. Hydroxyproline is produced by 
hydroxylation of proline66 and hydroxyproline is increased in human type 2 diabetic 
patients67 and nondiabetic obese subjects68. Hydroxyproline is a major component of 
collagen66, and collagen is increased in the skeletal muscle of these subjects, suggesting that 
hydroxyproline and collagen may play a role in insulin resistance in muscle68.  
 
Other acids altered between Burmese and non-Burmese cats 
Lactic, threonic and phosphoric acids were all decreased in Burmese cats whilst aminobutyric 
acid was increased. In humans with increased insulin resistance, lactate production is 
decreased69, and it was also decreased in our cohort of Burmese cats.  Although there was no 
significant relationship between lactic acid and insulin in our cohort of Burmese cat, there 
 235 
 
was a positive correlation with the glucose:insulin ratio, consistent with the finding in 
humans69. 
 
Alterations in carbohydrate metabolism  
Fructose and glucose 
Burmese cats had decreased fructose compared to non-Burmese cats. In humans, increased 
serum fructose is hypothesized to have a causative role in insulin resistance45,70 and 
hyperlipidemia71. In our study, fructose had no correlation with insulin or the glucose:insulin 
ratio. As reported previously (Chapter 5), glucose concentrations in all our Burmese cats 
were within the normal reference range. In the smaller sample group used for this current 
study, glucose was significantly decreased on metabolomic analysis and trended towards 
significantly decreased when measured with a portable glucose monitor. Glucose identified in 
metabolomics was positively correlated with fasting blood glucose measured by glucose 
meter. 
 
Succinate and glycerate  
Succinate and glycerate, an ester of glyceric acid was decreased in Burmese cats but glyceric 
acid, involved in the conversion of glucose to pyruvate, was not significantly different 
between Burmese and non-Burmese cats. Succinyl-coA is generated from succinate and the 
subsequent metabolite mevalonate, triggers insulin release in isolated rat pancreatic islets72. 
However, neither succinate no glycerate correlated with insulin in our cohort of cats. 
 
Glycerol-3-phosphate 
Glycerol-3-phosphate is a phosphoric ester of glycerol, and glycerol-3-phosphate is increased 
by stimulation of glucose transport by insulin73. Insulin also inhibits breakdown triglyceride 
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into glycerol and fatty acids74. Glycerol-3-phosphate was decreased in Burmese cats and 
there was no correlation between glycerol-3-phosphate and insulin. 
 
Alterations in urea 
Urea was significantly higher in Burmese cats than non-Burmese cats. All the study cats had 
blood urea levels within laboratory reference range, and none were diagnosed with renal 
disease based on serum urea and creatinine concentrations within the laboratory reference 
range. Similar results were found in cats in diabetic remission (Gottlieb, unpublished data). 
The increase in urea may be due to an increase in alanine metabolism through the glucose-
alanine cycle, where pyruvate is convert to alanine in the muscle and subsequently back to 
pyruvate in the liver by the TCA cycle because urea is a byproduct75. Alanine levels were 
also significantly increased in Burmese cats, and therefore, the increased urea levels may be 
due to increased alanine production in the muscle. In human males, urea, along with 10 other 
discriminators, were found to be biomarkers of impaired fasting glucose76, but a similar 
relationship was not found in our cat study. Further pyruvate was not increased in Burmese 
cats. 
 
MCP-1 
A novel finding in our study was that MCP-1 was significantly increased in Burmese cats.  
MCP-1 suppresses production of adiponectin77 and increased MCP-1 concentrations occur 
with obesity and are associated with type 2 diabetes in humans78-83. In humans and mice, 
MCP-1 induces inflammation in adipose tissue77,84-86. In severely obese human patients, 
MCP-1 protein expression was higher in omental fat than in subcutaneous fat, and was 
associated with increased macrophage infiltration into omental fat87. However, MCP-1 
concentrations were not increased in obese non-Burmese cats (Thesis Chapter 7). As 
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Burmese cats become obese, they develop a characteristic spherical appearance associated 
with prominent deposition of abdominal fat, rather than prominent subcutaneous inguinal fat 
deposits that domestic cats develop (per observations Rand), possibly making MCP-1 
expression more likely in Burmese cats. Increased MCP-1 concentrations are associated with 
decreased insulin sensitivity80,86,88, and our cohort of Burmese cats had increased insulin 
concentrations, and decreased glucose: insulin ratio, indicative of insulin resistance. Because 
of the effect of MCP-1 on insulin sensitivity, further investigation is warranted to determine 
if MCP-1 plays a role in the predisposition of Burmese to diabetes. 
 
Limitations of the study 
A limitation of our study was that adequate dietary information was only available for 6/19 
(32%) of the Burmese and 16/30 (53%) of the non-Burmese cats in our study. Dietary 
macronutrients have been shown to influence some of the biomarkers assessed in our study. 
For example, in cats, some amino acids and markers of lipid metabolism increase with diets 
of different macronutrient composition, specifically high protein (50% ME) and high fat 
(50% ME) diets respectively, but markers of carbohydrate and energy metabolism are less 
affected63. In our study, mean dietary protein and carbohydrate content were similar between 
groups, but dietary fat was higher in the Burmese cats. It is recommended that for future 
studies, cats should be on the same diet, or at least detailed dietary information should be 
available for inclusion in the statistical analysis. This was, however, difficult due to all cats 
being client-owned and collected information, though available for all cats, was unreliable. 
Only 23 of 64 metabolites that were different between Burmese and non-Burmese were 
identified. Additionally, the changes observed, although significant, are small and because 
the study used an untargeted approach and thus it is difficult to predict what the observed 
increased or decreased relative changes may mean physiologically. A future direction to this 
 238 
 
research would be a targeted metabolomic approach allowing quantitative measurements and 
identification of unknown metabolites that were significantly different in Burmese from non-
Burmese cats. Additionally, a larger cohort of cats with a more similar proportion of obese 
cats in each group would be useful to validate our findings. Our study was a cross-sectional 
study, and a longitudinal study is necessary to determine if some of the metabolites which 
were different in Burmese cats are indeed predictors of diabetes in cats. 
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Conclusion 
This study is the first to report metabolite differences between healthy non-Burmese and 
Burmese cats and it identified some biomarkers involved in amino acid, carbohydrate and 
lipid metabolism that are altered in Burmese cats, some of which are recognized to increase 
the risk of diabetes in humans. Further research is required to determine if these are useful as 
markers of metabolic dysfunction in cats at risk of developing diabetes. 
 
Funding 
The authors wish to thank Abbott Animal Health, USA and David Galbraith for funding 
towards the study. The authors report no real or perceived vested interests that relate to this 
manuscript, including relationships with the granting body or other entities whose products or 
services are related to topics covered in this manuscript that could be construed as a conflict 
of interest. 
  
Acknowledgements 
The authors would like to thank the Cat Clinics, Greencross Veterinary Clinics, Small 
Animal Hospital UQ St Lucia, participating owners and cats and Metabolomics Australia 
Footnotes 
a Idexx Laboratories, Brisbane Australia. 
b Abbott Alpha Trak© 
c Linco's Multi-Species Leptin Radioimmunoassay (RIA) Kit, Linco Research Inc, St Charles, 
MO 
d B-Bridge international, Otsuka, Tokyo, Japan 
e Nippon University 
 240 
 
f Morinaga Institute of Biological Science, Kanagawa, Japan  
g 13C6-sorbitol/
13C15N-Valine in water, 0.2 mg mL
-1 
h 0.029% (v/v) n dodecane, n-pentadecane, n-nonadecane, n-docosane, n-octacosane, n-
dotriacontane, n-hexatriacontane dissolved in pyridine 
i Gerstel 2.5.2 autosampler, a 7890A Agilent gas chromatograph and a 5975C Agilent 
quadrupole MS (Agilent, Santa Clara, USA). 
j Varian, Inc, Victoria, Australia 
k Agilent MassHunter Workstation Software, Quantitative Analysis, Version B.05.00/Build 
5.0.291.0 for GCMS 
l Max-Planck-Institute for Plant Physiology, Golm, Germany (http://csbdb.mpimp-
golm.mpg.de/csbdb/dbma/msri.html)  
m (13C6H4O6 – Sorbitol - (0.5 mg/mL), 13C5-15N-Valine - (0.5 mg/mL), 2-aminoanthracene - 
(0.25 mg/mL) Pentafluorobenzoic acid - (0.25 mg/mL)) 
n R version 3.3.1 (2016-06-21) -- "Bug in Your Hair" Copyright (C) 2016 The R Foundation 
for Statistical Computing. Metabolomics package for R user guide v.02 Last updated 1 
February 2013 
o GraphPad Prism version 7.01. GraphPad Software, Inc. La Jolla, CA, USA. 
 Reference Interval Draft Version, Copyright 2005, University of Cincinnati 
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Tables 
Table 8.1. Significant metabolites from GC-MS analysis of Burmese and non-Burmese 
senior cats. Values are expressed as loge fold-change of Burmese relative to the Non-
Burmese (control) group. P-values from unpaired t-test comparisons are presented as 
unadjusted, and adjusted using the Benjamini-Hochberg step-up false discovery rate method.  
P-values <0.05 were considered significant. 
Metabolite 
Loge fold 
change 
SEM 
Unadjusted 
P-value 
Adjusted 
P-value 
Amino Acids  
Alanine  0.630 0.165 <0.001 <0.01 
Aminobutyric acid 0.658 0.186 <0.001 <0.01 
Arginine  0.740 0.205 <0.001 <0.01 
Beta-Alanine  -0.527 0.058 <0.00001 <0.00001 
Cysteine 1.141 0.167 <0.00001 <0.00001 
Glutamine  0.799 0.236 <0.01 <0.01 
Hydroxyproline  1.172 0.328 <0.001 <0.01 
Phenylalanine 0.501 0.143 <0.01 <0.01 
Proline  0.725 0.237 <0.01 <0.01 
Tyrosine 0.760 0.195 <0.001 <0.01 
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Sugars 
Fructose -0.870 0.226 <0.001 <0.01 
Glucose -0.329 0.060 <0.00001 <0.0001 
Acids 
Glycerate -1.180 0.183 <0.00001 <0.00001 
Glycolic acid -0.420 0.077 <0.00001 <0.00001 
Lactic acid -0.262 0.093 <0.01 0.04 
Phosphoric acid -0.331 0.046 <0.00001 <0.00001 
Succinate -0.347 0.103 <0.01 <0.01 
Threonic acid -0.980 0.183 <0.00001 <0.00001 
Fatty Acids and Sterols 
Cholesterol -0.250 0.092 <0.01 0.02 
Monooctadecanoylglycerol -0.481 0.098 <0.0001 <0.001 
Octadecanoic (stearic) acid -0.218 0.082 0.01 0.04 
Other compounds     
Glycerol-3 phosphate -1.143 0.168 <0.00001 <0.00001 
Urea 0.184 0.066 <0.01 0.02 
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Table 8.2. Pearson correlations of significant identified metabolites from GC-MS analysis 
and measures of abnormal glucose metabolism and diabetes for all cats (Burmese and non-
Burmese). P-values <0.05 were considered significant 
Metabolite Measure of abnormal 
glucose metabolism 
and diabetes 
R-value P-values 
Amino Acids 
   
Alanine MCP-1 +0.30 0.04 
Arginine  Triglyceride +0.41 <0.01 
B-alanine Insulin -0.28 0.05 
Cysteine Insulin +0.38 <0.01 
Glutamine Insulin +0.50 <0.001 
Hydroxyproline  Insulin +0.37 <0.0001 
Phenylalanine Insulin 
Glucose:insulin ratio 
Triglyceride 
+0.40 
-0.29 
+0.34 
<0.01 
0.047 
0.02 
Proline Insulin 
MCP-1 
+0.48 
+0.34 
<0.001 
0.02 
Tyrosine Insulin 
Triglyceride 
+0.35 
+0.31 
0.01 
0.04 
Acids 
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Glycolic acid MCP-1 -0.33 0.02 
Lactic acid Glucose:insulin ratio  +0.41  <0.01 
Fatty acids and Sterols 
Monooctadecanoylgly
cerol 
fPLi -0.29 0.04 
Sugars  
   
Glucose Fasting glucose +0.29 
 
0.04 
 
Other compounds  
Glycerol-3-phosphate MCP-1 -0.31 0.03 
 
Urea fPLi +0.41 <0.01 
 
  
 245 
 
Figures 
Figure 8.1: Relative log abundance (RLA) plot where the median of each metabolite in the 
data matrix is visualized, and then subtracted this median from each metabolite. Red bars are 
Burmese and blue bars non-Burmese cats. 
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Figure 8.2. Bar Charts showing means, standard error of the means, and p-values calculated 
by unpaired t-test of measures associated with glucose metabolism and diabetes in non-
Burmese (n=30) and Burmese (n=19) senior cats.  ns is non-significant (p>0.10), * is 
significant at P<0.05, ** is significant at P<0.01.  
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Chapter 9: Conclusion  
The findings of this thesis have established and validated tests for screening, impaired fasting 
glucose and glucose tolerance in senior cats; the tests are easy to perform and designed to be 
used in a clinical setting. This thesis has also contributed to our understanding of the 
metabolic differences in cats at high risk of developing diabetes- namely obese and Burmese 
senior cats. The research presented in this thesis paves the way for early clinical diagnosis of 
prediabetes in cats, which may help prevent clinical disease in the future. 
Volume of distribution does not increase linearly with bodyweight and could lead to 
overweight and obese cats being incorrectly classified as having impaired glucose tolerance 
when interpreting the results of a glucose tolerance test. In chapter 4 (“Dosing obese cats 
based on body weight spuriously affects some measures of glucose tolerance”. Domest Anim 
Endocrinol. 2016 Oct;57:133-42), a retrospective study was performed using glucose 
concentration data from glucose tolerance and insulin sensitivity tests before and after cats 
were fed ad libitum for 9 to 12 months to promote weight gain. An important finding was that 
dosing glucose by bodyweight results in spurious effects on some measures of glucose 
tolerance in obese cats. Equations were developed to adjust either glucose dose or 2-h 
glucose to compensate for the volume of distribution effects of obesity. Based on these 
results, a glucose tolerance test requiring only 2 blood samples was standardised and 
validated for cats of all body condition scores, ranging from lean to obese. This feline 
equivalent to the human GTT provides clinical researchers and veterinary practitioners with a 
tool for identifying glucose intolerance in cats. This study demonstrated that testing of 
overweight and obese cats requires an adjustment to compensate for the ‘dosage’ effects of 
obesity, following guidelines outlined in this research. These findings have important 
implications for clinical studies assessing the effect of interventions on glucose tolerance 
when lean and obese cats are compared. 
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Evidence-based cutpoint values are important for diagnosing prediabetes in at risk cats, such 
as obese and Burmese cats. Because cats with impaired fasting glucose or glucose intolerance 
are at increased risk of diabetes, prediabetic cats need to be identified so management 
regimes can be implemented, including weight loss and dietary intervention. In chapter 5 
(“Diagnosis of prediabetes in cats: glucose concentration cut points for impaired fasting 
glucose and impaired glucose tolerance” Domest Anim Endocrinol. 2016 Oct;57:55-62. doi: 
10.1016/j.domaniend.2016.05.008. Epub 2016 May 26.), the methodology and cutpoints were 
established for fasting and 2-h blood glucose concentrations following the simplified 
intravenous glucose tolerance test designed in Chapter 4 for use in healthy cats 8 years and 
older with a range of body condition scores using ear/ paw samples and a portable glucose 
meter calibrated for feline blood. The upper cutpoint for fasting glucose was 117 mg/dL (6.4 
mmol/L) and for 2-h glucose was 176 mg/dL (9.8 mmol/L).  Burmese had significantly 
higher 2-h blood glucose concentrations at the higher dose rate, suggesting relative 
intolerance to glucose at higher doses and this warrants further investigation. 
 Casual blood glucose, defined as blood glucose measured unrelated to time of eating or type 
of food, is used as a screening test to diagnose diabetes in humans. Screening blood glucose 
measurement in cats represents a simple test, designed for use in a clinical setting. In Chapter 
6 (Cutpoints for screening and fasting blood glucose concentrations in healthy senior cats, 
Journal of Feline Medicine and Surgery, 2017, doi.org/10.1177/1098612X16685675), the 
measurement of screening blood glucose using a portable glucose meter validated for feline 
blood was standardized and the upper cutpoint of 188 mg/dL (10.5 mmol/L) established for 
ideal body condition cats. Another important finding was that behaviour score, BCS, fasting 
blood glucose concentration, and amount of carbohydrate consumed in the 2 to 6 hours 
before sampling collectively explained very little variability in screening blood glucose. It is 
recommended to retest cats with values from 117 mg/dL to 188 mg/dL (6.5 mmol/L to 10.5 
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mmol/L) 3-4 hours later. Cats with initial screening blood glucose > 188 mg/dL (10.5 
mmol/L), or a second screening blood glucose ≥117 mg/dL (6.5mmol/L) 3-4 hours after the 
first, should have fasting blood glucose and our simplified glucose tolerance test performed 
after overnight hospitalization using methodology developed in this thesis.  
Type 2 diabetes is the most common form of diabetes in humans and cats, and obesity is a 
risk factor. Metabolomic markers of obesity and predictors of diabetes have been identified in 
humans, but not in cats. In Chapter 7 (Metabolomic differences between lean and obese 
neutered senior cats and associations with glucose tolerance), metabolomic differences 
between lean and obese senior cats were identified, and associations of these metabolites with 
measures associated with glucose metabolism (screening, fasting and 2-h blood glucose 
following a glucose tolerance test) and diabetes related parameters (insulin, glucose:insulin 
ratio, leptin triglycerides, adiponectin, leptin:adiponectin ratio, fPLi and MCP-1) were 
established. Phenylalanine, and numerous fatty acids, glycolic acid and glycerol were 
increased and amino acid alanine was decreased in obese senior cats. Numerous associations 
between metabolites and other measures were identified: fatty acids were positively (and 
alanine negatively) correlated (P<0.05) with leptin, and glycolic acid and glycerol were 
positively correlated with insulin (P<0.05). The relationship between BCAA and fatty acids 
and diabetes has been documented in humans and fatty acids have been shown to be 
independant predictors of progression to diabetes in humans. Our study indicated a similar 
relationship between phenylalanine and obese cats and its relationship with insulin 
sensitivity. This study was the first to report the metabolomic markers of feline obesity and 
the association between metabolomic markers and hormonal variables in healthy senior cats 
and opened the path to forming a metabolomic footprint for these cats. This could prove 
useful in diagnosing prediabetes in cats and other species in the future. 
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As with obese cats, Burmese cats have been shown to be at high risk of developing diabetes. 
In fact, Burmese cats are 4 times more likely to develop diabetes than domestic cats. Our 
previous studies showed that Burmese cats may have relative intolerance to glucose at higher 
doses and others have found inherited alterations in lipid metabolism which may explain this 
increased risk of developing diabetes.  In chapter 8 (Metabolite differences between healthy 
senior Burmese and non-Burmese cats and associations between metabolites and measures of 
glucose metabolism) we identified metabolomic differences between Burmese and non-
Burmese cats and correlations between metabolites and measures associated with glucose 
metabolism. BCAA are increased in diabetic humans and associated with insulin resistance, 
and were also increased in Burmese cats and positively correlated with insulin, suggesting 
they may contribute to the metabolomic footprint of this breed. This study is the first to report 
metabolite differences between healthy non-Burmese and Burmese cats. These might prove 
useful markers of metabolic dysfunction in cats at high risk of developing diabetes, and 
improve understanding of the metabolic derangements associated with diabetes in Burmese 
cats. We also found there were some similarities in the expression profile between lean 
Burmese and obese domestic cats, and that these similarities may facilitate identification of 
biomarkers of obesity and diabetes risk that could be examined in future studies. 
In summary, this thesis has standardized and validated tests for screening blood glucose, 
impaired fasting glucose and impaired glucose tolerance in senior cats of all body condition 
scores. These tests are easy to perform and use in a clinical setting. The findings of this thesis 
also increased our understanding of the effects of obesity on blood glucose and demonstrated 
how results can be adjusted to allow the same cutpoints to be used in all cats, lean and obese. 
Additionally, the research in this thesis has identified metabolomic differences in cats at high 
risk of developing diabetes, namely obese and Burmese cats, which may aid in identifying 
cats more likely to develop diabetes in the future. 
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Appendices 
Appendix Table 5.1: Means (mmol/L), Standard Deviations (SD), Medians and Interquartile 
Ranges of blood glucose concentrations following an18 hour fast and 2 minutes (2-min) and 
2 hours (2-h) following an intravenous glucose bolus of 0.5 g/kg bodyweight during a 
simplified intravenous glucose tolerance test for subgroups of client owned cats aged 8 years 
and older. 
    Mean SD Median IQR 
Burmese (n=21)           
  Fasting 4.5 0.8 4.6 0.7 
  2-min 21.4 5.3 23.3   
  2-hr 6.3 2.1 6.2 2.5 
Non-Burmese (n=61)           
  Fasting 5 1.6 4.7 1.1 
  2-min 25 6 25.1   
  2-hr 6.6 2.5 5.7 2.9 
Lean (n=22)           
  Fasting 5.3 1.7 4.9 0.8 
  2-min 23.5 6.4 23.3   
  2-hr 5.6 1.4 5.3 1.35 
BCS 6 (n=8)           
  Fasting 4.8 0.6 4.7 0.9 
  2-min         
  2-hr 6.4 2.4 5.8 4 
BCS 7 overweight(n=12)           
  Fasting 5.2 2.3 4.5 0.9 
  2-min         
  2-hr 6.8 3.5 5.6 2 
BCS 8-9 Obese (n=19)           
  Fasting 4.7 0.9 4.7 1 
  2-min 26.2 5.5 25   
  2-hr 7.8 2.4 7.9 2 
Non-Burmese excl Obese 
(n=42)           
  Fasting 5.2 1.8 4.8 1 
  2-min 24.5 6.3 25.2   
  2-hr 6.1 2.3 5.4 1.8 
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Appendix Table 5.2: Percentage differences of Medians and Interquartile Ranges comparing 
the subgroups of client-owned cats aged 8 years and older following n 18 h fast and 2 h after 
a 0.5g/kg intravenous glucose bolus during a simplified intravenous glucose tolerance test. 
    
% 
Difference   
    Median IQR 
Burmese vs Non-Burmese       
  Fasting 2 57 
  2-h 9 16 
Burmese vs Lean       
  Fasting 7 14 
  2-h 17 85 
Burmese vs BCS 6       
  Fasting 2 32 
  2-h 8 58 
Burmese vs BCS 7       
  Fasting 3 12 
  2-h 32 27 
Burmese vs Obese       
  Fasting 2 50 
  2-h 27 16 
Non-Burmese Lean vs Obese       
  Fasting 4 31 
  2-h 49 59 
Non-Burmese Lean vs BCS 6       
  Fasting 4 16 
  2-h 8 193 
Non-Burmese Lean vs BCS 7       
  Fasting 10 16 
  2-h 5 46 
Non-Burmese BCS 6 vs 7       
  Fasting 6 0 
  2-h 4 100 
Non-Burmese Obese vs BCS 6       
  Fasting 0 14 
  2-h 37 84 
Non-Burmese Obese vs BCS 7       
  Fasting 6 14 
  2-h 42 9 
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Appendix Table 5.3: Adjustment of 2- h blood glucose concentration using equation from 
retrospective study (Reeve-Johnson, M., et al. (2016). Dosing obese cats based on body 
weight spuriously affects some measures of glucose tolerance. Domestic Animal 
Endocrinology 57: 133-142.)) of cats with 2- h blood glucose concentrations above reference 
interval upper limits. 
  
Adjustments for 2-h 
concentrations   
Adjusted 2-h 
concentration   
  Actual 2-h concentration BCS/9 Method a 
Method 
b. 
1 11.6 7 11.4 11.4 
2 11.6 8 11.3 11.5 
3 15.7 7 15.5 14 
4 12.5 8 12.2 12.5 
5 12.9 9 12.5 11 
6 11.3 9 10.9 10.1 
 
 
Appendix Table 5.4: Adjustment of 2-h blood glucose concentration using equation from 
retrospective study (Reeve-Johnson, M., et al. (2016). Dosing obese cats based on body 
weight spuriously affects some measures of glucose tolerance. Domestic Animal 
Endocrinology 57:133-142.) with data from this study of cats with 2-h blood glucose 
concentrations above reference interval upper limits. 
  
Adjustments for 2-h 
concentrations   
Adjusted 2-h 
concentration   
  Actual 2-h concentration BCS/9 Method a 
Method 
b. 
1 11.6 7  11.9 
2 11.6 8  12 
3 15.7 7  15.2 
4 12.5 8  12.9 
5 12.9 9  12.3 
6 11.3 9  11.1 
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Appendix 7.1 Instrumentation, instrument settings and chromatographic conditions of GC-
MS analyses 
Instrumentation: Agilent 6520A ESI-QqTOF-MS with attached Agilent 1200 series HPLC 
System comprised of Degasser, Pump, Auto-sampler with attached chiller, Diode Array 
Detector. 
Instrument settings: Gas Temperature = 300C; Drying Gas = 10 L/min; Nebulizer = 40-45 
psig; VCap = 3500V; Fragmentor = 150V, Skinner = 65V, OCT 1 RF Vpp = 750V. Acquisition 
range 70-1700 m/z, Rate = 1.5-3 spectra/s. Agilent Reference Mass solution co-infused through 
dual ionisation source for online mass calibration. Each sample was run on positive and 
negative mode. Autosampler cooled to 7C. 
Chromatographic Conditions: 
Reverse Phase: Zorbax Eclipse XDB-C18, 2.1 mm x 100 mm, 1.8 μm (Agilent) column; 
solvent (A) is 0.1% formic acid in Milli-Q water and solvent (B) is 0.1% formic acid in 
CH3CN; a solvent Flow rate: 0.4 mL/min with column temperature of 40°C; Gradient: A 10 
min linear gradient from 5% solvent (B) to 100% solvent (B), followed by a 2 min hold at 
100% solvent (B), then 5 min re-equilibration at 5% solvent (B) (total time of 17 minutes). 
Injection volume: 5 µL. 
ANP/HILIC: Cogent diamond Hydride 2.1 mm x 100 mm, 4 µm particle size (MicroSolv 
Technology, Brisbane, Australia) column; solvent (B) 90% ACN v/v with 0.1% ammonium 
acetate w/v and 0.1% acetic acid v/v; solvent (A) 100% deionised water with 0.1% ammonium 
acetate w/v and 0.1% acetic acid v/v (pH 3.4); solvent flow rate of 0.4 mL/min with column 
temperature at 50°C; Gradient: starting at 100% solvent (B) then linearly decreasing to 40% 
solvent (B) over 10 min, followed by a 1 min hold at 40% solvent (B) then re-equilibration at 
100% solvent (B) for 6 min (total time is 17 min). Injection volume: 5 µL. 
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Abbreviations: 
ESI-QqTOF-MS = Electrospray ionisation quadrupole time of flight mass spectrometer 
HPLC = High Performance Liquid Chromatography 
 
Appendix Figure 7.2: Volcano Plot of GC-MS data showing metabolites significantly 
different between obese cats compared to lean cats.  Metabolites with loge fold changes below 
zero are decreased in obese cats, and those above zero are increased. Metabolites shown in 
grey were not significantly different in obese cats.  
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Appendix 7.3: List of metabolites identified by the using a public domain mass spectra 
librarya and the in-house Metabolomics Australia mass spectral library which were not 
significantly different between lean and obese senior cats 
 
2-amino Malonic acid 
1-Monooctadecanoylglycerol 
2-amino Butyric acid 
2-amino- Malonic acid 
2-keto-L-Gluconic acid 
4-hydroxy Proline 
9,12-Octadecadienoic acid 
9-Octadecenoic acid 
Arginine 
Asparagine 
beta-Alanine 
beta-sitosterol 
Campesterol 
Cholesterol 
citric acid 
Cysteine 
Erythronic acid 
Fructose 
Glucose 
Glutamate 
Glutamine 
Glycerate 
Glycerol-3-Phosphate 
Glycine 
Heptadecanoic acid 
Hexadecanoic acid 
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Hexadecenoic acid 
Isoleucine 
Lactic acid 
Leucine 
Lysine 
Malic acid 
Monomethylphosphate 
myo Inositol 
Octadecanoic acid 
Phosphoric acid 
Phosphoric acid monomethylester 
Proline 
Pyroglutamic acid 
Pyruvic acid 
scyllo Inositol 
Serine-3TMS 
Succinate 
Threitol 
Threonic acid 
Threonine 
Tyrosine 
Urea 
Valine 
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Appendix Table 7.4 Pearson correlation of significant metabolites from GC-MS analysis of Lean and Obese senior cats and measures associated 
with abnormal glucose metabolism and diabetes. Correlations are for both lean and obese cats (n=35). P- values <0.05 were considered 
significant  
 
 
Metabolite Screening 
Blood 
Glucose 
Fasting 
Blood 
Glucose 
2-h 
Blood 
Glucose 
Leptin Adiponectin L:A 
ratio 
fpli Insulin Glucose: 
Insulin 
ratio 
Triglyceride MCP-1 
Alanine r= 0.02 
p=NS 
r= 0.06 
p=NS 
r= -0.45 
p<0.01 
r= -0.58 
p<0.001 
r= 0.19 
p= NS 
r= -
0.30 
p=NS 
r=-0.23 
p=NS 
r=0.19 
p=NS 
r=-0.04 
p=NS 
r=-0.12 
p=NS 
r=-0.12 
p=NS 
Phenylalanine r=0.05 
p=NS 
r=-0.12 
p=NS 
r=-0.20 
p=NS 
r=-0.13 
p=NS 
r=-0.12 
p=NS 
r=-0.03 
p=NS 
r=-0.34 
p<0.05 
r=0.50 
p<0.01 
r=-0.29 
p=NS 
r=0.28 
p=NS 
r=0.28 
p=NS 
9Z 
Hexadecenoic 
acid 
r=-0.03 
p=NS 
r=-0.31 
p=NS 
r=0.26 
p=NS 
r=0.36 
p<0.05 
r=-0.27 
p=NS 
r=0.11 
p=NS 
r=-0.32 
p=NS 
r=0.26 
p=NS 
r=-0.31 
p=NS 
r=0.27 
p=NS 
r=0.27 
p=NS 
Tetradecenoic 
acid 
r=0.01 
p=NS 
r=-0.29 
p=NS 
r=0.14 
p=NS 
r=0.24 
p=NS 
r=-0.20 
p=NS 
r=-0.00 
p=NS 
r=-0.16 
p=NS 
r=0.25 
p=NS 
r=-0.36 
p<0.05 
r=0.09 
p=NS 
r=0.09 
p=NS 
Glycerol r=-0.09 
p=NS 
r=-0.33 
p<0.05 
r=0.27 
p=NS 
r=0.28 
p=NS 
r=-0.22 
p=NS 
r=0.03 
p=NS 
r=-0.28 
p=NS 
r=0.35 
p<0.05 
r=-0.35 
p<0.05 
r=0.05 
p=NS 
r=0.05 
p=NS 
Glycolic acid r=-0.09 
p=NS 
r=-0.04 
p=NS 
r=0.23 
p=NS 
r=0.24 
p=NS 
r=-0.45 
p<0.01 
r=0.27 
p=NS 
r=0.05 
p=NS 
r=0.37 
p<0.05 
r=-0.07 
p=NS 
r=0.20 
p=NS 
r=0.20 
p=NS 
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Appendix Figure 8.1 Volcano Plot of GC-MS results showing metabolites that were 
different between Burmese and non-Burmese cats, Values on X axis are expressed as loge 
fold-change of Burmese relative to the Non-Burmese cats. Labels indicate known 
metabolites. The red line indicates threshold for significance (P<0.05).
 
 
 
Appendix 8.2: List of metabolites identified by the using a public domain mass spectra 
librarya and the in-house Metabolomics Australia mass spectral library which were not 
significantly different between Burmese and non-Burmese senior cats 
 
2-amino Malonic acid 
2-amino- Malonic acid 
2-keto-L-Gluconic acid 
Glycolic.acid
Beta-Alanine
Urea
Phosphoric acid
Tyrosine
Hydroxyproline
Threonic.acid
Glycerol-3-Phosphate
Arginine
Monooctadecanoylglycerol Alanine
Proline
Glycerate
Serine
Cysteine
Phenylalanine
Glutamine
Fructose
Glucose
Cholesterol
0
2
4
6
8
10
12
14
16
18
-2 -1.5 -1 -0.5 0 0.5 1 1.5 2 2.5
Log Fold Change (to base e)
-Log10 p-value
-----------------------------------------------------------------------------------------------
-----------------------------------------------
---- 
 273 
 
9,12-Octadecadienoic acid 
9-Octadecenoic acid 
9Z-Hexadecenoic acid 
Asparagine 
beta-sitosterol 
Campesterol 
citric acid 
Erythronic acid 
Glutamate 
Glycerol 
Glycine 
Heptadecanoic acid 
Hexadecanoic acid 
Hexadecenoic acid 
Isoleucine 
Leucine 
Lysine 
Malic acid 
Monomethylphosphate 
myo Inositol 
Phosphoric acid monomethylester 
Pyroglutamic acid 
Pyruvic acid 
scyllo Inositol 
Serine-3TMS 
Tetradecanoic acid 
Threitol 
Threonine 
Valine 
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 Appendix Table 8.3 Pearson correlation of significant metabolites from GC-MS analysis of Burmese and non-Burmese senior cats and known 
measures of glucose metabolism for all cats. P- values <0.05 were considered significant (P=ns not significant, p>0.1) 
Metabolite Screening 
Blood 
Glucose 
Fasting 
Blood 
Glucose 
2-h 
Blood 
Glucose 
Leptin Adiponectin L:A 
ratio 
fPLi Insulin Glucose:Insulin 
ratio 
Triglyceride MCP-1 
Amino Acids            
Alanine r=-0.18 
p=ns 
r=-0.14 
p=ns 
r=+0.07 
p=ns 
r=-0.01 
p=ns 
r=-0.18 
p=ns 
r=-0.13 
p=ns 
r=+0.27 
p=ns 
r=+0.08 
p=ns 
r=-0.14 
p=ns 
r=+0.16 
p=ns 
r=+0.30 
p=0.04 
Arginine r=-0.13 
p=ns 
r=-0.18 
p=ns 
r=+0.05 
p=ns 
r=+0.15 
p=ns 
r=-0.24 
p=ns 
r=+0.12 
p=ns 
r=+0.08 
p=ns 
r=+0.28 
p=ns 
 
r=-0.21 
p=ns 
r=+0.41 
p=0.004 
 
r=+0.17 
p=ns 
B-Alanine r=0.16 
p=ns 
r=+0.14 
p=ns 
r=-0.08 
p=ns 
r=+0.19 
p=ns 
r=+0.04 
p=ns 
r=+0.07 
p=ns 
r=-0.24 
p<0.05 
r=-0.28 
p=0.05 
r=+0.16 
p=ns 
r=-0.13 
p=ns 
r=-0.39 
p=0.006 
Cysteine r=-0.24 
p=ns 
r=-0.12 
p=ns 
r=0.09 
p=ns 
r=+0.06 
p=ns 
r=-0.20 
p=ns 
r=-0.06 
p=ns 
r=+0.26 
p=ns 
r=+0.38 
p=0.0064 
r=-0.21 
p=ns 
r=+0.20 
p=ns 
r=+0.27 
p=ns 
Glutamine r=-0.15 
p=ns 
r=-0.01 
p=ns 
r=-0.04 
p=ns 
r=+0.10 
p=ns 
r=-0.17 
p=ns 
r=-0.03 
p=ns 
r=+0.16 
p=ns 
r=+0.50 
p=0.0003 
r=-0.13 
p=ns 
r=+0.19 
p=ns 
r=+0.16 
p=ns 
Hydroxyproline r=-0.10 
p=ns 
r=-0.05 
p=ns 
r=-0.06 
 p=ns 
r=+0.00 
 p=ns 
r=-0.22 
p=ns 
r=-0.03 
 p=ns 
r=+0.18 
 p=ns 
r=+0.60 
p<0.0001 
r=-0.12 
p=ns 
r=+0.16 
 p=ns 
r=+0.15 
p=ns 
Phenylalanine r=-0.11 
p=ns 
r=-0.21 
p=ns 
r=-0.03 
p=ns 
r=+0.30 
p=ns 
r=-0.35 
p=0.05 
r=+0.06 
p=ns 
r=+0.09 
p=ns 
r=+0.402 
p=0.004 
r=-0.29 
p=0.047 
r=+0.34 
p=0.02 
r=+0.20 
p=ns 
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Proline r=-0.07 
p=ns 
r=-0.13 
p=ns 
r=-0.19 
p=0.09 
r=-0.01 
p=ns 
r=-0.23 
p=ns 
r=-0.16 
p=ns 
r=+0.14 
p=ns 
r=+0.48 
p=0.0006 
r=-0.15 
p=ns 
r=+0.09 
p=ns 
r=+0.34 
p=0.02 
Tyrosine r=-0.23 
p=ns 
r=-0.25 
p=ns 
r=+0.05 
p=ns 
r=+0.11 
p=ns 
r=-0.32 
p<0.05 
r=+0.04 
p=ns 
r=+0.17 
p=ns 
r=+0.35 
p=0.014 
r=-0.27 
p=ns 
r=+0.31 
p=0.04 
r=+0.24 
p=ns 
Urea r=-0.16 
p=ns 
r=-0.20 
p=ns 
r=-0.22 
p=ns 
r=-0.20 
p=ns 
r=+0.04 
p=ns 
r=-0.12 
p=ns 
r=+0.41 
p=0.0035 
r=+0.22 
p=ns 
r=-0.18 
p=ns 
r=+0.23 
p=0.06 
r=+0.33 
p=0.02 
Fatty Acids and sterols            
Cholesterol r=-0.05 
p=ns 
r=+0.04 
p=ns 
r=-0.19 
p=ns 
r=-0.11 
p=ns 
r=+0.06 
p=ns 
r=-0.13 
p=ns 
r=+0.12 
p=ns 
r=-0.14 
p=ns 
r=-0.01 
p=ns 
r=-0.08 
p=ns 
r=+0.12 
p=ns 
Monooctadecanoylglycerol r=-0.17 
p=ns 
r=-0.19 
 p=ns 
r=-0.04 
 p=ns 
r=+0.18 
 p=ns 
r=-0.08 
 p=ns 
r=+0.04 
 p=ns 
r=-0.29 
p=0.04 
r=-0.10 
 p=ns 
r=-0.15 
 p=ns 
r=-0.04 
 p=ns 
r=-0.26 
p=ns 
Octadecanoic acid (stearic 
acid) 
r=-0.06 
p=ns 
r=-0.07 
 p=ns 
r=-0.04 
 p=ns 
r=+0.17 
 p=ns 
r=-0.10 
p=ns 
r=-0.04 
 p=ns 
r=+0.09 
p=ns 
r=-0.13 
 p=ns 
r=-0.12 
 p=ns 
r=+0.06 
 p=ns 
r=+0.05 
 p=ns 
Glycerolipid metabolism            
Fructose r=0.05 
p=ns 
r=+0.17 
 p=ns 
r=+0.03 
p<0.05 
r=+0.04 
p=ns 
r=-0.20 
 p=ns 
r=+0.03 
p=ns 
r=-0.18 
 p=ns 
r=+0.05 
 p=ns 
r=+0.07 
 p=ns 
r=-0.13 
p=ns 
r=-0.25 
p=ns 
Glucose r=0.22 
p=ns 
r=+0.29 
 p=0.04 
r=+0.07 
p=ns 
r=+0.16 
 p=ns 
r=-0.12 
p=ns 
r=+0.07 
 p=ns 
r=-0.19 
p=ns 
r=-0.14 
 p=ns 
r=+0.21 
 p=ns 
r=+0.01 
 p=ns 
r=-0.18 
p=ns 
Glycerate r=0.08 
p=ns 
r=+0.06 
p=ns 
r=-0.10 
p=ns 
r=+0.12 
p=ns 
r=-0.16 
p=ns 
r=+0.04 
p=ns 
r=-0.22 
p=ns 
r=-0.03 
p=ns 
r=+0.07 
p=ns 
r=-0.01 
p=ns 
r=-0.24 
p=ns 
Glycerol 3 phosphate r=0.02 r=-0.05 r=+0.03 r=+0.21 r=+0.06 r=+0.05 r=-0.25 r=-0.13 r=-0.05 r=-0.02 r=-0.31 
 276 
 
 p=ns p=ns p=ns  p=ns p=ns p=ns  p=ns  p=ns  p=ns p=ns p=0.03 
Other acids            
Aminobutyric acid r=-0.18 
p=ns 
r=-0.18 
p=ns 
r=-0.07 
 p=ns 
r=-0.07 
 p=ns 
r=-0.21 
 p=ns 
r=-0.10 
 p=ns 
r=+0.03 
 p=ns 
r=-0.02 
 p=ns 
r=+0.13 
 p=ns 
r=+0.11 
 p=ns 
r=+0.03 
p=ns 
Glycolic acid r=0.06 
p=ns 
r=+0.07 
p=ns 
r=+0.07 
p=ns 
r=+0.30 
p=0.06 
r=-0.14 
p=ns 
r=+0.22 
p=ns 
r=-0.14 
p=ns 
r=-0.05 
p=ns 
r=+0.06 
 p=ns 
r=+0.10 
 p=ns 
r=-0.33 
p=0.02 
Lactic acid r=0.05 
p=ns 
r=+0.29 
p=ns 
r=+0.11 
p=ns 
r=-0.07 
 p=ns 
r=+0.26 
p=ns 
r=-0.05 
p=ns 
r=-0.09 
 p=ns 
r=-0.18 
 p=ns 
r=+0.41 
p=0.004 
r=-0.06 
 p=ns 
r=+0.18 
p=ns 
Phosphoric acid r=0.07 
p=ns 
r=+0.10 
p=ns 
r=-0.18 
p=0.10 
r=+0.05 
p=ns 
r=+0.06 
p=ns 
r=-0.05 
p=ns 
r=-0.08 
p=ns 
r=-0.24 
p=ns 
r=+0.05 
p=ns 
r=-0.24 
p=ns 
r=-0.26 
p=0.34 
Succinate r=-0.03 
p=ns 
r=-0.26 
p=ns 
r=-0.08 
p=ns 
r=+0.00 
p=ns 
r=+0.10 
p=ns 
r=-0.09 
p=ns 
r=-0.20 
p=ns 
r=-0.06 
p=ns 
r=-0.18 
p=ns 
r=-0.14 
p<0.05 
r=+0.08 
p=ns 
Threonic acid r=-0.00 
p=ns 
r=-0.06 
p=ns 
r=-0.00 
p=ns 
r=+0.21 
p=ns 
r=-0.17 
p=ns 
r=+0.06 
p=ns 
r=-0.19 
p=ns 
r=-0.01 
p=ns 
r=-0.02 
p=ns 
r=+0.10 
p=ns 
r=-0.18 
p=ns 
 
 
 
